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CHAPTER 1 
 
INTRODUCTION 
CHAPTER 1                                                                            INTRODUCTION 
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1. INTRODUCTION  
1.1. Virus 
 A virus is a small infectious intracellular organism, much smaller than a 
bacterium that must invade a living cell to reproduce (replicate). The virus 
attaches to a cell, enters it, and releases its DNA or RNA inside the cell. The 
virus's DNA or RNA is the genetic code containing the information needed to 
replicate the virus. The viral genetic material takes control of the cell and 
forces it to replicate the virus. The infected cell usually dies because the virus 
keeps it away from performing its normal functions. Before it dies, however, 
the cell releases new viruses, which go on to infect other cells1. 
Drugs that combat viral infections are called antiviral drugs. Antiviral drugs 
work by interfering with viral replication. Because viruses are tiny and 
replicate inside cells using the cells' own metabolic pathways, there are only a 
limited number of metabolic functions that antiviral drugs can target. 
Antibiotics are not effective against viral infections, but if a person has a 
bacterial infection in addition to a viral infection, an antibiotic is often 
necessary. Human immunovirus (HIV) decreases the immunity called AIDS. 
 
Retrovirus structure2: 
 
Figure 1.1: Structure of retrovirus   
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Retroviruses have enveloped particles, somewhat variable in size/shape 
but~100nm diameter. The envelope carries a virus-encoded glycoprotein, 
which forms spikes in the membrane. There are certain structural/functional 
similarities between the envelope glycoprotein and the influenza 
haemagglutinin . The mature protein is cleaved into 2 polypeptides:  
The outer envelope glycoprotein (SU), the major antigen of the virus, 
responsible for receptor binding, linked by disulphide bonds.   
The trans-membrane glycoprotein (TM), holds the SU protein in the envelope, 
responsible for membrane fusion.  
 
Inside the membrane is the matrix (MA) protein, rather amorphous. This 
largely obscures the capsid (CA), which is believed to be icosahedral. CA is 
the most abundant protein in the particle (~33% total weight). Inside the 
capsid is the core = RNA genome + NC protein + RT + IN. This is usually a 
conical, electron-dense structure clearly visible in -ve stained E.M. pictures 
(matrix and capsid appear amorphous)3. 
 
1.2 Virus function and life cycle 
As viruses have no metabolic machinery of their own, they have to attach to 
and penetrate a living host cell-animal, plant or bacterial-and use the victim's 
own metabolic processes to replicate. The first step in this process is 
facilitated by polypeptide binding sites on the envelope or capsid, interacting 
with receptors on the host cell. These 'receptors' are normal membrane 
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constituents-receptors for cytokines, neurotransmitters or hormones, ion 
channels, integral membrane glycoproteins, etc. The receptor-virus complex 
enters the cell (often by receptor-mediated endocytosis), during which time 
the virus coat may be removed by host cell enzymes (often lysosomal in 
nature). Some bypass this route. Once in the host cell, the nucleic acid of the 
virus then uses the host cell's machinery for synthesizing nucleic acids and 
proteins that are assembled into new virus particles. The actual way in which 
this occurs varies between DNA and RNA viruses. 
? Replication in DNA viruses 
Viral DNA enters the host cell nucleus, where transcription into mRNA occurs 
catalyzed by the host cell RNA polymerase. Translation of the mRNA into 
virus-specific proteins then takes place. Some of these proteins are enzymes 
that then synthesize more viral DNA, as well as proteins comprising the viral 
coat and envelope. After assembly of coat proteins around the viral DNA, 
complete virions are released by budding or after host cell lysis. 
? Replication in RNA viruses 
Enzymes within the virion synthesize its mRNA from the viral RNA template, 
or sometimes the viral RNA serves as its own mRNA. This is translated by the 
host cell into various enzymes, including RNA polymerase (which directs the 
synthesis of more viral RNA), and also into structural proteins of the virion. 
Assembly and release of virions occurs as explained above. With these 
viruses, the host cell nucleus is usually not involved in viral replication, 
although some RNA viruses (e.g. Orthomyxo viruses) replicate exclusively 
within the host nuclear compartment. 
? Replication in retroviruses 
The virion in retroviruses contains a reverse transcriptase enzyme (virus 
RNA-dependent DNA polymerase), which makes a DNA copy of the viral 
RNA. This DNA copy is integrated into the genome of the host cell, and it is 
then termed a provirus. The provirus DNA is transcribed into both new viral 
genome RNA as well as mRNA for translation in the host into viral proteins, 
and the completed viruses are released by budding. Many retroviruses can 
replicate without killing the host cell4,5. 
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1.3 Cause and types of viral infection 
Human cells are vulnerable to viruses, and when the body is exposed to viral 
particles, the immune system will try to destroy these particles and eliminate 
them from the system. A lowered immune system allows the virus to more 
easily attach itself to available cells, often bringing about general symptoms 
such as fever, chills, and muscle aches. This also makes it easier for the virus 
to replicate, and thus advances symptoms until the immune system can fight 
the virus off. 
? Symptoms of Viral Infections 
Viral infections come with a variety of symptoms ranging from mild to severe. 
Symptoms may vary depending on what part of the body is affected, type of 
viruses, age, and overall health of the affected person6. 
These symptoms can include: 
? Fever 
? Muscle aches 
? Runny nose 
? Headache 
? Chills 
? Diarrhea 
? Coughing 
? Sneezing 
? Vomiting 
More severe symptoms include: 
? Personality changes 
? Neck stiffness 
? Dehydration 
? Seizures 
? Paralysis of the limbs 
? Confusion 
? Back pain 
? Loss of sensation 
? Impaired bladder and bowel function 
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? Sleepiness that can progress into a coma or death 
 
1.4 Antiviral drugs7 
Because viruses hijack many of the metabolic processes of the host cell itself, 
it is difficult to find drugs that are selective for the pathogen. However, there 
are some enzymes that are virus-specific, and these have proved to be useful 
drug targets. Most currently available antiviral agents are effective only while 
the virus is replicating. 
? Classification of Antiviral drugs based on mechanism of action 
1. Nucleoside reverse transcriptase inhibitors: 
eg. Abacavir, Adefovir Dipivoxil, Didanosine, Emtricitabine, 
Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine 
2. Non-nucleoside reverse transcriptase inhibitors: 
eg.Efavirenz, Nevirapine 
3. Protease inhibitors: 
eg. Amprenavir, Atazanavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, 
Saquinavir 
4. Viral DNA polymerase inhibitors: 
eg. Aciclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, 
Idoxuridine, Penciclovir 
5. Inhibitors of HIV fusion with host cells: 
eg. Enfurvitide 
6. Inhibitors of viral coat disassembly and neuraminidase inhibitors: 
eg. Amantadine, Oseltamivir, Zanamivir 
7. Biologics and immunomoduators: 
eg. Interferon-a, Pegylated interferon-a, Inosine Pranobex, Palivizumab 
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Figure 1.2: Schematic diagram of infection of a CD4+cell by an HIV virion with 
the series of action of the two main classes of anti-HIV drugs 
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1.5 Approach to drug therapy 
1.5.1 Approaches by life cycle stage 
? Before cell entry 
One antiviral strategy is to interfere with the ability of a virus to infiltrate a 
target cell. The virus must go through a sequence of steps to do this, 
beginning with binding to a specific "receptor" molecule on the surface of the 
host cell and ending with the virus "uncoating" inside the cell and releasing its 
contents. Viruses that have a lipid envelope must also fuse their envelope 
with the target cell, or with a vesicle that transports them into the cell, before 
they can uncoat. 
? Entry inhibitor 
A very early stage of viral infection is viral entry, when the virus attaches to 
and enters the host cell. A number of "entry-inhibiting" or "entry-blocking" 
drugs are being developed to fight HN. HN most heavily targets the immune 
system's white blood cells known as "helper T cells", and identifies these 
target cells through T-cell surface receptors designated "CD4" and flCCRS". 
Attempts to interfere with the binding of HIV with the CD4 receptor have failed 
to stop mv from infecting helper T cells, but research continues on trying to 
interfere with the binding of HN to the CCRS receptor in hopes that it will be 
more effective. 
? Uncoating inhibitor 
Inhibitors of uncoating have also been investigated8, 9. Amantadine and 
Rimantadine have been introduced to combat influenza. These agents act on 
penetration uncoating10. Pleconaril works against rhinoviruses, which cause 
the common cold, by blocking a pocket on the surface of the virus that 
controls the uncoating process. This pocket is similar in most strains of 
rhinoviruses and enteroviruses, which can cause diarrhea, meningitis, 
conjunctivitis, and encephalitis. 
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1.5.2 During viral synthesis 
A second approach is to target the processes that synthesize virus 
components after a virus invades a cell. 
? Reverse transcription 
One way of doing this is to develop nucleotide or nucleoside analogues that 
look like the building blocks of RNA or DNA, but deactivate the enzymes that 
synthesize the RNA or DNA once the analogue is incorporated. This approach 
is more commonly associated with the inhibition of reverse transcriptase (RNA 
to DNA) than with "normal" transcriptase (DNA to RNA).The first successful 
antiviral, acyclovir, is a nucleoside analogue, and is effective against Herpes 
virus infections. The first antiviral drug to be approved for treating HIV, 
Zidovudine (AZT), is also a nucleoside analogue. 
? Translation / antisense 
Genomics has not only helped find targets for many antivirals, it has provided 
the basis for an entirely new type of drug, based on "antisense" molecules. 
These are segments of DNA or RNA that are designed as complementary 
molecule to critical sections of viral genomes, and the binding of these 
antisense segments to these target sections blocks the operation of those 
genomes. A Phosphorothioate antisense drug named Fomivirsen has been 
introduced, used to treat opportunistic eye infections in AIDS patients caused 
by cytomegalovirus, and other antisense antivirals are in development. An 
antisense structural type that has proven especially valuable in research is 
Morpholino antisense11, 12. 
? Protease inhibitors 
Some viruses include an enzyme known as a protease that cuts viral protein 
chains apart so they can be assembled into their final configuration. HIV 
includes a protease, and so considerable research has been performed to find 
"protease inhibitors': to attack HIV at that phase of its life cycle13. Protease 
inhibitors became available in the 1990s and have proven effective, though 
they can have unusual side effects, for example causing fat to build up in 
unusual places14. Improved protease inhibitors are now in development. 
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1.6 DRUG PROFILE 
1.6.1 Tenofovir disoproxil fumarate15, 16, 17 
Structure 
N
N
N
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O P O
O
O O O
O
O O
O
CH3
NH2
HOOC
H
H
COOH
 
Chemical Name 9 - [(R) -2 - [[bis [[(isopropoxy carbonyl) oxy] methoxy] 
phosphinyl] methoxy] propyl] adenine fumarate 
CAS No. 147127-20-6 
Merck Index No. 9146 
Molecular 
Formula 
C19H30N5O10P –C4H4O4 
Molecular weight 635.52 g/mol 
State and 
Solubility                
White to off white crystalline powder. Approximately 13.4 
mg/ml, soluble in distilled water at 25°C. 
Melting Point          279°C 
pKa 3.75 
Mechanism of 
action 
Tenofovir belongs to a class of antiretroviral drugs known 
as nucleotide analogue reverse transcriptase inhibitors 
(NaRTIs), which block reverse transcriptase, an enzyme 
crucial to viral production in HIV-infected people. 
Tenofovir inhibits the activity of HIV reverse transcriptase 
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by competing with the natural substrate deoxyadenosine 
5'-triphosphate and, after incorporation into DNA, by DNA 
chain termination. 
Pharmacokinetics ? The oral bioavailability in fasted patients is 
approximately 25%. Administration of food (high fat 
meal containing 40 to 50% fat) increases the oral 
bioavailability, with an increase in the AUC of 
approximately 40%. 
? Tenofovir is eliminated by a combination of glomerular 
filtration and active tubular secretion. There may be 
competition for elimination with other compounds that 
are also renally eliminated. 
Uses  and 
Administration 
? For the treatment of HIV-l or chronic hepatitis B: The 
dose of tenofovir disoproxil fumarate) is 300 mg once 
daily taken orally, without regard to food. 
? In the treatment of chronic hepatitis B, the optimal 
duration of treatment is unknown. 
Side Effects liver damage - nausea, stomach pain, low fever, loss of 
appetite, dark urine, clay-colored stools, jaundice, lactic 
acidosis - muscle pain or weakness, numb or cold feeling 
in your arms and legs, dizziness, trouble breathing, 
stomach pain, nausea with vomiting, slow or uneven heart 
rate, dizziness, or feeling very weak or tired, kidney 
problems -increased thirst and urination, loss of appetite, 
weakness, constipation, urinating less than usual or not at 
all, fever, chills, body aches, flu symptoms. 
Contraindications Tenofovir is indicated in combination with other 
antiretroviral agents for the treatment of HIV-1 infection in 
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adults. There are no study results demonstrating the 
effect of tenofovir on the clinical progression of HIV. It 
also has activity against lamivudine-resistant HBV. 
Storage Store at room temperature at 77°F (25°C) away from light 
and moisture. 
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1.6.2 Efavirenz18-23 
Structure 
N
H
O
Cl
O
F3C
 
Chemical Name (4S) – 6 – chloro – 4 - (cyclopropy ethynyl) - I,4 - 
dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. 
CAS No. 154598-52-4 
Merck Index No. 3521 
Molecular Formula C14H9ClF3NO2 
Molecular weight 315.68 g/mol 
State and Solubility  White to slightly pink crystalline powder. It is practically 
insoluble in water, soluble in methanol. 
Melting Point            139-141 °C 
pKa 10.2 
Mechanism  of 
action 
Efavirenz is an HIV-1 specific, non - nucleoside reverse 
transcriptase inhibitor (NNRTl). EFV activity is mediated 
predominantly by noncompetitive inhibition of HIV-I 
reverse transcriptase (RT) 
Pharmacokinetics ? In HIV-I-infected patients at steady state, mean Cmax, 
mean Cmin, and mean AUC were dose proportional 
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following 200-mg, 400-mg, and 600-mg daily doses. 
Time-to-peak plasma concentrations were 
approximately 3-5 hours and steady-state plasma 
concentrations were reached in 6-10 days.  
? Efavirenz is highly bound (approximately 99.5-
99.75%) to human plasma proteins, predominantly 
albumin.  
? Efavirenz is principally metabolized by the cytochrome 
P450 system to hydroxylated metabolites with 
subsequent glucuronidation of these hydroxylated 
metabolites. These metabolites are essentially 
inactive against HIV-1. The in vitro studies suggest 
that CYP3A and CYP2B6 are the major isozymes 
responsible for Efavirenz metabolism. 
 Administration The recommended dosage of Efavirenz is 600 mg, once 
daily, in combination with a protease inhibitor and/or 
nucleoside analogue reverse transcriptase inhibitors. It 
is recommended that Efavirenz be taken on an empty 
stomach, preferably at bedtime. Dosing at bedtime may 
improve the tolerability of nervous system symptoms. 
Side Effects Psychiatric symptoms, nervous system symptoms, rash 
Contraindications It is never used alone and is always given in 
combination with other drugs. The decision on when to 
start treatment should take into account CD4 count, HIV 
viral load, treatment history, resistance profiles and 
patient preference.   
Storage It should be stored at room temperature at 77°F (25°C) 
away from light and moisture. 
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1.6.3 Ritonavir24-28 
Structure 
NS
CH3 CH3
N N
H
CH3CH3
O
N
H
OH
N
H
O
O
S
NCH3
O
 
Chemical Name 10 – Hydroxy – 2 – methyl – 5 - (I – methyl ethyl) –I - [2 -
(l - methy lethyl) – 4 - thiazolyl] - 3, 6 – dioxo - 8, I1 - bis 
(phenyl methyl) - 2,4,7,12- tetraazatridecan – 13 - oic 
acid, 5 -thiazolylmethyl ester. 
CAS No. 155213-67-5 
Merck Index No. 8283 
Molecular Formula C37H48N6O5S2 
Molecular weight 720.95 g/mol 
State  and 
Solubility                 
A white to light tan powder. Freely soluble in methanol 
and ethanol and Insoluble in water. 
Melting Point            207-209°C 
pKa 14.22 
Mechanism  of 
action 
Ritonavir reversibly binds to the active site of the HIV 
protease, preventing polypeptide processing and 
subsequent virus maturation. Virus particles are 
produced in the presence of ritonavir but are 
noninfectious. 
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Pharmacokinetics ? Tmax is approximately 3-5 hours on oral 
administration. 98-99 % bound to human serum 
proteins and it is independent of concentration.  
? The major biotransformation pathways consisted of 
monooxygenation and dioxygenation. Others are 
glucuronidation, N-dealkylation, hydrolysis, and 
oxygenation with dehydrogenation. 
? Majority of the administered drug is recovered in the 
feces and urine (79% and 13% respectively). The 
terminal elimination half-life is approximately 7 hours 
at steady state. 
Administration By mouth with food or up to 2 hours after food, usually 2 
times daily 
Side Effects Gastrointestinal and include nausea, vomiting, diarrhea, 
anorexia, abdominal pain, and taste perversion. 
Accidental injury, allergic reaction, back pain, cachexia, 
chest pain, chills, facial edema, facial pain, flu syndrome, 
hormone level altered, hypothermia, kidney pain, neck 
pain, neck rigidity, pelvic pain, photosensitivity reaction, 
and substernal chest pain 
Contraindications Concomitant therapy of ritonavir with a variety of 
medications may result in serious and sometimes fatal 
drug interactions. These interactions can occur with 
strong inhibitors, strong or moderate inducers or 
substrates of hepatic cytochrome P450 CYP3A4 isoform. 
Midazolam and triazolam are contraindicated, 
carbamazepine decreased metabolism, possible toxicity, 
Cisapride decreased metabolism, possible prolongation 
of Q-T interval and life-threatening arrhythmias , 
disulfiram (with Ritonavir oral preparation) – decreased 
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metabolism of Ritonavir. 
Storage It should be stored at 2° to 8°C protected from light. 
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1.6.4 Lopinavir29-30 
Structure 
NH N
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Chemical Name [1S-[1R*,(R*), 3R*, 4R*]] –N –[4- [[ (2,6 –dimethyl 
phenoxy) acetyl]amino]-3-hydroxy-5-phenyl- 1-phenyl 
methyl) pentyl] tetrahydro-alpha-(1-methylethyl)-2-oxo-
1(2H)-pyrimidine acetamide. 
CAS No. 192725-17-0 
Merck Index No. 5573 
Molecular Formula C37H48N4O5 
Molecular weight 628.8008 g/mol 
State  and 
Solubility                 
white to light tan powder. freely soluble in methanol and 
ethanol, soluble in isopropanol and practically insoluble 
in water. 
Melting Point            279°C 
pKa 13.98 
Mechanism  of 
action 
Lopinavir inhibits the HIV viral protease enzyme. This 
prevents cleavage of the gag-pol polyprotein and, 
therefore, improper viral assembly results. This 
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subsequently results in non-infectious, immature viral 
particles. 
Pharmacokinetics ? Administered alone, Lopinavir has insufficient 
bioavailability; however, like several HIV protease 
inhibitors, its blood levels are greatly increased by low 
doses of ritonavir, a potent inhibitor of cytochrome 
P450 3A4. 
? Lopinavir is highly bound to plasma proteins (98-
99%). 
?  Lopinavir is extensively metabolized by the hepatic 
cytochrome P450 system, almost exclusively by the 
CYP3A isozyme. 
Uses  and 
Administration 
Treatment of HIV infections in combination with other 
antiviral agents. Administer with food. Not to be 
administered with the drugs like dihydroergotamine, 
ergonovine, ergotamine, methylergonovine, triazolam, 
astemizole, pimozide, cisapride, propafenone, 
terfenadine, flecainide, midazolam. 
Side Effects Diarrhoea, nausea, vomiting, bloating, headache, 
dyslipidaemias raised LFTs 
Contraindications Concurrent administration with drugs that are highly 
dependent on CYP3A or CYP2D6 for clearance and for 
which elevated plasma levels are associated with 
serious or life-threatening reactions. 
Storage It should be stored at 2° to 8°C protected from light. 
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2. LITERATURE REVIEW 
2.1 OFFICIAL COMPENDIA METHODS FOR DETERMINATION OF 
ANTIRETROVIRAL AGENTS 
Sr. 
No. 
Matrix Method Parameters Ref. 
No. 
1. Tenofovir HPLC Stationary phase – Stainless steel 
column (25 cm x 4.6 mm, 5 μm) 
packed with octadecyl silane 
bonded to porous silica  
Mobile phase - Acetonitrile :  0.05M 
sodium dihydrogen phosphate  ( pH 
2.3) (40:60 v/v) 
Flow rate - 1 mL/min. 
Detection wavelength - 260 nm. 
1 
2. Tenofovir 
tablet 
HPLC Stationary phase – Stainless steel 
column (15 cm x 4.6 mm, 5 μm) 
packed with octadecyl silane 
bonded to porous silica  
Mobile phase - Acetonitrile :  0.05M 
sodium dihydrogen phosphate  ( pH 
2.3) (40:60 v/v) 
Flow rate - 1 mL/min. 
Detection wavelength - 260 nm. 
1 
3. Tenofovir 
disoproxil 
fumarate   and 
Emtricitabine 
tablet 
HPLC Stationary phase – Stainless steel 
column (5 cm x 4.6 mm,  3μm) 
packed with octadecyl silane 
bonded to porous silica  
Column temperature - 40ºC,  
Mobile phase - Acetonitrile :  
monobasic potassium phosphate 
buffer (pH 3.0) (80:20 v/v) 
Flow rate – 1.5 mL/min. 
1 
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Detection wavelength - 260 nm. 
4. Ritonavir HPLC Stationary phase – Stainless steel 
column (15 cm x 4.6 mm,  5μm) 
packed with octadecyl silane 
bonded to porous silica  
Mobile phase - Acetonitrile :  
sodium acetate buffer (pH 4.0) 
(45:55 v/v) 
Flow rate – 1 mL/min. 
Detection wavelength - 239 nm. 
1 
5.  Ritonavir HPLC Stationary phase – Stainless steel 
column (15 cm x 4.6 mm; 3 μm) 
packed withıend capped butyl silyl 
silica gel  
Temperature - 60 °C 
Mobile phase A – Butanol : 
tetrahydrofuran : acetonitrile : 
potassium dihydrogen phosphate 
buffer (5:8:18:69 v/v/v/v)  
Mobile phase B - Butanol : 
tetrahydrofuran : acetonitrile : 
potassium dihydrogen phosphate 
buffer (5:8:47:40 v/v/v/v) 
Flow rate-- 1.0 mL/min. 
Detectionıwavelength - 240 nm. 
Injection volume -50 μL 
2 
6. Ritonavir tablet 
and capsule 
HPLC Stationary phase – Stainless steel 
column (5 cm x 4.6 mm, 3.5 μm) 
packed with octadecyl silane 
bonded to porous silica  
Column temperature - 45ºC 
Mobile phase – Acetonitrile : 
sodium acetate buffer (pH 4.0) 
1 
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(45:55 v/v) 
Flow rate—2.5 mL/min. 
Detectionıwavelength - 240 nm. 
7. Ritonavir and 
Lopinavir 
capsule 
HPLC Stationary phase – Stainless steel 
column (5 cm x 4.6 mm, 5 μm) 
packed with octadecyl silane 
bonded to porous silica  
Mobile phase - Acetonitrile : 
methanol : potassium dihydrogen 
orthophosphate buffer (pH 3.0) 
(42.5:12.5:45 v/v/v) 
Flow rate-- 1.0 mL/min. 
Detectionıwavelength - 210 nm. 
3 
8. Ritonavir and 
Lopinavir 
tablet  
HPLC Stationary phase – Stainless steel 
column (15 cm x 4.6 mm, 5 μm) 
packed with octadecyl silane 
bonded to porous silica  
Mobile phase A - Acetonitrile : 
methanol (80:20 v/v) 
 B - Mobile phase A : potassium 
dihydrogen ortho phosphate buffer 
solution (pH 3.0) (55:45 v/v) 
Flow rate-- 1.5 mL/min. 
Detectionıwavelength - 210 nm. 
3 
9. Efavirenz (API, 
tablet and 
capsule) 
HPLC Stationary phase – Stainless steel 
column (25 cm x 4.6 mm, 5 μm) 
packed with base deactivated 
octadecyl silyl silica gel  
Mobile phase - Acetonitrile : 0.86 % 
w/v ammonium dihydrogen 
phosphate buffer ( pH 3.0 ± 0.05) 
(50:50 v/v) 
Flow rate-- 1.5 mL/min. 
3 
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Detectionıwavelength - 254 nm. 
10. Lopinavir HPLC Stationary phase – Stainless steel 
column (25 cm x 4.6 mm, 5 μm) 
Packed with octyl silane bonded to 
porous silica  
Mobile phase - Solution B : 0.05 M 
potassium dihydrogen phosphate 
buffer (pH 3.0) (55:45 v/v) 
Solution B : Acetonitrile : methanol 
(80:20 v/v) 
Flow rate - 1.5 mL/min. 
Detectionıwavelength - 210 nm. 
3 
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2.2 REPORTED METHODS FOR DETERMINATION OF ANTIRETROVIRAL 
AGENTS 
2.2.1 Reported methods for determination of Tenofovir disoproxil 
fumarate with other drugs 
Sr. 
No. 
Matrix Method Parameters Ref. 
No. 
1.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Emtricitabine) 
RP-HPLC Stationary phase - Agilent C18 
column 
Mobile phase – Methanol : 
Phosphate buffer (pH 7.0) (65:35 
v/v)  
Detection wavelength -260 nm. 
Flow rate - 1.0 mL/min., 
Linearity range - 5 - 70 µg/mL, 
4 
2.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Lamivudine) 
HPTLC Stationary phase - Merck HPTLC 
aluminium plates of silica gel 60 
F254, (20 × 10 cm) with 250 µm 
thickness 
Mobile phase - Chloroform: 
methanol: toluene (8:2:2 v/v/v) 
Detection wavelength -  265nm. 
5 
3.  Tablet  
(Tenofovir 
Disoproxil 
Fumarate and 
Emtricitabine) 
Spectro-
photometry 
1st method – wavelength 262 nm 
as λ1 (isobestic point) and 281 
nm as λ2 (λmax of Emtricitabine) 
2nd method - wavelength 281nm 
3rd method – First derivative 
spectroscop, wavelength 
226.5nm for tenofovir and 298.5 
nm for emtricitabine 
Linearity range – 4 – 24 µg/mL 
6 
4.  Tablet 
(Tenofovir 
RP-HPLC Stationary phase - Agilent 
eclipse XDB-C18 (5 µm, 4.6 mm 
7 
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Disoproxil 
Fumarate and 
Lamivudine) 
× 150 mm) column 
Mobile phase - Methanol : 0.02 
M potassium dihydrogen ortho 
phosphate (pH 3.0) (60:40 v/v))  
Detection wavelength -  260nm. 
Flow rate: 0.9 mL/min. 
Linearity range: 5 - 50 µg/mL, 
5.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate, 
rilpivirine and 
Emtricitabine) 
LC Stationary phase - Hypersil BDS 
C18 column 
Mobile phase - Gradient elution 
using containing acetonitrile, 0.2 
M Potassium dihydrogen 
phosphate and Water. 
Solvent for active ingredients -  
DMSO : distilled water (1:1) 
8 
6.  API RP-HPLC Stationary phase - RP-18 column 
(25 mm × 4.6 mm, porous 
material) 
Mobile phase - water (pH 4.0 
adjusted with acetic acid) :  
methanol (60:40 v/v) 
9 
7.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Lamivudine) 
Spectro-
photometry  
Wave length - 259 nm 
Solvent – Methanol: water (50:50 
v/v) 
Linearity range - 5.0-30.0 µg/mL 
10 
8.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Lamivudine) 
First 
derivative 
spectro-
photometry  
Wave length - 249 nm for 
tenofovir and 281 nm for 
lamivudine 
Solvent – Distilled water 
Linearity range - 10 – 60 µg/mL 
for tenofovir and 5 -30 µg/mL for 
lamivudine 
11 
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9.  API and Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Emtricitabine) 
RP-HPLC Stationary phase - Phenomenex 
Luna C18 (150 mm × 4.6 mm, 
particle size 5 µm) column 
Mobile phase - Acetonitrile: 
methanol: water (30:50:20 v/v/v) 
Detection wavelength – 258 nm. 
Flow rate - 0.6 mL/min. 
Retention time – 3.49 min. 
Linearity range - 1– 6 µg/mL 
12 
10.  Bulk and Tablet 
(Tenofovir 
Disoproxil 
Fumarate, 
Efavirenz and 
Emtricitabine) 
UPLC Column - BEH Ph column 
Mobile phase - Potassium 
dihydrogen phosphate buffer (pH 
6.5) : methanol : acetonitrile 
(45:27.5:27.5 v/v/v)  
Detection wavelength – 260 nm. 
Linearity range - 0.024-0.088 
µg/mL 
Retention time - less than 1.5 
min 
 
 
13 
11.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Emtricitabine) 
Spectro-
photometry 
Wavelength -  259 nm 
(Tenofovir) and 281 nm 
(Emtricitabine) 
Linearity range -  6-48 µg/mL 
Solvent - Methanol 
14 
12.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate and 
Emtricitabine) 
RP-HPLC Stationary phase - Luna C18 (25 
cm× 4.60 mm, particle size 5 
µm) column 
Mobile phase – Acetonitrile : 
potassium dihydrogen phosphate 
buffer (pH 3.0±0.05) : triethyl 
amine (70:30:0.5 v/v/v) 
15 
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Detection wavelength - 260nm 
Retention time - 2.27 min 
Linearity range - 5-50 µg/mL 
13.  Tablet 
(Tenofovir 
Disoproxil 
Fumarate, 
Efavirenz and 
Emtricitabine) 
RP-HPLC Stationary phase - Inertsil ODS 
3V column 
Mobile phase - Gradient 
composition of 0.02M Sodium 
dihydrogen orthophosphate as 
mobile phase A and mixture of 
methanol and water (85:15 v/v) 
as mobile phase B 
Flow rate - 1.5 mL/min 
Detection wavelength - 265nm 
Retention time - 8.8 min 
Linearity range - 12-180 µg/mL 
 
16 
14.  Rat Plasma 
(with several 
antiretroviral 
nucleosides) 
HPLC Stationary phase - Atlantis C18 
column 
Mobile phase - 5 mM acetic acid-
hydroxylamine buffer  (pH 7) : 
acetonitrile gradient elution 
Linearity range - 30-10,000 
ng/mL 
Detection wavelength - 260nm 
17 
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2.2.2 Reported methods for determination of Tenofovir disoproxil 
fumarate  
Sr. 
No 
Matrix Method Parameters Ref
.No 
1.  Tablet Spectro-
photometry 
1st method - Complexation with 
ammonium molybdate 
Wavelength - 495 nm 
Molar absorptivity - 1234.09 
mol/L/cm 
2nd method - Complexation with 
picric acid 
Wavelength – 465 nm 
Molar absorptivity - 12,330.92 
mol/L/cm 
18 
2.  Human Plasma Isotope 
dilution 
MALDI-triple 
quadrupole 
tandem mass 
spectrometry 
m/z 288.0 176.2 and m/z 
293.2 181.2 for TNV 
LOD -  0.10 µmol/L 
LOQ -  0.04 µmol/L 
Observed plasma TNV 
concentrations ranged between 
0.11 and 0.76 µmol/L 
19 
3.  API and Tablet  UV 
spectroscopy 
Wavelength - 261nm. 
Solvent – 0.1N HCl 
Linearity range - 5 – 90 µg/mL 
20 
4.  Tablet Spectro-
photometry 
1st method  
 Reduction in presence of 1,10-
phenanthroline  
Wavelength – 500.2 nm.  
Linearity range -  2-10 µg/mL. 
2nd method  
 Reduction in presence of 2, 2- 
bipyridyl  
21 
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Wavelength - 511.2 nm.  
Linearity range - 5-25 µg/mL. 
3rd method – oxidation  
Wavelength - 640 nm  
Linearity range - 5-25 µg/mL. 
5.  API and tablet RP-HPLC Stationary phase - Base 
deactivated C18 column 
(Hypersil BDS 25 cm × 4.6 mm, 
5 µm) maintained at 30°C. 
Mobile phase – Acetonitrile :  
tetrabutylammonium phosphate 
buffer (pH 6) : water:  
A – (2:20:78 v/v/v)  
B – (65:20:15 v/v/v). 
Flow rate  - 1.0 mL/min 
Linearity range -  0.1µg/mL -  
0.15 mg/mL. 
22 
6.  Tablet RP-HPLC Stationary phase - Luna C18 (25 
cm × 4.6 mm, 5 µm) 
Mobile phase - 0.1% formic 
acid : acetonitrile ( 50:50 v/v) 
Flow rate - 0.8 mL/min 
Retention time: 6.718 min. 
Linearity range - 5-30 µg/mL 
Detection wavelength - 305nm. 
23 
7.  Human Plasma RP-HPLC Stationary phase - C18 (25 cm × 
4.6 mm, 5 µm) 
Mobile phase – Acetonitrile : 
Water (75:25 v/v) 
Flow rate - 1mL/min. 
Linearity range - 0.2-10 µg/mL 
Detection wavelength - 259nm. 
Internal standard - Piroxicam  
24 
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2.2.3 Reported methods for determination of Ritonavir with other drugs 
Sr. 
no. 
Matrix Method Parameters Ref. 
no. 
1.  Human 
Plasma 
(Atazanavir 
and Ritonavir) 
LC-MS/MS Stationary phase – Ascentis C18 
column (50 mm ×4.6 mm, 5 µm) 
Elution mode - Gradient 
Linearity range - 19.1 ng/mL - 
2066.3 ng/mL 
Imprecision -  < 13.8% 
Inaccuracy - ± 7.1% 
25 
2.  Solid Lipid 
Nanoparticle 
(Ketoconazole
, Ritonavir and 
Lopinavir) 
RP-LC Stationary phase - Kromasil C18 
column (250 mm × 4.5 mm, 5 
µm) 
Mobile phase – Acetonitrile : 
0.2% triethylamine (pH 6.5) 
(60:40 v/v) Detection wave 
length -  210 nm 
Flow rate - 1 mL/min. 
26 
3.  API 
(Intermediate 
of Ritonavir 
and Lopinavir) 
Chiral LC  Stationary phase - chiralcel OD-
H column (250mm × 4.6 mm, 5 
µm) 
Mobile phase - n-Hexane :  
ethanol : trifluoroacetic acid :  
triethylamine (950:50:1:1 v/v) 
Detection wave length - 210 nm 
Flow rate - 1.0 mL/min. 
27 
4.  Human 
Plasma 
(Ritonavir, 
Etravirine, and 
9 Other 
Antiretroviral 
LC-MS/MS Stationary phase: C18 HPLC 
column (Waters Sunfire 100 mm 
× 2.1 mm, 3.5 µm) 
Elution mode - Gradient  
Flow rate - 0.3 mL/min. 
Precision -  ±20% 
28 
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Agents) Accuracy – 80 – 120% 
5.  Human 
Plasma 
(Lopinavir and 
Ritonavir) 
Ultrafast 
LC-MS/MS  
Stationary phase - HT column 
(30 mm × 2.1 mm,   1.8 µm) 
Mobile phase – Acetonitrile : 
water (55:45 v/v) 
Flow rate - 0.5 mL/min. 
29 
6.  Human 
Plasma 
(with other 
HIV protease 
inhibitors) 
HPLC-MS Stationary phase - ODS3 column 
(50 mm x 2.0 mm, 5 µm) 
Mobile phase - Acetate buffer 
(pH 5) : methanol  
Elution mode - Gradient 
Flow rate - 0.5 mL/min. 
30 
7.  Soft Gelatin 
Capsule 
(Lopinavir and 
Ritonavir) 
LC-MS Stationary phase - LiChrospher 
100 RP-18 (250 mm × 4.6 mm, 5 
µm) 
Mobile phase – Acetonitrile : 
water : methanol (53:37:10 v/v/v) 
Flow rate - 1.0 mL/min. 
Detection wavelength - 210 nm. 
31 
8.  Tablet 
(Atazanavir 
sulfate and 
Ritonavir) 
Spectro-
photometry 
Solvent - Methanol 
Wavelength - 238.5 nm as λmax 
of ritonavir and 249.5 nm for 
atazanavir sulfate 
Linearity range - 10-50 µg/mL 
32 
9.  Tablet 
(Ritonavir and 
Lopinavir) 
Spectro-
photometry 
Solvent - Methanol 
Wavelength - 239 nm and 259 
nm as λmax of ritonavir and 
lopinavir respectively. 
Isoabsoptive point - 257.4 nm. 
Linearity range - 5-30 µg/mL 
33 
10.  Tablet 
(Ritonavir and 
Lopinavir) 
Spectro-
photometry 
Solvent -  Acetonitrile 
Wavelength - 239 nm and 259 
nm as λmax of ritonavir and 
34 
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lopinavir respectively. 
Simultaneous equation method 
Linearity range - 5-50 µg/mL for 
ritonavir and 20-120 µg/mL for 
lopinavir 
11.  Tablet 
(Ritonavir and 
Lopinavir) 
Spectro-
photometry 
Wavelength - 240 nm and 259 
nm as λmax of ritonavir and 
lopinavir respectively. 
Simultaneous equation method 
Solvent - Methanol 
Linearity range - 15-55 µg/mL for 
ritonavir and 10-50 µg/mL for 
lopinavir 
35 
12.  Human 
Plasma 
(16 anti -HIV 
agents) 
HPLC Stationary phase - C18 Symmetry 
column (250 mm × 4.6 mm, 5 
µm) 
Mobile phase : 0.01 M KH2PO4  
buffer : acetonitrile  
Elution mode - Gradient 
Flow rate - 1.0 mL/min 
Detection wave length - 240 nm 
36 
13.  Human 
Plasma 
(Saquinavir 
and Ritonavir) 
RP- HPLC Stationary phase - C18 column 
(150 mm ×4.6 mm, 5 µm) 
Mobile phase - Acetonitrile : 70 
mM KH2PO4 buffer (pH 5) (46:54 
v/v) 
Detection wave length - 210 nm. 
Retention time - 8.3 min. 
37 
14.  Human 
Plasma 
(nine 
antiretroviral 
agents) 
HPLC Stationary phase - C8 column. 
Mobile phase - Gradient mobile 
phase 
25 mM KH2PO4 : methanol :  
acetonitrile  
38 
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Detection wavelength -  210 nm 
LOQ -  50 ng/mL 
15.  Human 
Plasma 
(with other 
antiproteases) 
HPLC Stationary phase - Two Ph 
columns (100 mm × 4.6 mm, and 
250 mm × 4.6 mm) 
Mobile phase -  Acetonitrile : 
0.03 M disodium hydrogen 
phosphate (55:45 v/v) 
Detection wavelength - 240 nm 
Linearity range - 0.05 to 10 
µg/mL 
39 
16.  Human Serum 
(Ritonavir and 
Saquinavir) 
HPLC Stationary phase - C8 column 
after solid phase extraction with 
C18 cartridge 
Detection wavelength – 240 nm. 
Linearity range - 0.5-32 µg/mL 
40 
17.  Human 
Plasma 
(Indinavir, 
Amprenavir, 
Nelfinavir and 
its active 
metabolite 
M8, 
Saquinavir, 
Ritonavir, 
Lopinavir, 
Nevirapine 
and Efavirenz) 
HPLC Stationary phase - C18 column. 
Mobile phase -  Binary gradient 
elution with solvent A and B 
 
A - Acetonitrile : 0.025M tetra 
methyl ammonium perchlorate 
(55:45 v/v) 
 
B - Methanol : 0.025M tetra 
methyl ammonium perchlorate 
(55:45 v/v) 
Detection wavelength - 259 nm, 
LOQ - 0.10 mg/L 
41 
18.  Human 
Plasma 
(Indinavir, 
Ritonavir and 
HPLC  Stationary phase - Stainless 
steel column packed with 5 µm 
Phenomenex phenyl hexyl 
material operated at 40 0C 
42 
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Lopinavir ) Mobile phase – Acetonitrile : 10 
mM Potassium phosphate buffer 
(50:50 v/v). 
LOQ - 100 µg/mL 
 
19.  Tablet 
(Lopinavir and 
Ritonavir) 
HPTLC Stationary phase - Aluminium 
backed silica gel 60F254 HPTLC 
plate 
Mobile phase - Ethyl acetate : 
ethanol : toluene: diethylamine 
(7:2.0:0.5:0.5 v//v/v/v) 
Detection wavelength - 266 nm 
Linearity range - 2-10 µg/mL 
43 
20.  Capsule  
(Lopinavir and 
Ritonavir) 
HPTLC Stationary phase - Aluminium 
backed silica gel 60F254 HPTLC 
plate 
Mobile phase – Toluene : ethyl 
acetate : methanol : ammonia 
 ( 6.5:2.5:0.5:0.5 v/v/v/v) 
LOD - 1.5 ng/spot and 4.6 
ng/spot 
LOQ – 21.00 ng/spot and 5.10 
ng/spot for lopinavir and ritonavir 
respectively 
Linearity range - 6.5 - 20.00 µg 
/spot and 1.5 - 5.00 µg /spot for 
lopinavir and ritonavir 
respectively 
44 
21.  Capsule  
(Lopinavir and 
Ritonavir) 
HPTLC Stationary phase – Aluminum 
backed silica gel 60F254 HPTLC 
plate 
Mobile phase – Toluene : ethyl 
acetate : methanol : glacial 
45 
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acetic acid (7.0:2.0:0.5:0.5 
v/v/v/v) 
Linearity range - 6.67-20.00 and 
1.6- 5.00 µg/spot for lopinavir 
and ritonavir, respectively 
LOQ – 7.00 ng/spot and 21.00 
ng/spot for lopinavir and ritonavir 
respectively 
Detection wavelength – 263 nm 
22.  Human 
Plasma 
(Indinavir, 
Amprenavir, 
Saquinavir, 
Ritonavir, 
Nelfinavir and 
Efavirenz) 
HPLC Stationary phase – Nucleosil 
(100 mm x 4.6 mm, 5 µm) C18 
AB column 
Mobile phase - Acetonitrile :  
phosphate buffer ( pH 5.15) 
Elution mode - Gradient 
Detection wavelength - 201 nm 
Retention time: 26.5 min for 
ritonavir 
Internal standard - Clozapine 
46 
23.  Human 
Plasma 
(Indinavir, 
Amprenavir, 
Saquinavir, 
Ritonavir  and 
Nelfinavir) 
RP-HPLC Stationary phase - Narrowbore 
C18 column  
Gradient elution 
Detection wavelength - Dual 
detection at 265 and 210 nm 
Linearity range - 25-10000 
ng/mL 
47 
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2.2.4 Reported methods for determination of Ritonavir 
Sr. 
No 
Matrix Method Parameter Ref
No. 
1.  API and tablet  RP-HPLC  Stationary phase - HiQSil C18 
column (25 cm × 4.60 mm,  5 µm) 
Mobile phase – Methanol :  
acetonitrile : water ( 87:10:3 v/v/v) 
Detection wavelength - 240 nm 
retention time : 3.6 min. 
Flow rate : 1.0 mL/min. 
Linearity range - 25-200 µg/mL 
48 
2.  API LC-MS/MS  Stationary phase - Waters XTerra 
C18 column (250 mm × 4.6 mm, 5 
µm) 
Mobile phase – Water : methanol : 
acetonitrile (40:20:40 v/v/v) 
49 
3.  Capsule Spectro-
photometry 
Method – 2nd derivative 
spectroscopy 
Wavelength - 222.3 nm 
Solvent - Methanol  
Linearity range - 10.0-30.0 µg/mL 
Correlation coefficient – 0.9995 
50 
4.  API and tablet HPLC Stationary phase - Hypersil BDS 
C18 column (25 cm × 4.6 mm, 5 
µm),  
Mobile phase – Acetonitrile :  
phosphate buffer (pH 4.0) : water, 
gradient mobile phase 
Detection wavelength - 240 nm 
51 
5.  Soft Gelatin 
Capsule 
LC- MS Stationary phase – Reverse phase 
C8 (125mm × 4.0 mm , 5 µm) 
Mobile phase - Methanol : water 
52 
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(67:33 v/v) 
Detection wavelength - 210 nm 
Linearity range - 100-300 µg/mL 
6.  Tablet Spectro- 
photometry 
Wavelength - 510 nm 
Linearity range -  20-100 µg/mL 
Reagent for chemical derivatization 
-  Methanol and ferric chloride 
53 
7.  API and tablet RP-HPLC 
and HPTLC  
HPLC Method 
Stationary phase - Eclipse XBD C18 
RP column (150mm x 4.6mm, 
15µm) 
Mobile phase – Acetonitrile : water 
(60:40 v/v) 
Detection wavelength - 209 nm 
Flow rate - 1.4mL/min. 
HPTLC Method 
Stationary phase - Aluminum 
backed silica gel 60F254 HPTLC 
plate 
Mobile phase – Toluene : ethyl 
acetate : methanol : glacial acetic 
acid) (7.0:2.0:0.5:0.5 v/v/v/v) 
Detection wavelength - 263 nm 
54 
 
 
 
 
 
 
 
 
CHAPTER 2                                                                  LITERATURE REVIEW 
 
40 
 
2.2.5 Reported methods for determination of Efavirenz with other drugs 
Sr. 
No. 
Matrix Method Parameter Ref
No. 
1.  Tablet 
(Zidovudine, 
Lamivudine 
and Efavirenz) 
RP-HPLC-
DAD 
Stationary phase - Phenomenex 
C18 column (250 mm × 4.6 mm, 
5μm)  
Mobile phase - Binary gradient 
acetonitrile : water  
Detection wave length - 248nm 
Linearity range - 40μg/mL 
55 
2.  API and tablet 
(Saquinavir 
mesylate and 
Efavirenz) 
Spectro- 
photometry 
Wavelength - 239 and 247 nm for 
saquinavir mesylate and efavirenz 
respectively 
Solvent - Methanol 
Linearity range - 1.25-10 µg/mL for 
saquinavir mesylate and 2.5-12.5 
µg/mL for efavirenz  
56 
3.  Human 
Plasma 
(Six HIV 
protease 
inhibitors and 
two non-
nucleoside 
reverse 
transcriptase 
inhibitors) 
HPLC Method for extraction – Liquid-
liquid extraction with diethyl ether 
Stationary phase – RP C18 column, 
Mobile phase - Acetonitrile : 50 mM 
phosphate buffer (pH 5.65) 
gradient mobile phase 
Detection wavelength - 240 nm 
Linearity range - 100-10000 ng/mL 
LOQ – 50 ng/mL 
57 
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2.2.6 Reported methods for determination of Efavirenz 
Sr. 
No 
Matrix Method Parameter Ref
.No 
1.  Tablet  RP-HPLC Stationary phase - Hypersil BDS 
C18 (250 mm × 4.6 mm, 5µm) 
column 
Mobile phase – Acetonitrile : 0.03M 
KH2PO4 buffer (pH 3.2) (60:40 v/v)  
Flow rate -  0.8mL/min 
Detection wavelength -  260 nm 
Retention time - 10.549 min 
Linearity range - 12-144 μg/mL, 
LOD -  0.12 µg/mL, 
LOQ -  0.36 µg/mL 
58 
2.  Tablet  RP-HPLC Stationary phase - C18 (250 mm × 
3.9 mm, 10 µm) column 
Mobile phase – Acetonitrile :  water 
: orthophosphoric acid (70:30:0.1 
v/v/v) 
Detection wavelength -  252 nm 
59 
3.  API and tablet RP-HPLC Stationary phase - Sunfire C18 (250 
mm × 4.6 mm, 5µm) column 
Mobile phase - Methanol : 
acetonitrile (7:3 v/v) 
Detection wavelength - 249 nm 
Linearity range -  10-40μg/mL 
60 
4.  Saliva LC-MS/MS Stationary phase -  Phenomenex 
Kinetex C18 (150 mm × 3 mm, 2.6 
µm) column 
Mobile phase – Gradient elution 
with increasing the proportion of 
methanol 
61 
CHAPTER 2                                                                  LITERATURE REVIEW 
 
42 
 
Flow rate -  0.4 mL/min., 
Retention time -  6.5 min 
Linearity range -  3.125-100 µg/L 
LOD -  1.84 µg/L 
LOQ -  6.11µg/L, 
Ionization mode: electrospray 
positive ionization 
5.  API HPLC   Stationary phase - Chiralpak-IA, 
Detection wavelength -  252 nm 
Flow rate -  2.5 mL/min, 
Resolution -   > 4.0 
Correlation coefficient -  0.9999 
62 
6.  API HPLC Stationary phase: Chiralcel OD 
(250 mm × 4.6 mm, 10 µm) column 
containing tris- (3,5-dimethyl 
phenyl carbomate). 
Mobile phase - n-Hexane :  iso 
propyl alcohol (80:20 v/v) 
Detection wavelength -  254 nm 
Flow rate -  1.0 mL/min. 
Linearity range -  0.1- 6 µg/mL 
LOD -  0.03 µg/mL 
LOQ -  0.1 µg/mL 
63 
7.  API and tablet Spectro-
photometry 
Wavelength -  245 nm 
Solvent – Methanol : water (80:20) 
Linearity range -  5 - 50µg/mL. 
64 
8.  API and tablet Spectro-
photometry 
Wavelength -  247 nm 
Solvent -  Sodium lauryl sulfate 
(SLS) (1%w/v). 
65 
9.  API and 
capsule  
Spectro-
photometry 
Wavelength -  247nm for normal 
UV spectroscopy and 258 nm for 
first order derivative spectroscopy 
Solvent -  Acetonitrile, 
66 
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Linearity range -  4-24 µg/mL 
10.  API and tablet HPTLC Stationary phase - Aluminum plate 
precoated with silica gel 60 F254 
Mobile phase – Dichloromethane : 
methanol (5:0.3 v/v) 
Detection wavelength -  247 nm 
Linearity range -  400-2000 ng/spot 
Rf value -  0.72 ± 0.03 
67 
11.  API and tablet HPLC Stationary phase - Novak ph 
column 
Mobile phase -   Phosphate buffer : 
acetonitrile ( 50:50 v/v) 
Detection wavelength -  247 nm 
Linearity range -  0.05-0.15 mg/mL 
68 
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2.2.7 Reported methods for determination of Lopinavir with other drugs  
Sr. 
No. 
Matrix Method Parameter Ref. 
No. 
1.  Human 
Plasma 
(HIV non-
nucleoside 
reverse 
transcriptase 
inhibitors and 
protease 
inhibitors) 
UPLC Stationary phase - Acquity UPLC 
BEH C18 (150 mm × 2.1 mm,  1.7 
µm) column 
Mobile phase - Acetonitrile :  5mM 
trimethyl ammonium phosphate 
buffer (pH 3.0) in gradient mode 
Run time -  9.5 min. 
Linearity range –  0.1 -10 µg/mL 
Accuracy –  94.9 - 103.5% 
LOQ – 0.1µg/mL 
69 
2.  Tablet 
(Lopinavir and 
Ritonavir) 
RP-HPLC Stationary phase -  Phenomenex 
Gemini C18 (250 mm × 4.6 mm, 5 
µm) column 
Mobile phase  -  
Potassium dihydrogen phosphate 
buffer (pH 6.0 ± 0.1) : acetonitrile : 
methanol (50:35:15 v/v/v) 
Flow rate -  1.0 mL/min 
Detection wavelength -  254 nm 
Retention time -  6 min for lopinavir 
and 3.7 min for ritonavir 
70 
3.  Plasma 
 
HPLC-
MS/MS 
 
Internal standard: Quinoxaline 
Stationary phase - RP C18 (250 
mm × 4.6 mm, 5 µm) column 
Mobile phase - Acetonitrile : 0.05% 
formic acid in gradient mode 
Detection - Via selective reaction 
monitoring (SRM) on a triple-
quadrupole mass spectrometer 
71 
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Run time - 5 min. 
Correlation coefficient -  0.998 
4.  Syrup 
(Lopinavir and 
Ritonavir) 
HPLC Stationary phase -  RP C18 (250 
mm × 4.6 mm, 5 µm) column 
Mobile phase - 10 mM ammonium 
acetate buffer (pH 7) : acetonitrile 
(50:50 v/v) 
Flow rate - 1mL/min 
Detection wavelength -  245 nm 
Retention time - 14.7 min. and 
12.4 min. for lopinavir and ritonavir 
respectively. 
Correlation coefficient -  0.999 
72 
5.  Dry plasma 
spot 
(Nine anti-HIV 
drugs) 
HPLC-MS Internal standard - Quinoxaline 
Extraction - With 4 mL tert-butyl 
methyl ether (TBME) and 500 µL  
ammonia (15%) 
Supernatant dissolved in water :  
acetonitrile (60:40 v/v) 
Stationary phase –  Atlantis T3 
(150 mm x 2.1 mm, 3µm) column 
Mobile phase -  Water (0.05% 
formic Acid) : acetonitrile (0.05% 
formic acid) in gradient mode 
Detection - By ESI single 
quadrupole mass spectrometry 
73 
6.  Human 
Plasma 
(Lopinavir and 
Ritonavir) 
UPLC-ESI-
MS/MS 
 
Extraction- Solid phase by using 
Waters Oasis HLB cartridge 
Stationary phase – Waters acquity 
UPLC BEH C18 (50 mm × 2.1 mm, 
1.7 µm) column 
Mobile phase - 10 mM ammonium 
formate (pH 4.0) : methanol (10:90 
74 
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v/v) 
Run time - 1.2 min. 
Detection – By triple quadrupole 
mass spectrometer 
Linearity range -  29.6-14379 
ng/mL 
7.  Human 
Plasma 
(Raltegravir, 
Lopinavir and 
11 Other 
Antiretroviral 
Agents) 
HPLC -
PDA 
Internal standard - Quinoxaline 
Stationary phase -  RP C18 (150 
mm × 2.0 mm, 5 µm) column 
Mobile phase - Acetonitrile : 
phosphate buffer in gradient mode 
Run time -  28 min 
Correlation coefficient -  0.998 
75 
8.  Dried Blood 
Spot 
(Protease 
inhibitors and 
non-
nucleoside 
reverse 
transcriptase 
inhibitors) 
HPLC –MS 
 
Stationary phase -  RP C18 (150 
mm × 2.0 mm, 5 µm) column 
Mobile phase -  Acetonitrile,:  
methanol : 0.2M zinc sulphate in 
water (1:1:2 v/v/v) 
Run time -  10 min 
Detection - Triple quadrupole 
mass spectrometry 
Linearity range   0.1 – 20 mg/mL 
76 
9.  Human 
Plasma 
(Lopinavir, 
Darunavir, and 
10 other 
antiretroviral 
agents) 
HPLC-MS Internal standard - Quinoxaline 
Stationary phase -  RP C18 (150 
mm × 2.1 mm, 5 µm) column 
Mobile phase - Acetonitrile : water 
with 0.05% formic acid in gradient 
mode 
Run time -  25 min 
Detection – Mass spectrometry 
77 
10.  Human 
Plasma 
(HIV protease 
LC-MS Stationary phase -  RP C18 (150 
mm × 2.1 mm, 5 µm) column 
Mobile phase - Acetate buffer (pH 
78 
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inhibitors and 
non-
nucleoside 
reverse 
transcriptase 
inhibitors) 
5) : Methanol in gradient mode 
Flow rate - 0.25mL/min 
Run time -  10 min 
Detection - Triple quadrupole 
mass spectrometry 
Linearity range -   0.1 to 20 µg/mL 
11.  Peripheral 
blood 
mononuclear 
cells and 
human plasma 
(Lopinavir and 
Ritonavir) 
LC/MS/MS 
 
Extraction method – Liquid - liquid 
extraction 
Internal standard -  2H5-saquinavir 
Stationary phase – Phenomenex 
Jupiter Proteo C12 90A (100 mm × 
2mm, 4µm) column 
Mobile phase - Acetonitrile : 20 
mM ammonium acetate buffer : 
aqueous acetic acid (55:45:0.1 v/v) 
Run time – 6 min. 
Detection – Electrospray tandem 
mass spectrometry 
LOQ - 4.0 ng/mL in plasma, 0.2 
ng/mL in ultrafiltrate and 0.1 
ng/cell pellet  in PBMCs 
79 
12.  Human 
Plasma 
(Non-
nucleoside 
reverse 
transcriptase 
inhibitor and 
Protease 
inhibitor)  
HPLC Stationary phase -  S-3 (150 mm × 
2.1 mm, 5 µm) column  
 
Mobile phase – 
 25 mM potassium phosphate (pH 
4.9) : acetonitrile (52:48 v/v) 
 
Detection -  212 nm 
Accuracy -  91.0 - 112.8% 
80 
13.  Human 
Plasma 
(Amprenavir, 
HPLC with 
UV and 
fluorimetric 
Stationary phase - Allsphere hexyl 
(150 mm × 4.6 mm, 5 µm) column  
Extraction method - Liquid liquid 
81 
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Indinavir, 
Atazanavir, 
Ritonavir, 
Lopinavir, 
Saquinavir, 
Nelfinavir, and 
M8-Nelfinavir 
metabolite) 
detection extraction with Hexane from 
buffered samples with borate 
buffer pH 9.0 
Mobile phase – Acetonitrile : 
methanol : 15 mM sodium 
dihydrogen phosphate buffer (pH 
4.5) (35:20:45 v/v/v) 
Flow rate – 1.0 mL/min. 
Detection wavelength – 215 nm in 
UV and 280 and 340 nm in 
fluorimetry as excitation and 
emission wavelengths respectively 
Linearity range - 0.025–10 mg/L 
14.  Human 
Plasma 
(Lopinavir and 
Nevirapine) 
HPLC after 
solid 
phase 
extraction 
Internal standard - Clozapine 
Extraction - Solid-phase extraction 
on a solid phase cartridge 
Stationary phase – Nucleosil (100 
mm, 5 µm) column 
Mobile phase - Acetonitrile : 
phosphate buffer (pH 5.07) :  
0.02% sodium heptane sulfonate 
in gradient elution mode 
Detection wavelength -  201 and 
282 nm 
82 
15.  Human 
Plasma 
(Indinavir, 
Amprenavir, 
Ritonavir, 
Lopinavir, 
Saquinavir, 
Nelfinavir and 
the Nelfinavir 
HPLC Stationary phase – Nova-Pak C18 
(150 mm × 3.9 mm, 5 µm) column  
Mobile phase –  Acetonitrile : 5mM 
sodium dihydrogen phosphate 
buffer (pH 6.0) containing 
triethylamine 
Detection wavelength -  210 and 
239 nm 
Linear range: 25–5000 ng /mL 
83 
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active 
metabolite M8) 
 
 
 
 
16.  Human 
Plasma 
(HIV protease 
inhibitors and 
non-
nucleoside 
reverse 
transcriptase 
inhibitors) 
HPLC Stationary phase – Zorbax C18 
(150 mm × 4.6 mm, 3.5 µm) 
column  
Mobile phase  – 50 mM phosphate 
monobasic buffer  (pH 4.5) : 
methanol : acetonitrile with TFA 
(25:15:60 v/v/v)  
Flow rate -  0.9-1.1 mL/min 
Run time - 30 min 
Linearity range - 25–5000 ng/mL 
84 
17.  Human 
Plasma 
(16 anti-HIV 
drugs) 
HPLC Stationary phase – Symmetry C18 
(250 mm × 4.6 mm, 5 µm) column 
Mobile phase -  0.01 M KH2PO4 : 
acetonitrile in gradient mode 
Detection wavelength - 240 and 
260 nm 
Flow rate - 1 mL/min 
Run time - 35 min 
85 
18.  API and tablet 
(Lopinavir, 
Ritonavir and 
Efavirenz) 
HPLC Stationary phase – RP C18 (250 
mm × 4.6 mm, 5 µm) column 
Mobile phase – Acetonitrile :  
methanol : tetramethyl ammonium 
perchlorate (TMAP) in dilute 
aqueous trifluoroacetic acid (45:5: 
50 v/v/v) 
Column temperature -  30ºC 
86 
19.  Tablet 
(Lopinavir and 
Ritonavir) 
RP-HPLC Stationary phase– RP 
phenomenex - luna C18 (250 mm × 
4.6 mm, 5 µm) column 
Mobile phase - Acetonitrile :  
87 
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triethylamine  (67:33 v/v) 
Internal standard - Ambroxol 
LOD -  30 ng/mL 
Recovery - 99.9% 
20.  API 
(Lopinavir) 
MALDI –
TOF mass 
spectro-
metry 
Matrix – Meso tetrakis (pentafluoro 
phenyl) porphyrin 
Spotting technique - Brushing with 
prestructured target plates 
Samples cleaning - By solid-phase 
extraction plate  
Samples spotting - By a pipetting 
robot 
88 
21.  Human 
Plasma 
(Six HIV 
protease 
inhibitors, one 
metabolite, 
and two non-
nucleoside 
reverse 
transcriptase 
inhibitors) 
RP-HPLC Extraction method -  Liquid - liquid 
extraction by diethyl ether From 
250 µL plasma samples 
Stationary phase – X-TERRA 
column 
Mobile phase – Water (with 3 mM 
pyrolidine) : acetonitrile (58:42 v/v)  
Detection - UV detection with 
diode array detector 
Linearity range -  25 ng/mL - 9000 
ng/mL 
89 
22.  Human 
Plasma 
(Amprenavir, 
Indinavir, 
Lopinavir, 
Nelfinavir,  M8 
Nelfinavir 
metabolite, 
Ritonavir, 
Efavirenz,  
Column 
liquid 
chromato-
graphy 
Extraction method – Solid phase 
extraction  
Stationary phase – Novapak RP 
C18  (150 mm × 2.1 mm,  4 µm) 
column 
Mobile phase A - Buffer (pH 5) : 
acetonitrile : methanol 
(42.5:28:29.5 v/v/v) over first 32 
min. and 22 min after mobile 
phase B 
90 
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and 
Saquinavir) 
(Buffer consisted of 0.5% 5.8M 
orthophosphoric acid and 0.02% 
triethylamine adjusted at pH 5.0 
with 10 mol sodium hydroxide 
Mobile phase B – Acetonitrile : 
water (75:25 v/v) for 38 min. 
Flow rate – 0.45 mL/min. 
Detection wavelength – Dual 
detection at 265 nm and 210 nm 
Linearity range -  25 - 5,000 ng/mL 
23.  Human 
Plasma 
(Lopinavir , 
Indinavir, 
Amprenavir, 
Saquinavir, 
Ritonavir  and 
Nelfinavir) 
HPLC Extraction - With 500µl 0.1M 
ammonium hydroxide solution and       
5 mL tertiary butyl ether 
Stationary phase – C18 (250 mm x 
4.6 mm, 5µm) column 
Mobile phase - 50 mM phosphate 
buffer (pH 5.40) : acetonitrile 
(50:50 v/v) 
Detection wavelength -  215 nm 
91 
24.  Peripheral 
blood 
mononuclear 
cells 
(Fourteen 
antiretroviral 
agents) 
HPLC-MS Internal standard - Quinoxaline 
Extraction - With methanol : water 
(70:30 v/v) 
Supernatant dissolved in water :  
acetonitrile (60:40 v/v) 
Stationary phase –  Atlantis T3 
(150 mm x 2.1 mm, 3µm) column 
Mobile phase -  Water (0.05% 
formic Acid) : acetonitrile (0.05% 
formic acid) in gradient mode 
Detection - By ESI single 
quadrupole mass spectrometry 
Linearity range - 0.1 to 32 ng/mL 
92 
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25.  Peripheral 
blood 
mononuclear 
cells 
(10 anti-
retrovirals) 
LC-MS/MS Extraction - With methanol : water 
(60:40 v/v) 
Stationary phase – Symmetry 
Shield RP 18 (50 mm x 2.1 mm) 
column 
Eluent composition 
A – 10 mM ammonium acetate : 
10 mM formic acid (50:50 v/v) 
B -  Acetonitrile : 10 mM formic 
acid (50:50 v/v) 
Mobile phase –  A : B (95:5 v/v) 
from 0 – 2 min.  
Linear gradient elution upto A : B 
(10:90 v/v) at 12 min. 
Detection - Electro spray positive 
ionization 
Linearity range - 0.25-125 ng/mL 
Correlation coefficient -  > 0.99 
93 
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2.2.8  Reported methods for determination of Lopinavir  
Sr. 
No 
Matrix Method Parameter Ref. 
No. 
1.  Tablet Spectro-
photometry 
 
1st derivative spectroscopy 
Wavelength - 220 nm 
Solvent - Methanol 
Linearity range -  5 – 35 µg/mL  
LOD - 0.844 µg/mL 
LOQ - 2.558 µg/mL 
94 
2.  API and tablet RP-HPLC Stationary phase –  Zorbax SB 
C18 5 µm column 
Mobile phase - Phosphate buffer 
(pH 4.0 ): acetonitrile (55:45 v/v) 
Flow rate - 1.5 mL /min 
Detection wavelength -  210 nm 
95 
3.  API HPLC  Stationary phase – YMC Pack 
ODS-AQ column 
Mobile phase - 0.02 M KH2PO4 
(pH 2.5) : acetonitrile in gradient 
mode 
Temperature -  450C 
Detection wavelength -  210 nm 
LOD - 0.028 µg/mL - 0.063 µg/mL 
LOQ - 0.084 µg/mL - 0.192 µg/mL 
96 
4.  Cerebo spinal 
fluid and 
plasma 
LC-MS Stationary phase – Waters 
Symmetry C18  (250 mm × 4.6 
mm, 5 µm) column  
Mobile phase – 5 mM ammonium 
acetate buffer (pH 3.5) : 
acetonitrile (95:5 v/v) 
Linearity range -  0.313-25.0 
ng/mL 
97 
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Detection - By triple quadrupole 
mass spectrometer 
5.  API and tablet HPLC Stationary phase – C8 column 
Mobile phase - 50 mM potassium 
phosphate buffer : acetonitrile : 
methanol (40:50:10 v/v/v) 
Flow rate - 1 mL/min 
Detection wavelength -  210 nm 
98 
6.  Human 
Plasma 
HPLC  Extraction – Liquid solid 
extraction on OASIS HLB column 
Stationary phase – Xterra, C8 
(150mm x 3.9 mm) column 
Mobile phase – acetonitrile : 
water (41:59 v/v) 
Detection wavelength -  210 nm 
Linearity range - 0.187-10.0 µg/ 
mL 
LOQ -  0.187 µg/mL 
99 
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3. AIM OF PRESENT WORK 
Most of the antiviral agents are used in HIV, herpes, hepatitis B and C and 
influenza A and B viruses.  
 
Objective of the present work: 
All the manufacturing industries are using sophisticated instruments like 
HPLC, HPTLC and LC-MS; hence the aim of the present work was to develop 
and validate sensitive and selective methods for the determination of novel 
antiretroviral agents in bulk and their pharmaceutical formulations. Literature 
review reveals that very few methods are reported for estimation of Lopinavir, 
Ritonavir, Efavirenz and Tenofovir disoproxil fumarate. Therefore it was 
thought of interest to develop and validate stability indicating RP-HPLC, 
HPTLC and UV spectroscopic methods for determination of selected drugs in 
bulk, their dosage forms and biological fluid. 
 
Specific aim of the present work: 
 
? To develop and validate stability indicating reverse phase high 
performance liquid chromatographic method for estimation of Efavirenz 
and Tenofovir disoproxil fumarate.  
 
? To develop and validate reverse phase high performance liquid 
chromatographic method for estimation of Lopinavir and Ritonavir in 
bulk and their combined tablet dosage form. 
 
? To apply the developed RP-HPLC methods for determination of 
Efavirenz, Tenofovir disoproxil fumarate, Lopinavir and Ritonavir in 
plasma and to validate the developed RP-HPLC methods for 
determination of selected drugs in plasma.  
 
? To develop and validate high performance thin layer chromatographic 
(HPTLC) methods for estimation of Tenofovir disoproxil fumarate,  
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Efavirenz, Lopinavir and Ritonavir in bulk and their combined tablet 
dosage form.  
 
? To develop and validate difference and derivative UV 
Spectrophotometric  methods for the estimation of Efavirenz, Tenofovir 
disoproxil fumarate and Ritonavir in bulk and tablet dosage form. 
 
? Statistical comparision of the developed methods by applying F-test 
(ANOVA) and paired t-test.  
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4. STABILITY INDICATING RP-HPLC METHODS FOR 
DETERMINATION OF ANTIRETROVIRAL AGENTS  
4.1. STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION 
OF EFAVIRENZ  
 
4.1.1 EXPERIMENTAL: 
4.1.1.1 Instrumentation 
 A Perkin Elmer (USA) HPLC system (series 200) equipped with Perkin 
Elmer series 200 pump  system having back pressure 5000 psi, 
manual injector of 20 µL loop, UV-Visible detector and Brownlee C18 
column (250 mm x 4.6 mm i.d., 5 µm) 
 BP211D,Sartorious Gottingen AG (Germany),  analytical balance 
 An ultra-sonic cleaner (TEC-4, Roop Telesonic Ultrasonix) 
 A Shimadzu model 1800 double beam UV/Vis. spectrophotometer with 
a pair of 10 mm matched quartz cells 
 
4.1.1.2 Reagents and Materials 
 Efavirenz (EFV) was kindly gifted by Aurobindo Pharmaceuticals Ltd., 
Hyderabad, India. 
 Acetonotrile and water HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Tablets (ESTIVA 600®, Genix Pharma) containing efavirenz (600 mg) 
were purchased from local market. 
 Nylon membrane filter 0.45 μm (Gelman laboratory, Mumbai, India)  
 Hydrogen peroxide, sodium hydroxide and hydrochloric acid (36%) AR 
grade (Finar Chemicals Pvt. Ltd, Ahmedabad, India)  
 Ammonium acetate crystalline pure (E. Merck, Mumbai, India) 
 
4.1.1.3 Chromatographic Conditions 
The chromatographic separation was achieved on Brownlee C18 column, 
using mobile phase comprised of acetonitrile : 10mM ammonium acetate 
buffer (pH 6.5 ± 0.05) (80:20 v/v), at a flow rate of 1.0 mL/min. The mobile 
phase was filtered through nylon 0.45 µm membrane filter and was degassed 
before use. The determination was carried out at 254 nm wavelength by UV-
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Visible detector. The injection volume was 20 µL and total run time was 10 
min. The analysis was performed at 25 ± 2 0C temperatures. 
 
4.1.1.4 Preparation of the Mobile Phase 
The mobile phase was prepared by mixing 80 mL acetonitrile and 20 mL 
10mM ammonium acetate buffer (pH 6.5 ± 0.05) previously filtered through 
0.45 µm nylon membrane filter. The mobile phase was degassed for 15 
minutes by sonicating the solution before use. 
 
4.1.1.5 Preparation of standard solution 
Accurately weighed EFV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with acetonitrile to obtain a standard stock 
solution (1 mg/mL).  
 
4.1.1.5A Preparation of working standard solution (10 µg/mL) 
Standard solution (0.1 mL) was transferred in a 10 mL volumetric flask and 
diluted up to the mark with mobile phase. 
 
4.1.1.5B  Preparation of hydrochloric acid (0.1N) 
Accurately transferred 0.85 mL concentrated hydrochloric acid (36%) to 100 
mL volumetric flask and diluted up to the mark with distilled water.  
 
4.1.1.5C  Preparation of sodium hydroxide (0.1N) 
Accurately weighed and transferred 0.4 gm sodium hydroxide to 100 mL 
volumetric flask, dissolved in 60 mL distilled water and diluted up to the mark 
with distilled water.  
 
4.1.1.6 Selection of Wavelength for Determination 
The working standard solution of EFV (10 µg/mL) was scanned in the range of 
200-400 nm using mobile phase as blank. Maximum absorbance was 
observed at 254 nm which was selected for the determination. 
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4.1.1.7 Analysis of Tablet Dosage Form 
Twenty tablets were weighed and average weight was calculated. The tablets 
were finely powdered; a quantity of powder equivalent to 25 mg EFV was 
weighed accurately and transferred to a 25 mL volumetric flask containing 15 
mL acetonitrile, and sonicated for 15 minutes. Allowed to stand at room 
temperature for 5 min and the volume was made up to the mark with 
acetonitrile to obtain the sample stock solution (1 mg/mL). The solution was 
filtered through 0.45 μm membrane filter. Aliquot (1 mL) was taken and 
transferred to 10 mL volumetric flask and volume was made up to the mark 
with acetonitrile to give a solution containing 100 µg/ml EFV. The solution (2 
mL) was transferred to 10 mL volumetric flask and diluted up to the mark with 
mobile phase to give a solution containing 20 µg/mL EFV. An aliquot (20 µL) 
was injected and the chromatogram was recorded. The peak area was noted 
and the amount of EFV was calculated from the regression equation. 
 
4.1.1.8 FORCED DEGRADATION STUDY 
EFV was subjected to various forced degradation conditions to effect partial 
degradation of the drug preferably in 20-80% range. The study provides 
information about the conditions in which the drug is unstable so that 
measures can be taken during formulation to avoid potential instabilities. 
 
4.1.1.8.1 Effect of Acid, Alkaline and Neutral Hydrolysis 
Accurately weighed EFV (10 mg) was transferred to three different 50 mL 
volumetric flasks and dissolved in acetonitrile (10 mL). Hydrochloric acid 
(0.1N, 5 mL), sodium hydroxide (0.1N, 5 mL) and water (5 mL) were added to 
separate flasks containing drug samples and mixed properly for acidic, 
alkaline and neutral degradation respectively and stored at room temperature 
for 72 h.  
The samples were neutralized with base or acid as appropriate and diluted up 
to the marks with acetonitrile to obtain stock solutions (200 µg/mL). Dilutions 
were made with mobile phase to obtain the degraded EFV solutions (25 
µg/mL). 
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4.1.1.8.2 Effect of Oxidation 
Accurately weighed EFV (10 mg) was transferred to a 50 mL volumetric flask 
and dissolved in acetonitrile (10 mL). Hydrogen peroxide solution (3%, 5 mL) 
was added, mixed properly, and stored at room temperature for 72 h. The 
sample was diluted up to the mark with acetonitrile to obtain stock solution 
(200 µg/mL). Dilution was made with mobile phase to obtain the degraded 
EFV solution (25 µg/mL). 
 
4.1.1.8.3 Effect of Heat 
 EFV (10 mg)  was distributed over a glass plate and kept in an oven at 60°C 
for 72 h, then EFV was transferred in a 50 mL volumetric flask and dilutions 
were made with mobile phase to obtain the degraded EFV solution (25 
µg/mL). 
 
4.1.1.8.4 Effect of Light 
EFV solution (prepared by dissolving 10 mg EFV in 10 mL acetonitrile in 50 
mL volumetric flask) was exposed to sun light for 48 h, while EFV (10 mg) in 
powder state was exposed to UV light for 48 h. After exposure, dilutions were 
made to obtain the degraded EFV solutions (25 µg/mL). Aliquots (20 µL) of 
the stressed samples were injected into the HPLC system as described under 
chromatographic conditions (4.1.1.3), and the chromatograms were recorded. 
 
4.1.1.9 METHOD VALIDATION 
As per the ICH guideline Q2 (R1), the method validation parameters like 
specificity, linearity, accuracy, precision, limit of detection, limit of quantitation 
and robustness were studied. 
 
4.1.1.9.1 Solution Stability 
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentage of initial time period was compared with these 
two time periods. The change in the assay percentage was calculated. The 
difference between assay results should not be more than 2 % for formulation, 
and 0.5% for API. 
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4.1.1.9.2 Specificity 
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in presence of component that may be expected to 
be present in the sample matrix. Chromatograms of EFV solutions and 
degraded samples were studied in order to provide an indication of the 
stability indicating properties and specificity of the method. The stress 
conditions employed were acidic, alkaline, neutral, oxidative, thermal and 
photolytic, the degraded samples were analyzed against freshly prepared 
sample solutions using UV-visible detector. Specific conditions are described 
in 4.1.1.8. 
 
4.1.1.9.3 Linearity (Calibration Curve) 
Standard solutions (0.05, 0.1, 0.15, 0.2, 0.25 and 0.3 mL equivalent to 5.0, 
10.0, 15.0, 20.0, 25.0 and 30.0 µg/mL of  EFV) were transferred in a series of 
10 mL volumetric flasks and diluted to the mark with mobile phase. An aliquot 
(20 µL) of each solution was injected under the operating chromatographic 
conditions as described earlier. Calibration curve was constructed by plotting 
peak areas versus concentrations, and the regression equation was 
calculated. Each response was average of three determinations. 
 
4.1.1.9.4 Accuracy (% Recovery) 
Accuracy of the method was determined by calculating percentage recovery 
of EFV by the standard addition method. Known amount of standard solutions 
of EFV (0, 5, 10 and 15 µg/mL) were added to a pre-analyzed sample solution 
of EFV (10 µg/mL). Each solution was injected in triplicate and the percentage 
recovery was calculated by measuring the peak areas and fitting these values 
into the regression equation of the calibration curve. 
 
4.1.1.9.5 Precision 
Repeatability was checked by repeatedly (n = 6) injecting EFV solution (10 
µg/mL) and recording the chromatogram. Intra-day and inter-day precisions of 
the developed method was determined by measuring the corresponding 
responses 3 times on the same day and on 3 different days over a period of 1 
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week for 3 different concentration of  EFV (10.0, 20.0 and 30.0 µg/mL). The 
results were reported in terms of relative standard deviation. 
 
4.1.1.9.6 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
4.1.1.9.7 Robustness 
Robustness was studied by analyzing the samples of EFV by deliberate 
variation in the method parameters. The change in the response of EFV was 
noted. Robustness of the method was studied by changing the extraction time 
of EFV from tablet dosage form by ± 2 min, composition of mobile phase by ± 
2% of organic solvent, wavelength by ± 2 nm, flow rate by ± 0.2 mL/min and 
column oven temperature by ± 2ºC. The changes in the response of EFV 
were noted and compared with the original one. 
 
4.1.1.9.8 System-Suitability Test 
System suitability tests were used to verify that the resolution and 
repeatability of the system were adequate for the analysis intended. The 
parameters used in this test were retention time, tailing factor and theoretical 
plates of chromatographic peak as RSD of peak area for replicate injections. 
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4.1.2 RESULTS AND DISCUSSION: 
4.1.2.1 Selection of Column and Mobile Phase 
As per the published literature and knowledge of the molecule, reverse phase 
liquid chromatography (RP-HPLC) is suitable for analysis of EFV. In case of 
RP-HPLC various columns are available, but as the main aim of the method 
was to resolve the compound from degraded products, CI8 column (250 mm x 
4.6 mm i.d., 5 µm particle size) was preferred over the other columns. 
Resolution is the most important criteria for the method, it is imperative to 
achieve good resolution among the compound and degraded products. As per 
the value of pKa and solubility of compound various composition of mobile 
phase were tried.  
The chromatographic conditions were optimized with a view to develop a 
stability indicating assay method, which can separate the drug from its 
degradation products with good resolution. Mobile phase consisting of 
acetonitrile : 10mM ammonium acetate buffer (pH 6.5 ± 0.05) (80:20 v/v) at a 
flow rate of 1.0 mL/min, was found to be satisfactory to obtain well-resolved 
peaks with better reproducibility and repeatability for EFV. 
 
(a) 
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(b) 
Figure 4.1.1: Chromatogram of EFV with retention time of 4.41 min from (a) 
standard (30 µg/mL); and (b) tablet dosage form (20 µg/mL) 
4.1.2.2 METHOD VALIDATION 
4.1.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2-8°C (3 
days) was evaluated. It was found that the difference in assay results was not 
more than 2 % for formulation, and 0.5% for API, indicating stability of EFV 
solution. 
 
4.1.2.2.2 Specificity 
The developed analytical method was found to be specific as there was no 
inference of any related impurities after the stress degradation study (Figure 
4.1.2). It was shown that the EFV peaks were free from excipients and co-
eluting impurities. 
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(a) 
 
(b) 
 
(c) 
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(d) 
 
(e) 
 
(f) 
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(g) 
Figure 4.1.2: Chromatograms of EFV after (a) acidic hydrolysis; (b) basic 
hydrolysis; (c) neutral hydrolysis; (d) oxidative degradation; (e) thermal 
degradation; (f) photolytic (Sun light) degradation, (g) photolytic (UV light) 
degradation 
4.1.2.2.3 Linearity 
The linear correlation was obtained between peak area and concentration of 
EFV in the range of 5-30 µg/mL, the linearity of the calibration curve was 
validated by the value of correlation coefficient of the regression (r), the 
regression analysis of the calibration curves is listed in Table 4.1.1 
 
Figure 4.1.3: Calibration curve of EFV 
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Table 4.1.1: Optical and regression characteristics (n=3) 
Parameter EFV 
Linearity range (µg/mL) 5-30 
Linearity equation y = 38217x + 72833 
LOD (µg/mL) 0.062 
LOQ (µg/mL) 0.187 
Correlation coefficient (r) 0.9960 
 
 
4.1.2.2.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 98.86-101.12 %, which 
indicated accuracy of the method. 
Table 4.1.2: Results of recovery study (n=3) 
Amount 
Taken 
(µg/mL) 
 
Amount 
added 
(µg/mL) 
 
Amount 
found 
(µg/mL) 
 
Recovery ± S.D, % % RSD 
10 0 10.05 100.50 ± 0.92 0.92 
10 5 14.83 98.86 ± 1.65 1.65 
10 10 19.90 99.50 ± 1.37 1.37 
10 15 25.28 101.12 ± 0.77 0.77 
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4.1.2.2.5 Precision 
The % RSD for repeatability of EFV was found to be 1.25. 
The value of % RSD for intra-day precision was found to be in the range of 
0.93 - 1.15% and inter-day precision was found to be in the range of 1.07 - 
1.22 %, which indicated that the method was precise. 
Table 4.1.3 Results of repeatability (n=6) 
Drug 
 
EFV 
Peak area 
1 443614.0 
2 454953.1 
3 443275.4 
4 445228.7 
5 448743.8 
6 438564.2 
Mean 445729.9 
SD 5590.19 
% RSD 1.25 
 
Table 4.1.4 Results of Intra-day and Inter-day precision (n=3) 
EFV 
(µg/mL) 
Intra-day precision Inter-day precision 
Mean peak area ± SD % RSD Mean peak area ± SD % RSD 
10 443614.0 ± 4152.12 0.93 448745.3 ± 4836.18 1.07 
20 875777.0 ± 9638.35 1.10 878418.6 ± 9858.21 1.12 
30 1200410.0 ± 13864.16 1.15 1201059.6 ± 14728.26 1.22 
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4.1.2.2.6 Limit of detection and limit of quantification 
The Limit of detection (LOD) for EFV was found to be 0.062 µg/mL. while the 
Limit of quantification (LOQ) was 0.187 µg/mL. 
 
4.1.2.2.7 Robustness 
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
wavelength and flow rate of the mobile phase. 
 
4.1.2.2.8 System-Suitability Test 
The % RSD of system-suitability test parameters was found satisfactory. The 
results are listed in Table 4.1.5 
Table 4.1.5: System suitability test parameters (n = 6) 
No. Retention time, 
Min. 
Tailing factor Theoretical 
plates 
1 4.41 1.49 9282.12 
2 4.41 1.49 9254.23 
3 4.35 1.48 9237.48 
4 4.27 1.49 9187.75 
5 4.38 1.47 9265.58 
6 4.41 1.45 9176.38 
Mean 4.37 1.48 9233.92 
SD 0.055 0.016 42.88 
% RSD 1.26 1.08 0.46 
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4.1.2.3 Analysis of Tablet Dosage Form 
The proposed RP-HPLC method was successfully applied for determination of 
EFV from tablet dosage form. The percentage of EFV was found to be 
satisfactory; which was comparable with the corresponding label claim. 
Table 4.1.6: Analysis results of tablet dosage form (n=3) 
Formulation Labelled amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
ESTIVA 600® 600 597.90 99.65 ± 1.72 
 
 
4.1.2.4 RESULTS OF DEGRADATION STUDY 
Forced degradation study of EFV was carried out under various stress 
conditions and resultant chromatograms are depicted in Figure 4.1.2. 
 
4.1.2.4.1 Effect of Acid, Alkaline and Neutral Hydrolysis 
EFV was found to undergo minute decomposition about 2.4% under acidic 
stress condition with a degradation product at retention time of about 2.30 min 
and 74.88 % decomposition under  alkaline stress condition with a major 
degradation product at retention time of about 3.88 min and minor 
degradation product at retention time of about 2.30 min (Figure. 4.1.2 (a, b) 
respectively. Under neutral degradation condition, no degradation was 
observed.(Figure 4.1.2 (c)). Hence,  EFV was found to be highly degradable 
in basic condition, and very minute degradable in acidic condition but not 
degradable in neutral condition. 
 
4.1.2.4.2 Effect of Oxidation 
In oxidation stress condition, almost 7.5 % of EFV was degraded and 
degradation peak appeared in chromatogram at 2.30 min retention time. 
(Figure 4.1.2 (d)), 
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4.1.2.4.3 Effect of Heat 
Under dry thermal stress condition, EFV was degraded about 8.3 % with 
degradation product at retention time of about 2.58 and 6.83 min. (Figure 
4.1.2 (e)). 
 
4.1.2.4.4 Effect of light 
When EFV in solution state was exposed to sun light; and EFV in powder 
state was exposed to UV light, no degradation was observed, respectively 
(Figure 4.1.2 (f,g)).  
The samples exposed to acidic, alkaline, neutral, oxidative, thermal and 
photolytic conditions were colorless. In Photolytic stability, EFV was found to 
be stable showing no degradation. All degradates were resolved from EFV 
peak and the percentage degradation for each condition indicated that there 
was no interference from degradates in determination of the EFV in tablet 
dosage form. Thus, the proposed, method was found to be "Stability 
Indicating". 
Table 4.1.7: Results of stress degradation study  
Stress conditions/duration % Degradation 
Acidic/0.1N HCl 72 h 2.40 
Alkaline/ 0.1N NaOH / 72 h 74.88 
Neutral/water/ 72 h 0.00 
Oxidative/ 3% H202/ 72 h 7.50 
Photolysis/ Sun light/ 48 h 0.00 
Photolysis/ UV light/48 h 0.00 
Thermal 60°C / 72 h 8.30 
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4.1.3 CONCLUSION:  
An isocratic stability indicating reverse phase liquid chromatographic method 
has been developed and validated for the estimation of EFV in tablet dosage 
form, the method was found to be specific as there was no interference of any 
co-eluting impurities after stress degradation study. The proposed method 
was found to be simple, accurate, precise, sensitive and robust. Hence, it can 
be used successfully for the routine analysis of EFV in pharmaceutical dosage 
forms, and for analysis of stability samples obtained during accelerated 
stability study 
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4.2 STABILITY INDICATING RP-HPLC METHOD FOR DETERMINATION 
OF TENOFOVIR DISOPROXIL FUMARATE 
4.2.1 EXPERIMENTAL: 
4.2.1.1. Instrumentation 
            Same as described under 4.1.1.1 
 
4.2.1.2 Reagents and Materials 
 Tenofovir disoproxil fumarate (TNV) was kindly gifted by Aurobindo 
Pharmaceuticals Ltd., Hyderabad, India. 
 Acetonotrile and water HPLC grade (Rankem, RFCL Ltd., New Delhi). 
 Tablets (TENOF®, Genix Pharma) containing tenofovir disoproxil 
fumarate (300 mg) were purchased from local market. 
 Nylon membrane filter 0.45 μm (Gelman laboratory, Mumbai, India)  
 Hydrogen peroxide, sodium hydroxide and hydrochloric acid (36%) AR 
grade (Finar Chemicals Pvt. Ltd, Ahmedabad, India)  
 Ammonium acetate crystalline pure (E. Merck, Mumbai, India) 
 
4.2.1.3 Chromatographic conditions 
 Same as described under 4.1.1.3 
 
4.2.1.4 Preparation of the Mobile Phase 
Same as described under 4.1.1.4 
 
4.2.1.5 Preparation of standard solution 
Accurately weighed TNV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with acetonitrile to obtain a standard stock 
solution (1mg/mL).  
 
4.2.1.5A Preparation of working standard solution (10 µg/mL ) 
Standard solution (0.1 mL) was transferred in a 10 mL volumetric flask and 
diluted up to the mark with mobile phase. 
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4.2.1.5B  Preparation of hydrochloric acid (0.1N) 
Same as described under 4.1.1.5B 
 
4.2.1.5C  Preparation of sodium hydroxide (0.1N) 
Same as described under 4.1.1.5C 
 
4.2.1.6 Selection of Wavelength for Determination 
The working standard solution of TNV (10 µg/mL) was scanned in the range 
of 200-400 nm using mobile phase as blank. Significant absorbance was 
observed at 254 nm which was selected for the determination. 
 
4.2.1.7 Analysis of Tablet Dosage Form 
Twenty tablets were weighed and average weight was calculated. The tablets 
were finely powdered; a quantity of powder equivalent to 25 mg TNV was 
weighed accurately and transferred to a 25 mL volumetric flask containing 15 
mL acetonitrile, and sonicated for 15 minutes. Allowed to stand at room 
temperature for 5 min and the volume was made up to the mark with 
acetonitrile to obtain the sample stock solution (1 mg/mL). The solution was 
filtered through 0.45 μm membrane filter. Aliquot (1 mL) was taken and 
transferred to 10 mL volumetric flask and volume was made up to the mark 
with acetonitrile to give a solution containing 100 µg/ml TNV. The solution (2 
mL) was transferred to 10 mL volumetric flask and diluted up to the mark with 
mobile phase to give a solution containing 20 µg/mL TNV. An aliquot (20 µL) 
was injected and the chromatogram was recorded. The peak area was noted 
and the amount of TNV was calculated from the regression equation. 
 
4.2.1.8 FORCED DEGRADATION STUDY 
TNV was subjected to various forced degradation conditions to effect partial 
degradation of the drug. The study provides information about the conditions 
in which the drug is unstable so that measures can be taken during 
formulation to avoid potential instabilities. 
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4.2.1.8.1 Effect of Acid, Alkaline and Neutral Hydrolysis 
Accurately weighed TNV (10 mg) was transferred to three different 50 mL 
volumetric flasks and dissolved in acetonitrile (10 mL). Hydrochloric acid 
(0.1N, 5 mL), sodium hydroxide (0.1N, 5 mL) and water (5 mL) were added to 
separate flasks containing drug samples and mixed properly for acidic, 
alkaline and neutral degradation respectively and stored at room temperature 
for 72 h. The samples were neutralized with base or acid as appropriate and 
diluted up to the marks with acetonitrile to obtain stock solutions (200 µg/mL). 
Dilutions were made with mobile phase to obtain the degraded TNV solutions 
(25 µg/mL). 
 
4.2.1.8.2 Effect of Oxidation 
Accurately weighed TNV (10 mg) was transferred to a 50 mL volumetric flask 
and dissolved in acetonitrile (10 mL). Hydrogen peroxide solution (3%, 5 mL) 
was added, mixed properly, and stored at room temperature for 72 h. The 
sample was diluted up to the mark with acetonitrile  to obtain stock solution 
(200 µg/mL). Dilution was made with mobile phase to obtain the degraded 
TNV solution (25 µg/mL). 
 
4.2.1.8.3 Effect of Heat 
TNV (10 mg)  was distributed over a glass plate and kept in an oven at 60°C 
for 72 h, then TNV was transferred in a 50 mL volumetric flask and dilutions 
were made with mobile phase to obtain the degraded TNV solution (25 
µg/mL). 
 
4.2.1.8.4 Effect of Light 
TNV solution (prepared by dissolving 10 mg TNV in 10 mL acetonitrile in 50 
mL volumetric flask) was exposed to sun light for 48 h, while TNV (10 mg) in 
powder state was exposed to UV light for 48 h. After exposure, dilutions were 
made to obtain the degraded TNV solutions (25 µg/mL). Aliquots (20 µL) of 
the stressed samples were injected into the HPLC system as described under 
chromatographic conditions (4.1.1.3), and the chromatograms were recorded. 
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4.2.1.9 METHOD VALIDATION 
As per the ICH guideline Q2 (R1), the method validation parameters like 
specificity, linearity, accuracy, precision, limit of detection, limit of quantitation 
and robustness were studied. 
 
4.2.1.9.1 Solution Stability 
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentage of initial time period was compared with these 
two time periods. The change in the assay percentage was calculated. The 
difference between assay results should not be more than 2 % for formulation, 
and 0.5% for API. 
 
4.2.1.9.2 Specificity 
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in presence of component that may be expected to 
be present in the sample matrix. Chromatograms of TNV solutions and 
degraded samples were studied in order to provide an indication of the 
stability indicating properties and specificity of the method. The stress 
conditions employed were acidic, alkaline, neutral, oxidative, thermal and 
photolytic, the degraded samples were analyzed against freshly prepared 
sample solutions using UV visible detector. Specific conditions are described 
in 4.2.1.8. 
 
4.2.1.9.3 Linearity (Calibration Curve) 
Standard solutions (0.05, 0.1, 0.15, 0.2, 0.25 and 0.3 mL equivalent to 5.0, 
10.0, 15.0, 20.0, 25.0 and 30.0 µg/mL of  TNV) were transferred in a series of 
10 mL volumetric flasks and diluted to the mark with mobile phase. An aliquot 
(20 µL) of each solution was injected under the operating chromatographic 
conditions as described earlier. Calibration curve was constructed by plotting 
peak areas versus concentrations, and the regression equation was 
calculated. Each response was average of three determinations. 
 
 
 
CHAPTER 4                               STABILITY INDICATING RP-HPLC METHOD  
 
91 
 
4.2.1.9.4 Accuracy (% Recovery) 
Accuracy of the method was determined by calculating percentage recovery 
of TNV by the standard addition method. Known amount of standard solutions 
of TNV (0, 5, 10 and 15 µg/mL) were added to a pre-analyzed sample solution 
of TNV (10 µg/mL). Each solution was injected in triplicate and the percentage 
recovery was calculated by measuring the peak areas and fitting these values 
into the regression equation of the calibration curve. 
 
4.2.1.9.5 Precision 
Repeatability was checked by repeatedly (n = 6) injecting TNV solution (10 
µg/mL) and recording the chromatogram. Intra-day and inter-day precisions of 
the developed method was determined by measuring the corresponding 
responses 3 times on the same day and on 3 different days over a period of 1 
week for 3 different concentration of  TNV (10.0, 20.0 and 30.0 µg/mL). The 
results were reported in terms of relative standard deviation. 
 
4.2.1.9.6 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
 
4.2.1.9.7 Robustness 
Robustness was studied by analyzing the samples of TNV by deliberate 
variation in the method parameters. The change in the response of TNV was 
noted. Robustness of the method was studied by changing the extraction time 
of TNV from tablet dosage form by ± 2 min, composition of mobile phase by ± 
2% of organic solvent, wavelength by ± 2 nm, flow rate by ± 0.2 mL/min and 
column oven temperature by ± 2ºC. The changes in the response of TNV 
were noted and compared with the original one. 
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4.2.1.9.8 System-Suitability Test 
System suitability tests were used to verify that the resolution and 
repeatability of the system were adequate for the analysis intended. The 
parameters used in this test were retention time, tailing factor and theoretical 
plates of chromatographic peak as RSD of peak area for replicate injections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4                               STABILITY INDICATING RP-HPLC METHOD  
 
93 
 
4.2.2 RESULTS AND DISCUSSION: 
4.2.2.1 Selection of Column and Mobile Phase 
As per the published literature and knowledge of the molecule, it suggested 
reverse phase liquid chromatography (RP-HPLC) is suitable for analysis of 
TNV. In case of RP-HPLC various columns are available, but as the main aim 
of the method was to resolve the compound from degraded products, CI8 
column (250 mm x 4.6 mm i.d., 5 µm particle size) was preferred over the 
other columns. Resolution is the most important criteria for the method, it is 
imperative to achieve good resolution among the compound and degraded 
products. As per the value of pKa and solubility of compound various 
composition of mobile phase were tried.  
The chromatographic conditions were optimized with a view to develop a 
stability indicating assay method, which can separate the drug from its 
degraded products with good resolution. Mobile phase consisting of 
acetonitrile : 10mM ammonium acetate buffer (pH 6.5 ± 0.05) (80:20 v/v) at a 
flow rate of 1.0 mL/min, was found to be satisfactory to obtain well-resolved 
peaks with better reproducibility and repeatability for TNV. 
 
 
(a) 
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(b) 
Figure 4.2.1: Chromatogram of TNV with retention time of 2.95 min from (a) 
standard (30 µg/mL)  and (b) tablet dosage form (20 µg/mL) 
 
4.2.2.2 METHOD VALIDATION 
4.2.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2-8°C (3 
days) was evaluated. It was found that the difference in assay results was not 
more than 2 % for formulation, and 0.5% for API, indicating stability of TNV 
solution. 
 
4.2.2.2.2 Specificity 
The developed analytical method was found to be specific as there was no 
inference of any related impurities after the stress degradation study (Figure 
4.2.2). It was shown that the TNV peaks were free from excipients and co-
eluting impurities. 
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(a) 
 
(b) 
 
(c) 
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(d) 
 
(e) 
 
(f) 
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(g) 
Figure 4.2.2: Chromatograms of TNV after (a) acidic hydrolysis; (b) basic 
hydrolysis; (c) neutral hydrolysis; (d) oxidative degradation; (e) thermal 
degradation; (f) photolytic (Sun light) degradation, (g) photolytic (UV light) 
degradation 
 
4.2.2.2.3  Linearity 
The linear correlation was obtained between peak area and concentration of 
TNV in the range of 5-30 µg/mL, the linearity of the calibration curve was 
validated by the value of correlation coefficient of the regression (r), the 
regression analysis of the calibration curves is listed in Table 4.2.1 
 
Figure 4.2.3: Calibration curve of TNV 
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Table 4.2.1: Optical and regression characteristics (n=3) 
Parameter TNV 
Linearity range (µg/mL) 5-30 
Linearity equation y = 27558x + 20206 
LOD (µg/mL) 0.055 
LOQ (µg/mL) 0.166 
Correlation coefficient (r) 0.9970 
 
4.2.2.2.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 97.66-100.89 %, which 
indicated accuracy of the method. 
 
Table 4.2.2: Results of recovery study (n=3) 
Amount 
Taken 
(µg/mL) 
 
Amount 
added 
(µg/mL) 
 
Amount 
found 
(µg/mL) 
 
Recovery ± S.D, 
% 
% RSD 
10 0 9.76 97.66 ± 1.54 1.54 
10 5 14.76 98.42 ± 1.79 1.79 
10 10 20.17 100.89 ± 0.84 0.84 
10 15 25.06 100.24 ± 1.19 1.19 
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4.2.2.2.5 Precision 
The % RSD for repeatability of TNV was found to be 1.08. The value of % 
RSD for intra-day precision was found to be in the range of 0.78 - 1.00% and 
inter-day precision was found to be in the range of 1.06 - 1.22 %, which 
indicated that the method was precise. 
Table 4.2.3: Results of repeatability (n=6) 
Drug 
 
TNV 
Peak area 
1 309824.0 
2 315686.0 
3 308876.0 
4 306549.0 
5 307652.0 
6 312484.0 
Mean 310178.5 
SD 3377.17 
% RSD 1.08 
 
Table 4.2.4: Results of Intra-day and Inter-day precision (n=3) 
TNV 
(µg/mL) 
Intra-day precision Inter-day precision 
Mean peak area ± SD % RSD Mean peak area ± SD % RSD 
10 309824.0 ± 2415.28 0.78 304587.4 ± 3245.17 1.06 
20 585770.0 ± 5871.26 1.00 589472.1 ± 7187.33 1.22 
30 842658.0 ± 6857.84 0.81 842764.2 ± 9564.21 1.13 
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4.2.2.2.6 Limit of detection and limit of quantification 
The Limit of detection (LOD) for TNV was found to be 0.055 µg/mL. while the 
Limit of quantification (LOQ) was 0.166 µg/mL. 
 
4.2.2.2.7 Robustness 
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
and wavelength and flow rate of the mobile phase. 
 
4.2.2.2.8 System-Suitability Test 
The % RSD of system-suitability test parameters was found satisfactory. The 
results are listed in Table 4.2.5 
 
Table 4.2.5: System suitability test parameters (n = 6) 
No. Retention time, 
Min. 
Tailing factor Theoretical 
plates 
1 2.95 1.42 9193.01 
2 2.95 1.40 9157.22 
3 2.95 1.40 9078.1 
4 2.93 1.41 9121.66 
5 2.91 1.42 9044.24 
6 2.90 1.42 9156.0 
Mean 2.93 1.41 9125.038 
SD 0.022 0.0098 55.42 
% RSD 0.76 0.69 0.60 
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4.2.2.3 Analysis of Tablet Dosage Form 
The proposed RP-HPLC method was successfully applied for determination of 
TNV from tablet dosage form. The percentage of TNV was found to be 
satisfactory; which was Comparable with the corresponding label claim. 
Table 4.2.6: Analysis results of tablet dosage form (n=3) 
Formulation Labelled amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
TENOF® 300 296.46 98.82 ± 1.61 
 
 
4.2.2.4 RESULTS OF DEGRADATION STUDY 
Forced degradation study of TNV was carried out under various stress 
conditions and resultant chromatograms are depicted in Figure 4.2.2. 
 
4.2.2.4.1 Effect of Acid, Alkaline and Neutral Hydrolysis 
TNV was found to undergo 31.32 and 90.00 % decomposition under acidic 
and alkaline stress conditions respectively with a degradation product at 
retention time of about 2.12 min and 2.10 min (Figure. 4.2.2 (a, b) 
respectively. Under neutral degradation condition, 78.32% degradation was 
observed with a degradation product at retention time of 2.07 min.(Figure 
4.2.2 (c)). Hence, TNV was found to be highly degradable in basic and neutral 
condition, and moderately degradable in acidic condition.  
 
4.2.2.4.2 Effect of Oxidation 
In oxidation stress condition, almost 17.64 % of TNV was degraded and 
degradation peak appeared in chromatogram at 2.10 min retention time. 
(Figure 4.2.2 (d)), 
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4.2.2.4.3 Effect of Heat 
Under dry thermal stress condition, TNV was degraded about 32.16%  and 
degradation peak appeared in chromatogram at 2.07 min retention time. 
(Figure 4.2.2 (e)). 
 
4.2.2.4.4 Effect of light 
When TNV in solution state was exposed to sun light; and TNV in powder 
state was exposed to UV light, no degradation was observed, respectively 
(Figure 4.2.2 (f,g)).  
The samples exposed to acidic, alkaline, neutral, oxidative, thermal and 
photolytic conditions were colorless. In Photolytic stability, TNV was stable 
showing no degradation. All degradates were resolved from TNV peak and 
the percentage degradation for each condition  indicated that there was no 
interference from degradates in determination of the TNV in tablet dosage 
form. Thus, the proposed, method was found to be "Stability Indicating". 
 
Table 4.2.7: Results of stress degradation study  
Stress conditions/duration % Degradation 
Acidic/0.1N HCl / 72 h 31.32 
Alkaline/ 0.1N NaOH / 72 h 90.00 
Neutral/water / 72 h 78.32 
Oxidative/ 3% H202 / 72 h 17.64 
Photolysis/ Sun light / 48 h 0.00 
Photolysis/ UV light / 48 h 0.00 
Thermal 60°C / 72 h 32.16 
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4.2.3 CONCLUSION:  
An isocratic stability indicating reverse phase liquid chromatographic method 
has been developed and validated for the estimation of TNV in tablet dosage 
form, the method was found to be specific as there was no interference of any 
co-eluting impurities after stress degradation study. The proposed method 
was found to be simple, accurate, precise, sensitive and robust. Hence, it can 
be used successfully for the routine analysis of TNV in pharmaceutical 
dosage forms, and for analysis of stability samples obtained during 
accelerated stability study 
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5. RP-HPLC METHOD FOR SIMULTANEOUS 
DETERMINATION OF LOPINAVIR AND RITONAVIR IN 
BULK AND TABLET DOSAGE FORM 
 
5.1    EXPERIMENTAL: 
5.1.1 Instrumentation 
 A Perkin Elmer (USA) HPLC system (series 200) equipped with Perkin 
Elmer series 200 pump  system having back pressure 5000psi, manual 
injector of 20 µL loop capacity, UV-Visible detector and Brownlee C18 
column (250 mm x 4.6 mm i.d., 5µm) 
 BP211D, Sartorious Gottingen AG (Germany),  analytical balance 
 An ultra-sonic cleaner (TEC-4, Roop Telesonic Ultrasonix) 
 A Shimadzu model 1800 double beam UV/Vis. spectrophotometer with 
a pair of 10 mm matched quartz cells 
 pH meter (Testronix 35 420 A (ORION) 
 
5.1.2 Reagents and Materials 
 Lopinavir (LPV) and Ritonavir (RTV) were kindly gifted by Emcure 
Pharmaceuticals Ltd., Pune, India. 
 Acetonotrile, methanol and water HPLC grade (Rankem, RFCL Ltd., 
New Delhi). 
 Tablets (LOPIMUNE®, Cipla Ltd., Mumbai) containing Lopinavir (200 
mg) and Ritonavir (50 mg) were purchased from local market. 
 Nylon membrane filter 0.45 μm (Gelman laboratory, Mumbai, India)  
  Ammonium acetate crystalline pure(E. Merck, Mumbai, India)  
 Orthophosphoric acid HPLC grade (Spectrochem Pvt. Ltd., Mumbai) 
 
5.1.3 Chromatographic Condition 
The chromatographic separation was achieved on Brownlee C18 column. The 
HPLC system was operated isocratically, at 25°C column oven temperature, 
using mobile phase acetonitrile : 10mM ammonium acetate buffer (pH 4.5 ± 
0.05 adjusted with orthphosphoric acid) : methanol (40:30:30 v/v/v), at a flow 
rate of 1.0 mL/min. The mobile phase was filtered through nylon 0.45 µm 
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membrane filter and was degassed before use. The determination was carried 
out at 210 nm wavelength by UV-Visible detector. The injection volume was 
20 µL and total run time was 15 min. The analysis was performed at 25 ± 2 0C 
temperatures. 
 
5.1.4 Preparation of the mobile phase 
The mobile phase was prepared by mixing 40 mL acetonitrile, 30 mL 10mM 
ammonium acetate buffer (pH 4.5 ± 0.05 adjusted with orthphosphoric acid) 
and 30 mL methanol previously filtered through 0.45 µm nylon membrane 
filter. The mobile phase was degassed for 15 minutes by sonicating the 
solution before use. 
 
5.1.5 Preparation of Standard Solution 
Accurately weighed LPV (25 mg) and RTV (25 mg) were transferred to a 25 
mL volumetric flask, dissolved in and diluted to the mark with methanol to 
obtain a standard stock solution (1 mg/mL LPV and RTV).  
 
5.1.5A Preparation of working standard solution of LPV (10 µg/mL) 
Accurately weighed LPV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with methanol to obtain a standard stock 
solution (1 mg/mL LPV). The solution (0.1 mL) was transferred in a 10 mL 
volumetric flask and diluted to the mark with mobile phase. 
 
5.1.5B Preparation of working standard solution of RTV (10 µg/mL) 
Accurately weighed RTV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with methanol to obtain a standard stock 
solution (1 mg/mL RTV). The solution (0.1 mL) was transferred in a 10 mL 
volumetric flask and diluted to the mark with mobile phase. 
 
5.1.6 Selection of Wavelength for Determination 
The working standard solution of LPV (10 µg/mL) and RTV (10 µg/mL) were 
scanned in the range of 200 - 400 nm using methanol as blank and overlain 
spectra was obtained.  Both the drugs showed significant absorbance at 210 
nm which was selected for the determination. 
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5.1.7 Analysis of Tablet Dosage Form 
Twenty tablets were weighed and average weight was calculated. The tablets 
were powdered; a quantity of powder equivalent to 10mg LPV and 2.5 mg 
RTV was accurately weighed and transferred to a volumetric flask of 10 mL 
capacity. Methanol (6 mL) was transferred to volumetric flask and sonicated 
for 20 mins. The flask was shaken and volume was made up to the mark with 
methanol to obtain the sample stock solution (1000 µg/mL LPV and 250 
µg/mL RTV). The solution was filtered through 0.45 μm membrane filter. 
Aliquot (1 mL) was taken and transferred to 10 mL volumetric flask and diluted 
up to the mark with methanol to give a solution containing 100 µg/mL LPV and 
25 µg/mL RTV. The solution (2 mL) was transferred to 10 mL volumetric flask 
and diluted up to the mark with methanol to give a solution containing 20 
µg/mL LPV and 5 µg/mL RTV. An aliquot (20 µL) was injected and the 
chromatogram was recorded. The peak area was noted and the amount of 
LPV and RTV were calculated from the regression equations LPV and RTV. 
 
5.1.8 METHOD VALIDATION 
As per the ICH guideline Q2 (R1), the method validation parameters like 
specificity, linearity, accuracy, precision, limit of detection, limit of quantitation 
and robustness were studied. 
 
5.1.8.1 Solution Stability 
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentages of both the drugs at initial time period were 
compared with these two time periods. The change in the assay percentage 
was calculated. The difference between assay results should not be more 
than 2 % for formulation, and 0.5 % for API. 
 
5.1.8.2 Specificity 
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in presence of component that may be expected to 
be present in the sample matrix. Chromatograms of standard and sample 
solutions of LPV and RTV were compared in order to provide an indication of 
specificity of the method.  
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5.1.8.3 Linearity (Calibration Curve) 
Standard solutions (0.05, 0.1, 0.15, 0.2, 0.25, 0.3 and 0.35 mL equivalent to 
5.0, 10.0, 15.0, 20.0, 25.0, 30.0 and 35 µg/mL of LPV and RTV) were 
transferred in a series of 10 mL volumetric flasks and diluted to the mark with 
methanol. An aliquot (20 µL) of each solution was injected under the operating 
chromatographic conditions as described earlier. Chromatograms were 
recorded. Methanol (20 µL) blank was also injected under the same 
conditions and chromatogram of methanol was recorded for the correction of 
the response of methanol in the chromatograms containing responses of LPV 
and RTV. Calibration curves were constructed by plotting peak areas versus 
concentrations, and the regression equations were calculated. Each response 
was average of three determinations. 
 
5.1.8.4 Accuracy (% Recovery) 
Accuracy of the method was determined by calculating percentage recovery 
of LPV and RTV by the standard addition method. Known amount of standard 
solutions of LPV (0, 5, 10 and 15 µg/mL) and RTV (0, 5, 10 and 15 µg/mL) 
were added to a pre-analyzed sample solution of LPV (10 µg/mL) and RTV 
(10 µg/mL). Each solution (20 μL) was injected in triplicate and the percentage 
recovery was calculated by measuring the peak areas and fitting these values 
into the regression equations of the calibration curves. 
 
5.1.8.5 Precision 
Repeatability was checked by repeatedly (n = 6) injecting the solution 
containing LPV (10 µg/mL) and RTV (10 µg/mL) and recording the 
chromatograms. 
Intra-day and inter-day precisions of the developed method was determined 
by measuring the corresponding responses 3 times on the same day and on 3 
different days over a period of 1 week for 3 different concentration of  LPV 
(10.0, 20.0 and 30.0 µg/mL) and RTV (10.0, 20.0 and 30.0 µg/mL). The 
results were reported in terms of relative standard deviation. 
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5.1.8.6 Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
5.1.8.7 Robustness 
The robustness was studied by analyzing the samples of LPV and RTV by 
deliberate variation in the method parameters. The change in the response of 
LPV and RTV was noted.  
Robustness of the method was studied by changing the extraction time of 
LPV and RTV from tablet dosage form by ± 2 min, composition of mobile 
phase by ± 2% of organic solvents, wavelength by ± 2 nm, flow rate by ± 0.2 
mL/min and column oven temperature by ± 2ºC. The changes in the response 
of LPV and RTV were noted and compared with the original one. 
  
5.1.8.8 System-Suitability Test 
System suitability tests were used to verify that the resolution and 
repeatability of the system were adequate for the analysis intended. The 
parameters used in this test were retention time, tailing factor and theoretical 
plates of chromatographic peaks of LPV and RTV as RSD of peak areas for 
replicate injections. 
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5.2  RESULTS AND DISCUSSION: 
5.2.1 Selection of Column and Mobile Phase 
As per the published literature and knowledge of the molecule, reverse phase 
liquid chromatography (RP-HPLC) is suitable for analysis of LPV and RTV. In 
case of RP-HPLC various columns are available, but as the main aim of the 
method was to resolve the peaks of LPV and RTV, C18 column (250 mm x 4.6 
mm i.d., 5 µm particle size) was preferred over the other columns. Resolution 
is the most important criteria for the method, it is imperative to achieve good 
resolution among the compounds. As per the value of pKa and solubility of 
compounds various composition of mobile phase were tried. The buffers of 
various pH ranges (4 to 6) were tried. The best resolution was obtained with 
ammonium acetate buffer with pH 4.5 ± 0.05. 
The chromatographic conditions were optimized which can separate LPV and 
RTV with good resolution. Mobile phase consisting of acetonitrile : 10mM 
ammonium acetate buffer (pH 4.5 ± 0.05 adjusted with orthphosphoric acid) : 
methanol (40:30:30 v/v/v) at a flow rate of 1.0 mL/min, was found to be 
satisfactory to obtain well-resolved peaks with better reproducibility and 
repeatability for LPV and RTV. 
 
Figure 5.1: HPLC chromatogram of methanol blank at 210 nm 
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Figure 5.2: HPLC chromatogram of RTV (35 µg/mL) and LPV (35 µg/mL) 
standard with retention time of 9.90 and 12.25 min. respectively at 210nm 
 
 
Figure 5.3: HPLC chromatogram of RTV (5 µg/mL) and LPV (20 µg/mL) tablet 
sample with retention time of 9.88 and 12.17 min. respectively at 210nm 
 
5.2.2 METHOD VALIDATION 
5.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2 - 8°C (3 
days) was evaluated. It was found that the difference in assay results was not 
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more than 2 % for formulation, and 0.5% for API, indicating stability of LPV 
and RTV solution. 
 
5.2.2.2 Specificity 
The specificity of the method was determined by analyzing chromatogram of 
standard and sample solution. It was revealed that there was no interference 
from excipients or impurity was found in determination of LPV and RTV 
present in tablet which indicated that the proposed method was specific.  
 
5.2.2.3 Linearity 
Linear correlation was obtained between peak area and concentration of LPV 
and RTV in the range of 5-35 µg/ml., the linearity of the calibration curves 
were validated by the value of correlation coefficient of the regression (r), the 
regression analysis of the calibration curves is listed in Table 5.1 
 
 
Figure 5.4: Calibration curve of LPV 
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Figure 5.5: Calibration curve of RTV 
 
Table 5.1: Optical and regression characteristics (n=3) 
Parameter LPV RTV 
Linearity range (µg/mL) 5-35 5-35 
Linearity equation y = 34940x - 9443 y = 26807x – 15194 
LOD (µg/mL) 0.285 0.138 
LOQ (µg/mL) 0.863 0.418 
Correlation coefficient(r) 0.9970 0.9980 
 
 
5.2.2.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 97.31-100.41 % and 98.29-
101.54 % for LPV and RTV respectively, which indicated accuracy of the 
method. 
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Table 5.2: Results of recovery study (n=3) 
 
5.2.2.5 Precision 
The % RSD for repeatability of LPV and RTV were found to be 1.84 and 1.62 
respectively. 
 
Table 5.3 Results of repeatability (n=6) 
Drug 
 
LPV 
Peak area 
RTV 
Peak area 
1 328802.3 242595.5 
2 325673.2 239547.3 
3 330984.4 247658.3 
4 322154.8 245162 
5 319468.5 241358.9 
6 336042.6 236653.2 
Mean 327187.6 242162.5 
SD 6043.85 3930.03 
% RSD 1.84 1.62 
DRUG Amount 
taken 
(µg/mL) 
Amount 
added 
(µg/mL) 
Amount 
found 
(µg/mL) 
Recovery ± 
SD, % 
% RSD 
LPV 10 0 9.82 98.24 ± 1.21 1.21 
10 5 15.06 100.41 ± 1.39 1.39 
10 10 19.94 99.71 ± 0.97 0.97 
10 15 24.32 97.31 ± 1.14 1.14 
RTV 10 0 9.82 98.29 ± 0.89 0.89 
10 5 14.75 98.34 ± 1.46 1.46 
10 10 19.91 99.58 ± 1.66 1.66 
10 15 25.38 101.54 ± 0.79 0.79 
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The value of % RSD for intra-day precision was found to be in the range of 
0.71 - 0.91% and 0.69 - 0.91% while inter-day precision was found to be in 
the range of 1.01 - 1.28 % and 1.18 - 1.42% for LPV and RTV respectively, 
which indicated that the method was precise. 
 
Table 5.4 Results of Intra-day and Inter-day precision (n=3) 
Drug Con 
(µg/
mL) 
Intra-day precision Inter-day precision 
Mean peak area ± SD % 
RSD 
Mean peak area ± SD % 
RSD 
LPV 10 328802.31 ± 2865.34 0.87 326977.13 ± 4187.32 1.28 
20 682953.09 ± 4876.45 0.71 684132.15 ± 6973.25 1.01 
30 1018343.77 ± 9248.77 0.91 1016594.12 ± 12568.36 1.23 
RTV 10 242595.53 ± 1680.56 0.69 243865.45 ± 3467.41 1.42 
20 519441.60 ± 4769.74 0.91 518238.35 ± 6152.34 1.18 
30 783323.13 ± 6846.35 0.87 785182.91 ± 9587.73 1.22 
 
5.2.2.6 Limit of detection and limit of quantification 
The Limit of detection (LOD) was found to be 0.138 and 0.285 µg/mL while 
the Limit of quantification (LOQ) was 0.418 and 0.863 µg/mL for RTV and LPV 
respectively. 
 
5.2.2.7 Robustness 
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
and wavelength and flow rate of the mobile phase. 
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5.2.2.8 System-Suitability Test 
The % RSD of system-suitability test parameters was found satisfactory. 
Resolution between the peaks of LPV and RTV was found to be 4.095. The 
results are listed in Table 5.5 
 
Table 5.5: System suitability test parameters for LPV (n = 6) 
 
No. 
Retention time, 
Min. 
Tailing factor 
Theoretical 
plates 
1 12.25 1.18 6546.5 
2 12.17 1.18 6571.24 
3 12.25 1.20 6523.26 
4 12.20 1.18 6581.35 
5 12.25 1.19 6540.58 
6 12.22 1.17 6590.2 
Mean 12.22 1.18 6558.85 
SD 0.033 0.010 26.06 
% RSD 0.27 0.87 0.39 
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Table 5.6: System suitability test parameters for RTV (n = 6) 
No. Retention time, 
Min. 
Tailing factor Theoretical 
plates 
1 9.90 1.20 5334.77 
2 9.88 1.20 5371.4 
3 9.90 1.22 5289.72 
4 10.12 1.21 5319.51 
5 9.85 1.20 5327.86 
6 10.12 1.21 5346.63 
Mean 9.96 1.206 5331.64 
SD 0.124 0.008 27.32 
% RSD 1.24 0.67 0.51 
 
5.2.3 Analysis of Tablet Dosage Form 
The proposed RP-HPLC method was successfully applied for determination of 
LPV and RTV from combined tablet dosage form. The percentage of LPV and 
RTV were found to be satisfactory; which was comparable with the 
corresponding label claim. 
 
Table 5.7: Analysis results of tablet dosage form (n=3) 
 
Formulation Drug Labeled 
amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
LOPIMUNE® LPV 200 197.98 98.99 ± 1.22 
RTV 50 49.83 99.67 ± 1.25 
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5.3  CONCLUSION:  
An isocratic reverse phase high performance liquid chromatographic method 
has been developed and validated for the determination of LPV and RTV from 
tablet dosage form. The method was found to be specific as there was no 
interference of any excipients and impurities. The proposed method was 
found to be simple, accurate, precise, sensitive and robust. Hence, it can be 
used successfully for the routine analysis of LPV and RTV in their 
pharmaceutical dosage forms.  
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 6. DETERMINATION OF ANTIRETROVIRAL AGENTS IN 
BULK AND DOSAGE FORM USING HPTLC METHOD  
6.1 DETERMINATION OF EFAVIRENZ IN BULK AND TABLET DOSAGE 
FORM  
 
6.1.1 EXPERIMENTAL: 
6.1.1.1 Instrumentation: 
 A Camag HPTLC with Linomat V auto spotter and Camag Scanner-III 
 Camag flat bottom and twin trough developing chamber (10 cm x 10 cm)  
 HPTLC plates used were silica gel with fluorescent indicator 254 nm, layer 
thickness (0.2 mm) 10 cm x 10 cm aluminium (E-Merck-KgaA). 
 UV cabinet with dual wavelength UV lamp 
 Ultrasonic bath (TEC-4, Roop Telesonic Ultrasonix) 
 
6.1.1.2 Chemicals and materials: 
 Efavirenz (EFV) was kindly gifted by Aurobindo Pharmaceuticals Ltd., 
Hyderabad, India. 
  Ethyl acetate AR grade (Spectrochem Pvt. Ltd., Mumbai, India) 
 Toluene and methanol  HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Tablets (ESTIVA 600®, Genix Pharma) containing efavirenz (600 mg) were 
purchased from local market. 
 
6.1.1.3 Chromatographic conditions: 
6.1.1.3.1 Pre-treatment of HPTLC plates  
HPTLC plate was placed in twin-trough glass chamber containing methanol 
as mobile phase. Methanol was allowed to run up to the upper edge of plate 
(ascending method). The Plate was removed and allowed to dry in oven at 
600C for 5 min. For the actual experiment the plate was allowed to come to 
room temperature and used immediately.  
 
6.1.1.3.2 Chromatographic separation  
The chromatographic separation was achieved on HPTLC plates using mobile 
phase ethyl acetate : toluene (6:4 v/v).  EFV reference standard solution was 
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prepared using methanol as solvent. From the prepared standard solution, 
appropriate volume of  aliquots were applied to silica gel 60 F254 HPTLC 
plates (10 cm x 10 cm) as spot bands of 6mm using LINOMAT V. Mobile 
phase components were mixed prior to use and the development chamber 
was left for saturation with mobile phase vapors for 10 min before each run. 
Development of the plate was carried out by the ascending technique to a 
migration distance of 7 cm. Then the plates were allowed to dry. All the 
analysis was carried out in a laboratory with temperature control (25 ± 20C). 
Densitometry scanning was done in absorbance mode at 254 nm using a 
deuterium lamp. The slit dimensions were set at 6 mm x 0.30 mm, the 
scanning speed of 10 mm/s, and the data resolution at 100 µm/step. Single 
wavelength detection was performed since the main components were only 
analyzed.  
6.1.1.4 Preparation of the Mobile phase  
The mobile phase was prepared by mixing 6.0 mL ethyl acetate with 4.0 mL 
toluene. The mobile phase was transferred into a twin-trough chamber 
covered with lid and allowed to stand for 30 min before use. 
 
6.1.1.5 Preparation of Standard stock solution of EFV: 
EFV (100 mg) was accurately weighed and transferred into 100 mL volumetric 
flask ,and dissolved in methanol. The volume was made up to the mark with 
methanol. Aliquot was further 4 times diluted with methanol to get the final 
concentration of 250 µg/mL EFV which was used for calibration purpose.  
Aliquots (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µL) were applied to the HPTLC plate 
as bands of 6 mm. 
 
6.1.1.6  Selection of Wavelength for Determination  
The standard solution of EFV was scanned in the range of 200 - 400 nm 
against reagent blank. Maximum absorbance for the compound was observed 
at 254 nm which was selected for the determination. 
 
 
 
CHAPTER 6                                                                         HPTLC METHODS 
 
120 
 
6.1.1.7. Analysis of Tablet Dosage Form:  
Twenty tablets, each containing 600 mg of EFV, were weighed and their 
average weight was calculated. The tablets were finely powdered and powder 
equivalent to 100 mg EFV was accurately weighed and transferred in to 100 
mL volumetric flask. Methanol (60 mL) was added to it and shaken for 10 
minutes. The volume was made up to the mark with methanol. The solution 
was sonicated for 30min, filtered through the whatman no.41 filter paper. 
Aliquot was further 4 times diluted with methanol to get the final concentration 
of 250 µg/mL EFV. An aliquot (2 μL equivalent to 500 ng/spot EFV) was 
applied to the HPTLC plate. The plate was developed and analyzed as 
described under 6.1.1.3.2. The chromatogram was recorded. The peak area 
was noted and amount of EFV was calculated from the regression equation. 
 
6.1.1.8 METHOD VALIDATION  
As per ICH guidelines Q2 (R1), the method validation parameters studied 
were solution stability, specificity, linearity, accuracy, precision, limit of 
detection, limit of quantitation and robustness.  
 
6.1.1.8.1 Solution Stability  
Sample solutions were kept at 250C (24 hours) and 2 - 80C (3 days), 
respectively. Assay of initial time period was compared with these two time 
periods. The falls in the assay values were evaluated. The difference between 
assays should not be more than 2 % for formulation, and 0.5% for API.  
6.1.1.8.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in the presence of component that may be 
expected to be present in the sample matrix. Chromatograms of standard and 
sample solution of EFV were compared, and peak purity spectra at three 
different levels i.e., peak start (S), peak apex (M) and peak end (E) of a spot 
were recorded in order to provide an indication of specificity of the method.  
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6.1.1.8.3 Linearity (Calibration curve)  
Standard stock solution containing 1000 µg/mL EFV was prepared in 
methanol and 4 times diluted. Aliquots (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µL) were 
applied to the HPTLC plate to deliver 125, 250, 375, 500, 625 and 750 ng of 
EFV per spot. The plate was developed and analyzed as described under 
6.1.1.3.2. The chromatograms were recorded and the peak areas were noted. 
Calibration curve was constructed by plotting peak area versus concentration, 
and the regression equation was calculated. Each response was average of 
three determinations. 
 
6.1.1.8.4 Accuracy (% Recovery)  
The accuracy of the method was determined by calculating recovery of EFV 
by the standard addition method. Known amount of standard solutions of EFV 
(equivalent to 0, 125, 250 and 375 ng/spot) were applied to the sample spot of 
EFV (250 ng/spot) on the plate. Each solution was applied in triplicate. The 
plate was developed and analyzed as described under 6.1.1.3.2. The 
percentage recovery was calculated by measuring the peak areas and fitting 
these values into the regression equation of the calibration curve.  
 
6.1.1.8.5 Precision  
The repeatability of measurement of peak area was checked by repeatedly (n 
= 6) measuring area of one band of EFV (500 ng/spot), while repeatability of 
sample application was checked by repeatedly (n = 6) measuring area of six 
bands having same concentration of EFV (500 ng/spot) applied on the same 
plate without changing the position of plate. The intra-day and inter-day 
precisions of the proposed method was determined by measuring the 
corresponding responses 3 times on the same day and on 3 different days 
over a period of 1 week for 3 different concentrations of EFV (250, 500 and 
750 ng/spot). The results were reported in terms of relative standard 
deviation.  
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6.1.1.8.6 Limit of Detection and Limit of Quantification:  
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
6.1.1.8.7 Robustness  
The robustness was studied by analyzing the samples of EFV by deliberate 
variation in the method parameters. The change in the response of EFV was 
noted. Robustness of the method was studied by changing the extraction time 
of EFV from tablet dosage form by ± 2 min, composition of mobile phase by ± 
2% of organic solvent, development distance by ± 1 cm, wavelength by ± 2 
nm and temperature by ± 20C. The changes in the response of EFV were 
noted and compared with the original one. 
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6.1.2  RESULTS AND DISCUSSION:  
6.1.2.1 Selection of mobile phase  
Resolution is the most important criteria for the method, it is imperative to 
achieve good resolution among the compounds. As per the value of pKa and 
solubility of compound various composition of mobile phase were tried.  
The chromatographic conditions were optimized with mobile phase consisting 
of ethyl acetate : toluene (6:4 v/v), which was found satisfactory to obtain 
sharp, well defined EFV peak with better reproducibility and repeatability 
(Figure 6.1.1). 
 
 
Figure 6.1.1(a): HPTLC chromatogram of EFV (750 ng/spot) standard with 
corresponding Rf at 254 nm 
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Figure 6.1.1(b): HPTLC chromatogram of EFV (500 ng/spot) tablet sample 
with corresponding Rf at 254 nm 
 
6.1.2.2 METHOD VALIDATION  
6.1.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2-8°C (3 
days) was evaluated. It was found that the difference in assay results was not 
more than 2 % for formulation, and 0.5% for API, indicating stability of EFV 
solution. 
 
6.1.2.2.2 Specificity  
The proposed method was found to be specific as no interference of 
excipients or impurities was found in separation and determination of the peak 
purity of EFV, as r(S, M) = 0.9999 and r(M, E) = 0.9998 (Figure 6.1.2), and 
good correlation (r = 0.9999 and 0.9998) was obtained between standard and 
sample spectra of EFV, respectively. The peak purity and correlation > 0.99 
indicated that the method is specific. 
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Figure 6.1.2: Peak purity spectra of EFV from tablet dosage form 
6.1.2.2.3  Linearity 
Linear correlation was obtained between peak area and concentration of EFV 
in the range of 125- 750 ng/spot. The linearity of the calibration curve was 
validated by the value of correlation coefficients of the regression (r). The 
optical and regression characteristics are listed in Table 6.1.1. 
 
Figure 6.1.3: 3D Chromatogram showing peaks of EFV standards in different 
concentrations  
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Figure 6.1.4: Calibration curve of EFV 
Table 6.1.1: Optical and regression characteristics (n=3) 
Parameter EFV 
Linearity range (ng/spot) 125-750 
Linearity equation y = 9.024x + 734.4 
LOD (ng/spot) 8.36 
LOQ (ng/spot) 25.33 
Correlation coefficient (r) 0.9930 
 
6.1.2.2.4 Accuracy (% Recovery)  
Accuracy study was carried out by the standard addition method. The percent 
recovery was found in the range of 98.20 – 101.29 % for EFV, which indicated 
accuracy of the method.  
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Table 6.1.2: Results of recovery study (n=3) 
 
Drug 
Amount 
taken 
(ng/spot) 
Amount 
added 
(ng/spot) 
Amount 
found 
(ng/spot) 
 
Recovery ± 
SD, % 
 
% RSD 
 
EFV 
250 0 245.52 98.20 ± 1.43 1.43 
250 125 379.86 101.29 ± 0.69 0.69 
250 250 496.64 99.32 ± 0.86 0.86 
250 375 616.92 98.70 ± 1.64 1.64 
 
6.1.2.2.5 Precision  
The % RSD of the repeatability of measurement of peak area was found to be 
0.77; while of the repeatability of sample application was found to be 1.80 for 
EFV. The % RSD for intra-day precision was found to be in the range of 0.65 - 
0.92 %; while inter-day precision was found to be in the range of 0.90 - 1.24 
% for EFV, which indicated that the method was precise.  
 
Table 6.1.3: Results of repeatability (n=6) 
Drug 
 
EFV 
Measurement 
of peak area 
Sample 
application 
1 4275.0 4321.2 
2 4234.6 4286.7 
3 4284.2 4354.3 
4 4221.9 4408.4 
5 4312.3 4186.4 
6 4264.6 4257.9 
Mean 4265.43 4302.48 
SD 33.12 77.41 
% RSD 0.77 1.80 
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Table 6.1.4: Results of Intra-day and Inter-day precision (n=3) 
Drug 
 
Concen-
tration 
(ng/spot) 
 
Intra-day precision Inter-day precision 
Mean peak area 
± SD 
% 
RSD 
Mean peak area 
± SD 
% 
RSD 
EFV 250 3077.0 ± 27.38 0.89 3122.4 ± 28.41 0.91 
500 5418.0 ± 35.21 0.65 5346.6 ± 48.11 0.90 
750 7310.2 ± 67.56 0.92 7245.4 ± 89.96 1.24 
    
 6.1.2.2.6 Limit of detection and limit of quantification  
The Limit of detection (LOD) was found to be 8.36 ng/spot while the Limit of 
quantification (LOQ) was found to be 25.33 ng/spot for EFV.  
 
6.1.2.2.7 Robustness  
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
development distance, wavelength and temperature.  
 
6.1.2.2.8 Analysis of Tablet Dosage Form  
The proposed HPTLC method was successfully applied for determination of  
EFV from tablet dosage form. The percentage of EFV was found to be 
satisfactory, which was comparable with the corresponding label claim.  
 
Table 6.1.5: Analysis results of tablet dosage form (n=3) 
Formulation Drug Labelled 
amount (mg) 
Amount found 
(mg) 
Assay ± SD, % 
ESTIVA 600® EFV 600 594.66 99.11 ± 1.70 
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6.1.3 CONCLUSION:  
A high performance thin layer chromatographic method has been developed 
and validated for the determination of EFV from tablet dosage form. The 
method was found to be specific as there was no interference of excipients 
and impurity. The proposed method was found to be simple, accurate, 
precise, sensitive and robust. Hence, it can be used successfully for the 
routine analysis of EFV in pharmaceutical dosage forms. 
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6.2 DETERMINATION OF TENOFOVIR DISOPROXIL FUMARATE IN BULK 
AND TABLET DOSAGE FORM  
 
6.2.1 EXPERIMENTAL: 
6.2.1.1 Instrumentation: 
Same as described under 6.1.1.1. 
 
6.2.1.2 Chemicals and materials: 
 Tenofovir disoproxil fumarate (TNV) was kindly gifted by Aurobindo 
Pharmaceuticals Ltd., Hyderabad, India. 
 Ethyl acetate AR grade (Spectrochem Pvt. Ltd., Mumbai, India) 
 Formic acid AR grade (Astron Chemicals, Ahmedabad)  
 Methanol HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Tablets (TENOF®, Genix Pharma) containing tenofovir disoproxil fumarate 
(300 mg) were purchased from local market. 
 
6.2.1.3 Chromatographic conditions: 
6.2.1.3.1 Pre-treatment of HPTLC plates  
Same as described under 6.1.1.3.1 
 
6.2.1.3.2 Chromatographic separation  
The chromatographic separation was achieved on HPTLC plates using ethyl 
acetate : methanol : formic acid (7:2.5:0.5 v/v/v).  TNV reference standard 
solution was prepared using methanol as solvent. From the prepared 
standard solution, appropriate volume of  aliquots were applied to silica gel 60 
F254 HPTLC plates (10 cm x 10 cm) as spot bands of 6mm using LINOMAT V. 
Mobile phase components were mixed prior to use and the development 
chamber was left for saturation with mobile phase vapors for 10min before 
each run. Development of the plate was carried out by the ascending 
technique to a migration distance of 7 cm. Then the plates were dried. All the 
analysis were carried out in a laboratory with temperature control (25 ± 20C). 
Densitometry scanning was done in absorbance mode at 266 nm using a 
deuterium lamp. The slit dimensions were set at 6 mm x 0.30 mm, the 
scanning speed of 10 mm/s, and the data resolution at 100 µm/step. Single 
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wavelength detection was performed since the main components were only 
analyzed.  
 
6.2.1.4 Preparation of the Mobile phase  
The mobile phase was prepared by mixing 7.0 mL ethyl acetate, 2.5 mL 
methanol with 0.5 mL formic acid. The mobile phase was transferred into a 
twin-trough chamber covered with lid and allowed to stand for 30 min before 
use. 
 
6.2.1.5 Preparation of Standard stock solution of TNV 
TNV (100 mg) was accurately weighed and transferred into100 mL volumetric 
flask, and dissolved in methanol. The volume was made up to the mark with 
methanol. Aliquot was further 4 times diluted with methanol to get the final 
concentration of 250 µg/mL TNV which was used for calibration purpose.  
Aliquots (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µL) were applied to the HPTLC plates 
as bands of 6 mm. 
 
6.2.1.6  Selection of Wavelength for Determination 
The standard solution of TNV was scanned in the range of 200 - 400 nm 
against reagent blank. The drug showed significant absorbance at 266nm 
which was selected for analysis.  
 
6.2.1.7 Analysis of Tablet Dosage Form  
Twenty tablets, each containing 300 mg of TNV, were weighed and their 
average weight was calculated. The tablets were finely powdered and powder 
equivalent to 100 mg TNV was accurately weighed and transferred in to 100 
mL volumetric flask. Methanol (60 mL) was added to it and shaken for 10 
minutes. The volume was made up to the mark with methanol. The solution 
was sonicated for 30 min, filtered through the whatman no.41 filter paper. 
Aliquot was further 4 times diluted with methanol to get the final concentration 
of 250 µg/mL TNV. An aliquot (2 μL equivalent to 500 ng/spot TNV) was 
applied to the HPTLC plate. The plate was developed and analyzed as 
described under 6.2.1.3.2. The chromatogram was recorded. The peak area 
was noted and amount of TNV calculated from the regression equation. 
CHAPTER 6                                                                         HPTLC METHODS 
 
132 
 
6.2.1.8 METHOD VALIDATION  
As per ICH guidelines Q2(R1), the method validation parameters studied were 
solution stability, specificity, linearity, accuracy, precision, limit of detection, 
limit of quantitation and robustness.  
 
6.2.1.8.1 Solution Stability  
Sample solutions were kept at 250C (24 hours) and 2 - 80C (3 days), 
respectively. Assay of initial time period was compared with these two time 
periods. The falls in the assay values were evaluated. The difference between 
assays should not be more than 2 % for formulation, and 0.5% for API.  
 
6.2.1.8.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in the presence of component that may be 
expected to be present in the sample matrix. Chromatograms of standard and 
sample solution of TNV were compared, and peak purity spectra at three 
different levels i.e., peak start (S), peak apex (M) and peak end (E) of a spot 
were recorded in order to provide an indication of specificity of the method.  
 
6.2.1.8.3 Linearity (Calibration curve)  
Standard stock solution containing 1000 µg/mL TNV was prepared in 
methanol and 4 times diluted. Aliquots (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 µL) were 
applied to the HPTLC plate to deliver 125, 250, 375, 500, 625 and 750 ng of  
TNV per spot. The plate was developed and analyzed as described under 
6.2.1.3.2. The chromatograms were recorded and the peak areas were noted. 
Calibration curve was constructed by plotting peak area versus concentration, 
and the regression equation was calculated. Each response was average of 
three determinations. 
 
6.2.1.8.4 Accuracy (% Recovery)  
The accuracy of the method was determined by calculating recovery of TNV 
by the standard addition method. Known amount of standard solutions of TNV 
(equivalent to 0, 125, 250 and 375 ng/spot) were applied to the sample spot of 
TNV (250 ng/spot) on the plate. Each solution was applied in triplicate. The 
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plate was developed and analyzed as described under 6.2.1.3.2. The 
percentage recovery was calculated by measuring the peak areas and fitting 
these values into the regression equation of the calibration curve.  
 
6.2.1.8.5 Precision  
The repeatability of measurement of peak area was checked by repeatedly (n 
= 6) measuring area of one band of TNV (500 ng/spot), while repeatability of 
sample application was checked by repeatedly (n = 6) measuring area of six 
bands having same concentration of TNV (500 ng/spot) applied on the same 
plate without changing the position of plate. The intra-day and inter-day 
precisions of the proposed method was determined by measuring the 
corresponding responses 3 times on the same day and on 3 different days 
over a period of 1 week for 3 different concentrations of TNV (250, 500 and 
750 ng/spot). The results were reported in terms of relative standard 
deviation.  
 
6.2.1.8.6 Limit of Detection and Limit of Quantification  
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
 
6.2.1.8.7 Robustness  
The robustness was studied by analyzing the samples of TNV by deliberate 
variation in the method parameters. The change in the response of TNV was 
noted. Robustness of the method was studied by changing the extraction time 
of TNV from tablet dosage form by ± 2 min, composition of mobile phase by ± 
2% of organic solvent, development distance by ± 1 cm, wavelength by ± 2 
nm and temperature by ± 20C. The changes in the response of TNV were 
noted and compared with the original one. 
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6.2.2 RESULTS AND DISCUSSION:  
6.2.2.1 Selection of mobile phase  
Resolution is the most important criteria for the method, it is imperative to 
achieve good resolution among the compounds. As per the value of Ka and 
solubility of compound various composition of mobile phase were tried.  
The chromatographic conditions were optimized with mobile phase consisting 
of ethyl acetate : methanol : formic acid (7:2.5:0.5 v/v/v), which was found 
satisfactory to obtain sharp, well-defined TNV peak with better reproducibility 
and repeatability (Figure 6.2.1). 
 
 
Figure 6.2.1(a): HPTLC chromatogram of TNV (750 ng/spot) standard with 
corresponding Rf at 266 nm 
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Figure 6.2.1(b): HPTLC chromatogram of TNV (500 ng/spot) tablet sample 
with corresponding Rf at 266 nm 
 
6.2.2.2 METHOD VALIDATION  
6.2.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2 - 8°C (3 
days)  was evaluated. It was found that the difference in assay results was not 
more than 2 % for formulation, and 0.5% for API, indicating stability of TNV 
solution. 
 
6.2.2.2.2 Specificity  
The proposed method was found to be specific as no interference of 
excipients or impurities was found in separation and determination of the peak 
purity of TNV, as r(S, M) = 0.9999 and r(M, E) = 0.9998 (Figure 6.1.2), and 
good correlation (r = 0.9999 and 0.9998) was obtained between standard and 
sample spectra of TNV, respectively. The peak purity and correlation > 0.99 
indicated the method specificity. 
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Figure 6.2.2: Peak purity spectra of TNV from tablet dosage form 
6.2.2.2.3 Linearity  
Linear correlation was obtained between peak area and concentration of TNV 
in the range of 125- 750 ng/spot. The linearity of the calibration curve was 
validated by the value of correlation coefficients of the regression (r). The 
optical and regression characteristics are listed in Table 6.2.1. 
 
Fig 6.2.3:  3D Chromatogram showing peaks of TNV standards in different 
concentrations  
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Fig. 6.2.4: Calibration curve of TNV 
Table 6.2.1: Optical and regression characteristics (n=3) 
Parameter TNV 
Linearity range (ng/spot) 125-750 
Linearity equation y = 22.44x + 1797. 
LOD (ng/spot) 7.90 
LOQ (ng/spot) 23.93 
Correlation coefficient (r) 0.9910 
 
6.2.2.2.4 Accuracy (% Recovery)  
Accuracy study was carried out by the standard addition method. The percent 
recovery was found in the range of 98.75 – 101.34 % for TNV, which indicated 
accuracy of the method.  
Table 6.2.2: Results of recovery study (n=3) 
 
Drug 
Amount 
taken 
(ng/spot) 
Amount 
added 
(ng/spot) 
Amount 
found 
(ng/spot) 
 
Recovery± 
SD, % 
 
% RSD 
 
TNV 
250 0 246.87 98.75 ± 0.87 0.87 
250 125 371.73 99.13 ± 1.65 1.65 
250 250 506.70 101.34 ± 1.39 1.39 
250 375 617.87 98.86 ± 0.94 0.94 
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6.2.2.2.5 Precision  
The % RSD of the repeatability of measurement of peak area was found to be 
0.41; while of the repeatability of sample application was found to be 0.70 for 
TNV. The % RSD for intra-day precision was found to be in the range of 0.71-
1.48 %; while inter-day precision was found to be in the range of 0.93 - 1.53% 
for TNV, which indicated that the method was precise.  
 
Table 6.2.3: Results of repeatability (n=6) 
Drug 
 
TNV 
Measurement 
of peak area 
Sample 
application 
1 13455.1 13417.5 
2 13489.6 13387.2 
3 13375.4 13564.1 
4 13532.7 13402.6 
5 13479.8 13365.3 
6 13511.4 13582.4 
Mean 13474 13453.18 
SD 55.13 94.77 
% RSD 0.41 0.70 
 
Table 6.2.4: Results of Intra-day and Inter-day precision (n=3) 
Drug 
 
Concen-
tration 
(ng/spot) 
 
Intra-day precision Inter-day precision 
Mean peak area  
± SD 
 
% 
RSD 
Mean peak area  
± SD 
 
% 
RSD 
TNV 250 7587.0 ± 54.11 0.71 7616.4 ± 71.46 0.93 
500 13455.1 ± 175.87 1.30 13564.2 ± 195.38 1.44 
750 18383.0 ± 272.63 1.48 18422.4 ± 283.15 1.53 
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 6.2.2.2.6 Limit of detection and limit of quantification  
The Limit of detection (LOD) was found to be 7.90 ng/spot while the Limit of 
quantification (LOQ) was found to be 23.93 ng/spot  for TNV.  
 
6.2.2.2.7 Robustness  
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
development distance, wavelength and temperature.  
 
6.2.2.2.8 Analysis of Tablet Dosage Form  
The proposed HPTLC method was successfully applied for determination of 
TNV from tablet dosage form. The percentage of TNV was found to be 
satisfactory, which was comparable with the corresponding label claim.  
 
Table 6.2.5: Analysis results of tablet dosage form (n=3) 
Formulation Drug Labelled 
amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
TENOF® TNV 300 296.70 98.90 ± 1.47 
             
6.2.3 CONCLUSION:  
A high performance thin layer chromatographic method has been developed 
and validated for the determination of TNV from tablet dosage form. The 
method was found to be specific as there was no interference of excipients 
and impurity. The proposed method was found to be simple, accurate, 
precise, sensitive and robust. Hence, it can be used successfully for the 
routine analysis of TNV in pharmaceutical dosage forms. 
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6.3 DETERMINATION OF LOPINAVIR AND RITONAVIR IN BULK AND 
THEIR COMBINED TABLET DOSAGE FORM  
 
6.3.1 EXPERIMENTAL: 
6.3.1.1 Instrumentation: 
Same as described under 6.1.1.1 
 
6.3.1.2 Chemicals and materials: 
 Lopinavir (LPV) and Ritonavir (RTV) were kindly gifted by Emcure 
Pharmaceuticals Ltd., Pune, India. 
  Chloroform HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 1,4-dioxane  GC grade (Spectrochem Pvt. Ltd., Mumbai) 
 Methanol HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Tablets (LOPIMUNE®, CiplaLtd) containing Lopinavir (200 mg) and 
Ritonavir (50 mg) were purchased from local market. 
 
6.3.1.3 Chromatographic conditions: 
6.3.1.3.1 Pre-treatment of HPTLC plates  
Same as described under 6.1.1.3.1 
 
6.3.1.3.2 Chromatographic separation  
The chromatographic separation was achieved on HPTLC plates using 
chloroform: 1,4- dioxane (7:3 v/v).  LPV and RTV reference standard solution 
was prepared using methanol as solvent. From the prepared standard 
solution, appropriate volume of  aliquots were applied to silica gel 60 F254 
HPTLC plates (10 cm x 10 cm) as spot bands of 6mm using LINOMAT V. 
Mobile phase components were mixed prior to use and the development 
chamber was left for saturation with mobile phase vapors for 10min before 
each run. Development of the plate was carried out by the ascending 
technique to a migration distance of 7 cm. Then the plates were dried on a hot 
plate .All the analysis were carried out in a laboratory with temperature control 
(25 ± 20C). Densitometry scanning was done in absorbance mode at 210 nm 
using a deuterium lamp. The slit dimensions were set at 6 mm x 0.30 mm, the 
scanning speed of 10 mm/s, and the data resolution at 100 µm/step. Single 
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wavelength detection was performed since the main components were only 
analyzed.  
6.3.1.4 Preparation of the Mobile phase  
The mobile phase was prepared by mixing 7.0 mL chloroform with 3.0 mL 1,4-
dioxane. The mobile phase was transferred into a twin-trough chamber 
covered with lid and allowed to stand for 30 min before use. 
6.3.1.5  Preparation of Standard stock solution of LPV and RTV 
LPV (200 mg) and RTV (50 mg) were accurately weighed and transferred 
into100 mL volumetric flask ,and dissolved in methanol. The volume was 
made up to the mark with methanol. The resulting stock solution was further 
10 times diluted with methanol to get the final concentration of 200 µg/mL LPV 
and 50 µg/mL RTV which was used for calibration purpose of both the drugs. 
Aliquots (0.8, 1.6, 2.4, 3.2, 4.0 and 4.8 µL) were applied to the HPTLC plates 
as bands of 6 mm. 
 
6.3.1.6   Selection of Wavelength for Determination 
The standard solutions of LPV and RTV were scanned in the range of 200-
400 nm against reagent blank. Both the drugs showed significant absorbance 
at 210 nm which was selected for analysis. 
 
6.3.1.7  Analysis of tablet dosage form:  
For analysis of tablet dosage form, twenty tablets, each containing 200 mg of 
LPV and 50mg RTV, were weighed and their average weight was calculated. 
The tablets were finely powdered and powder equivalent to 200 mg LPV and 
50mg RTV was accurately weighed and transferred in to 100 mL volumetric 
flask. Methanol (60 mL) was added to it and shaken for 10 minutes. The 
volume was made up to the mark with methanol. The solution was sonicated 
for 30 min, filtered through the whatman no.41 filter paper. Aliquot was further 
10 times diluted with methanol to get the final concentration of 200 µg/mL LPV 
and 50 µg/mL RTV. An aliquot (3 μL equivalent to 600 ng/spot LPV and 150 
ng/spot RTV ) was applied to the HPTLC plate. The plate was developed and 
analyzed as described under 6.3.1.3.2. The chromatogram was recorded. The 
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peak areas of both the drugs were noted and amount of LPV and RTV were 
calculated from the regression equation of the respective drug. 
 
6.3.1.8 METHOD VALIDATION  
As per ICH guidelines Q2 (R1), the method validation parameters studied 
were solution stability, specificity, linearity, accuracy, precision, limit of 
detection, limit of quantitation and robustness.  
 
6.3.1.8.1 Solution Stability  
Sample solutions were kept at 250C (24 hours) and 2 - 80C (3 days), 
respectively. Assays of both the drugs at initial time period were compared 
with these two time periods. The falls in the assay values were evaluated. The 
difference between assays should not be more than 2 % for formulation, and 
0.5% for API.  
6.3.1.8.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte 
accurately and specifically in the presence of component that may be 
expected to be present in the sample matrix. Chromatograms of standard and 
sample solutions of LPV and RTV were compared, and peak purity spectra at 
three different levels i.e., peak start (S), peak apex (M) and peak end (E) of a 
spot were recorded in order to provide an indication of specificity of the 
method.  
 
6.3.1.8.3 Linearity (Calibration curve)  
Standard stock solution containing 2000 µg/mL LPV and 500 µg/mL RTV was 
prepared in methanol and 10 times diluted. Aliquots (0.8, 1.6, 2.4, 3.2, 4.0 and 
4.8 µL) were applied to the HPTLC plate to deliver 160, 320, 480, 640, 800 
and 960 ng of  LPV per spot and 40, 80, 120, 160, 200 and 240 ng of RTV per 
spot. The plate was developed and analyzed as described under 6.3.1.3.2. 
The chromatograms were recorded and the peak areas were noted. 
Calibration curve was constructed by plotting peak area versus concentration, 
and the regression equation was calculated. Each response was average of 
three determinations. 
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6.3.1.8.4 Accuracy (% Recovery)  
The accuracy of the method was determined by calculating recovery of LPV 
and RTV by the standard addition method. Known amount of standard 
solutions of LPV (equivalent to 0, 160, 320 and 480 ng/spot) and RTV 
(equivalent to 0, 40, 80 and 120 ng/spot) were applied to the sample spot of 
LPV (320 ng/spot) and RTV (80 ng/spot) respectively on the plate. Each 
solution was applied in triplicate. The plate was developed and analyzed as 
described under 6.3.1.3.2. The percentage recovery was calculated by 
measuring the peak areas and fitting these values into the regression 
equations of the calibration curves.  
 
6.3.1.8.5 Precision  
The repeatability of measurement of peak area was checked by repeatedly (n 
= 6) measuring area of one band of LPV (800 ng/spot) and RTV (200 
ng/spot), while repeatability of sample application was checked by repeatedly 
(n = 6) measuring area of six bands having same concentration of LPV (800 
ng/spot) and RTV (200 ng/spot) applied on the same plate without changing 
the position of plate. The intra-day and inter-day precisions of the proposed 
method was determined by measuring the corresponding responses 3 times 
on the same day and on 3 different days over a period of 1 week for 3 
different concentrations of LPV (320, 640 and 960 ng/spot) and RTV (80, 160  
and 240 ng/spot). The results were reported in terms of relative standard 
deviation.  
 
6.3.1.8.6 Limit of Detection and Limit of Quantification:  
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
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6.3.1.8.7 Robustness  
The robustness was studied by analyzing the samples of LPV and RTV by 
deliberate variation in the method parameters. The change in the response of 
LPV and RTV was noted. Robustness of the method was studied by changing 
the extraction time of LPV and RTV from tablet dosage form by ± 2 min, 
composition of mobile phase by ± 2% of organic solvent, development 
distance by ± 1 cm, wavelength by ± 2 nm and temperature by ± 20C. The 
changes in the response of LPV and RTV were noted and compared with the 
original one. 
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6.3.2  RESULTS AND DISCUSSION:  
6.3.2.1 Selection of mobile phase  
Resolution is the most important criteria for the method, it is imperative to 
achieve good resolution among the compounds. As per the value of Ka and 
solubility of compound various composition of mobile phase were tried.  
The chromatographic conditions were optimized with mobile phase consisting 
of chloroform : 1,4 - dioxane (7:3 v/v), which was found satisfactory to obtain 
sharp, well defined LPV and RTV peaks with better reproducibility and 
repeatability (Figure 6.3.1). 
 
 
Figure 6.3.1(a): HPTLC chromatogram of RTV (240 ng/spot) and LPV (960 
ng/spot) standard with corresponding Rf at 210 nm 
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Figure 6.3.1(b): HPTLC chromatogram of RTV (150 ng/spot) and LPV (600 
ng/spot) tablet sample with corresponding Rf at 210 nm 
 
6.3.2.2 METHOD VALIDATION  
6.3.2.2.1 Solution Stability 
The change in assay results after storage at 25°C (24 hours) and 2 - 8°C (3 
days) was evaluated. It was found that the difference in assay results was not 
more than 2 % for formulation, and 0.5% for API, indicating stability of LPV 
and RTV solution. 
 
6.3.2.2.2  Specificity  
The proposed method was found to be specific as no interference of 
excipients or impurities was found in separation and determination of the peak 
purity as r(S, M) = 0.9999 and r(M, E) = 0.9998 for LPV; r(S, M) = 0.9999 and 
r(M, E) = 0.9998 for RTV (Figure 6.1.2(a) and (b)), and good correlation (r = 
0.9999 and 0.9998) was obtained between standard and sample spectra of 
LPV and RTV, respectively. The peak purity and correlation > 0.99 indicated 
the method specificity. 
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Figure 6.3.2(a): Peak purity spectra of LPV from tablet dosage form 
 
 
 
Figure 6.3.2(b): Peak purity spectra of RTV from tablet dosage form 
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6.3.2.2.3 Linearity  
Linear correlation was obtained between peak area and concentration of LPV 
and RTV in the range of 160-960 ng/spot & 40-240 ng/spot, respectively. The 
linearity of the calibration curve was validated by the value of correlation 
coefficients of the regression (r). The optical and regression characteristics 
are listed in Table 6.3.1. 
 
Figure 6.3.3: 3D Chromatogram showing peaks of RTV and LPV standards in 
different concentrations 
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Figure 6.3.4: Calibration curve of LPV 
 
 
Figure 6.3.5: Calibration curve of RTV 
Table 6.3.1: Optical and regression characteristics (n=3) 
Parameter LPV RTV 
Linearity range (ng/spot) 160-960 40-240 
Linearity equation y = 10.46x + 2162.0 y = 24.68x + 289.0 
LOD (ng/spot) 9.56 6.82 
LOQ (ng/spot) 28.96 20.66 
Correlation coefficient (r) 0.9930 0.9990 
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6.3.2.2.4 Accuracy (% Recovery)  
Accuracy study was carried out by the standard addition method. The percent 
recovery was found in the range of 97.83-99.58 % and 97.69-101.28 % for 
LPV and RTV, respectively, which indicated accuracy of the method.  
 
Table 6.3.2: Results of recovery study (n=3) 
 
Drug 
Amount 
taken 
(ng/spot) 
Amount 
added 
(ng/spot) 
Amount 
found 
(ng/spot) 
 
Recovery ± 
SD, % 
 
% RSD 
 
LPV 
320 0 316.28 98.84 ± 0.84 0.84 
320 160 473.13 98.57 ± 0.37 0.37 
320 320 626.11 97.83 ± 1.74 1.74 
320 480 796.64 99.58 ± 1.32 1.32 
 
RTV 
80 0 81.02 101.28 ± 1.27 1.27 
80 40 119.11 99.26 ± 0.63 0.63 
80 80 156.3 97.69 ± 0.82 0.82 
80 120 198.68 99.34 ± 0.94 0.94 
 
6.3.2.2.5 Precision 
The % RSD of the repeatability of measurement of peak area was found to be 
0.90 and 0.98; while of the repeatability of sample application was found to be 
1.76 and 1.57 for LPV and RTV respectively. The % RSD for intra-day 
precision was found to be in the range of 0.21 - 1.06 % and 0.43 - 0.68 %; 
while inter-day precision was found to be in the range of 0.47 - 1.41 % and 
0.74 - 1.82 % for LPV and RTV, respectively, which indicated that the method 
was precise.  
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Table 6.3.3: Results of repeatability (n=6) 
Drug 
 
LPV RTV 
Measurement 
of peak area 
Sample 
application 
Measurement 
of peak area 
Sample 
application 
1 10626.5 10564.54 5278.4 5234.36 
2 10654.2 10156.87 5204.5 5376.95 
3 10471.6 10434.77 5232.9 5145.75 
4 10598.5 10226.45 5354.7 5172.67 
5 10432.3 10587.36 5263.8 5182.92 
6 10648.3 10257.24 5294.4 5227.76 
Mean 10571.9 10371.21 5271.44 5223.4 
SD 95.74 183.31 52.018 82.41 
% RSD 0.90 1.76 0.98 1.57 
              
 
Table 6.3.4: Results of Intra-day and Inter-day precision (n=3) 
Drug 
 
Concen-
tration 
(ng/spot) 
 
Intra-day precision Inter-day precision 
Mean peak area  
± SD 
 
% 
RSD 
Mean peak area 
± SD 
 
% RSD 
LPV 320 5502.41 ± 18.15 0.33 5567.64 ± 31.17 0.56 
640 9076.65 ± 19.06 0.21 8974.72 ± 42.18 0.47 
960 11878.12 ± 125.90 1.06 11842.41± 166.97 1.41 
RTV 80 2308.54 ± 10.38 0.45 2278.45 ± 41.46 1.82 
160 4141.62 ± 28.29 0.68 4235.54 ± 40.66 0.96 
240 6227.71 ± 26.82 0.43 6158.35 ± 45.57 0.74 
  
 6.3.2.2.6 Limit of detection and limit of quantification  
The Limit of detection (LOD) was found to be 9.56 ng/spot and 6.82 ng/spot 
while the Limit of quantification (LOQ) was found to be 28.96 ng/spot and 
20.66 ng/spot for LPV and RTV, respectively.  
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6.3.2.2.7 Robustness  
The method was found to be robust as the results were not significantly 
affected by slight variation in extraction time, composition of mobile phase, 
development distance, wavelength and temperature.  
 
6.3.2.2.8 Analysis of Tablet Dosage Form  
The proposed HPTLC method was successfully applied for determination of 
LPV and RTV from tablet dosage form. The percentage of LPV and RTV was 
found to be satisfactory, which was comparable with the corresponding label 
claim.  
 
Table 6.3.5: Analysis results of tablet dosage form (n=3) 
Formulation Drug Labelled 
amount (mg) 
Amount 
found (mg) 
Assay ± SD, % 
LOPIMUNE® LPV 200 198.20 99.10 ± 1.87 
RTV 50 49.36 98.72 ±  0.77 
             
6.3.3 CONCLUSION:  
A high performance thin layer chromatographic method has been developed 
and validated for the determination of LPV and RTV from tablet dosage form. 
The method was found to be specific as there was no interference of 
excipients and impurity. The proposed method was found to be simple, 
accurate, precise, sensitive and robust. Hence, it can be used successfully for 
the routine analysis of LPV and RTV in their combined pharmaceutical 
dosage forms. 
  
CHAPTER 7 
 
SPECTROPHOTOMETRIC 
DETERMINATION OF 
ANTIRETROVIRAL AGENTS IN 
TABLET DOSAGE FORM  
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 7. SPECTROPHOTOMETRIC DETERMINATION OF ANTIRETRO 
VIRAL AGENTS IN TABLET DOSAGE FORM  
7.1  DETERMINATION OF EFAVIRENZ  IN TABLET DOSAGE FORM  
 
7.1.1 EXPERIMENTAL:  
7.1.1.1 Instrumentation  
 A Shimadzu model 1800 double beam UV/Visile spectrophotometer 
with spectral width of 1 ± 0.2nm, wavelength accuracy of ± 0.1 nm and 
a pair of 10 mm matched quartz cells  
 BP211D,Sartorious Gottingen AG (Germany),  analytical balance 
  An ultra-sonic cleaner (TEC-4, Roop Telesonic Ultrasonix) 
 
7.1.1.2 Reagents and Materials  
 Efavirenz (EFV) was kindly gifted by Aurobindo Pharmaceuticals Ltd., 
Hyderabad, India. 
 Tablets (ESTIVA 600®, Genix Pharma) containing Efavirenz  (600 mg) 
were purchased from local market. 
 Methanol AR grade (SD Fine Chemicals Pvt. Ltd., Ahmedabad, India)  
 Whatman filter paper no. 41  
 Hydrochloric acid (36%) and sodium hydroxide AR grade (Finar 
Chemicals Pvt. Ltd, Ahmedabad, India)  
 
7.1.1.3 Preparation of Standard Solution 
Accurately weighed EFV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with methanol to obtain a standard stock 
solution (1 mg/mL). Aliquot (1 mL) was transferred to 10 mL volumetric flask and 
diluted up to the mark with methanol to obtain the working standard solution (100 
µg/mL) 
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7.1.1.3A  Preparation of hydrochloric acid (0.1N) 
Accurately transferred 0.85 mL concentrated hydrochloric acid (36%) to 100mL 
volumetric flask and diluted up to the mark with distilled water.  
 
7.1.1.3B  Preparation of sodium hydroxide (0.1N) 
Accurately weighed and transferred 0.4 gm sodium hydroxide to 100 mL 
volumetric flask, dissolved in 60 mL distilled water and diluted up to the mark with 
distilled water.  
 
7.1.1.4 Selection of Wavelength for Determination  
Aliquot (1 mL) was taken from EFV stock solution (100 µg/mL) in duplicate 10 ml 
volumetric flasks, and volumes were made up with 0.1N HCl and 0.1N NaOH 
respectively to prepare standard solutions containing 10 μg/ml EFV in 0.1N HCl 
and 0.1N NaOH.  The above solutions were scanned in the UV range of 200 nm 
to 400 nm to obtain difference spectra by keeping acidic form (i.e. EFV in 0.1N 
HCl) in reference cell and basic form (i.e. EFV in 0.1N NaOH) in sample cell 
using 0.1N HCl (in reference cell) and 0.1N NaOH (in sample cell) as  blank. The 
maximum absorbance was observed at 267.50 nm which was selected for 
analysis. 
 
7.1.1.5 Analysis of Tablet Dosage Form  
Twenty tablets were weighed and average weight was calculated. The tablets 
were powdered, a quantity of powder equivalent to 25 mg EFV was weighed and 
transferred to a 25 mL volumetric flask containing 15 mL methanol, and 
sonicated for 15 minutes. The flask was allowed to stand at room temperature for 
5 min and the volume was made up to the mark with methanol to obtain the 
sample stock solution (1 mg/mL). An aliquot (1 mL) from the stock solution was 
transferred to 10 mL volumetric flask and diluted up to the mark with methanol to 
obtain the working standard solution (100 µg/mL). The solution was filtered 
through whatman filter paper no. 41. An aliquot (1.5 mL) was taken in duplicate 
10 mL volumetric flasks, and volumes were made up to the mark with 0.1N HCl 
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and 0.1N NaOH respectively to prepare tablet test solutions containing 15 μg/mL 
EFV in 0.1N HCl and 0.1N NaOH.  The above solutions were scanned in the UV 
range of 200 nm to 400 nm to obtain difference spectra by keeping acidic form 
(i.e. EFV in 0.1N HCl) in reference cell and basic form (i.e. EFV in 0.1N NaOH) in 
sample cell using 0.1N HCl (in reference cell) and 0.1N NaOH (in sample cell) as  
blank. The difference absorbance of the sample solution was noted at 267.50 nm 
which was put in regression equation to calculate the amount of EFV. 
 
7.1.1.6 METHOD VALIDATION  
As per ICH guidelines Q2 (R1), the method validation parameters studied were 
solution stability, specificity, linearity, accuracy, precision, limit of detection, limit 
of quantitation and robustness.  
 
7.1.1.6.1 Solution Stability  
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentage of initial time period was compared with these 
two time periods. The change in the assay percentage was calculated. The 
difference between assay results should not be more than 2 % for formulation, 
and 0.5% for API. 
 
7.1.1.6.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte accurately 
and specifically in the presence of component that may be expected to be 
present in the sample matrix. Difference spectra of standard and sample 
solutions of EFV in 0.1N HCl (in reference cell) and 0.1N NaOH (in sample cell) 
were compared in order to provide an indication of specificity of the method.  
 
7.1.1.6.3 Linearity (Calibration Curve)  
Standard solutions (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mL equivalent to 5, 10, 15, 20, 
25 and 30 μg/mL) were transferred in a series of duplicate 10 mL volumetric 
flasks  and volumes were made up with 0.1N HCl and 0.1N NaOH respectively to 
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prepare series of standard solutions containing 5 - 30 μg/mL EFV in 0.1N HCl 
and 0.1N NaOH. All the above solutions were scanned in the UV range of 200 
nm to 400 nm to obtain their difference spectra by keeping acidic form (i.e. EFV 
in 0.1N HCl) in reference cell and basic form (i.e. EFV in 0.1N NaOH) in sample 
cell. Difference absorbance at 267.50 nm was noted for each solution. 
Calibration curve was constructed by plotting difference absorbance versus 
concentrations, and the regression equation was calculated. Each response was 
average of three determinations.  
 
7.1.1.6.4 Accuracy (% Recovery)  
Accuracy of the method was determined by calculating recovery of EFV by the 
standard addition method. Known amount of standard solutions of EFV (0, 5, 10 
and 15 μg/mL) were added to a pre-analysed sample solution of EFV (10 μg/mL). 
The percentage recovery was calculated by measuring the difference 
absorbances and fitting these values into the regression equation of the 
calibration curve. Each response was average of three determinations. 
 
7.1.1.6.5 Precision  
The repeatability of EFV was checked by repeatedly (n = 6) measuring difference 
absorbances of EFV solution (10 μg/mL).  
The intra-day and inter-day precisions of the proposed method was determined 
by measuring the corresponding responses 3 times on the same day and on 3 
different days over a period of 1 week for 3 different concentrations of EFV (10,  
20 and 30 μg/mL). The results were reported in terms of relative standard 
deviation.  
 
7.1.1.6.6 Limit of Detection and Limit of Quantification  
 Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
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LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
 
7.1.1.6.7 Robustness  
Robustness was studied by analyzing the samples of EFV by deliberate variation 
in the method parameters. The change in the response of EFV was noted. 
Robustness of the method was studied by changing the extraction time of EFV 
from tablet dosage form by ± 2 min, wavelength by ±1 nm and temperature by 25 
± 20C. The changes in the response of EFV were noted and compared with the 
original one.  
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7.1.2 RESULTS AND DISCUSSION:  
The satisfactory results were obtained with 0.1N HCl (in reference cell) and 0.1 
NaOH (in sample cell).  The wavelength of maximum absorbance of EFV in 0.1N 
HCl (reference) and 0.1N NaOH (sample)  was found to be at 267.50 nm (Figure 
7.1.1). 
 
 
(a) 
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(b) 
Figure 7.1.1: Difference spectra of EFV in 0.1 N HCl(reference) and 0.1N NaOH 
(sample) from (a) standard (25 μg/mL) and (b) tablet dosage form (15 μg/mL) 
 
7.1.2.1 METHOD VALIDATION  
7.1.2.1.1 Solution Stability  
The change in assay results after storage at 250C (24 hours) and 2 - 80C (3 days) 
was evaluated. It was found that the difference in assay results was not more 
than 2 % for formulation, and 0.5% for API, indicating stability of EFV solution.  
 
7.1.2.1.2 Specificity  
The analytical method was found to be specific as no interference of excipients 
and impurities was found in determination of the EFV  
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7.1.2.1.3 Linearity  
The Beer’s law was obeyed. Linear correlation was obtained between difference 
absorbance and concentration of EFV in the range of 5-30 μg/mL. The linearity of 
the calibration curve was validated by the value of correlation coefficient of the 
regression (r). The optical and regression characteristics are listed in Table 7.1.1. 
 
 
Figure 7.1.2: Calibration curve of EFV 
           
                  Table 7.1.1: Optical and regression characteristics (n=3) 
Parameter EFV 
Linearity range (µg/mL) 5-30 
Linearity equation y = 0.063x + 0.145 
LOD (µg/mL) 0.352 
LOQ (µg/mL) 1.066 
Correlation coefficient (r) 0.998 
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7.1.2.1.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 98.64 – 102.05 %, which indicated 
accuracy of the method. 
 
Table 7.1.2: Results of recovery study (n=3) 
Amount 
taken 
(µg/mL) 
 
Amount 
added 
(µg/mL) 
 
Amount 
found 
(µg/mL) 
Recovery ± S.D, % % RSD 
10 0 10.20 102.05 ± 1.31 1.28 
10 5 14.89 99.30 ± 1.16 1.16 
10 10 20.27 98.64 ± 0.58 0.58 
10 15 25.11 100.47 ± 0.83 0.83 
 
7.1.2.1.5 Precision 
The % RSD for repeatability of EFV was found to be 0.95. The value of % RSD 
for intra-day precision was found to be in the range of 0.93 – 1.06% and inter-day 
precision was found to be in the range of 1.19 - 1.31%, which indicated that the 
method was precise. 
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                               Table 7.1.3: Results of repeatability (n=6) 
Drug 
 
EFV 
Diff. absorbance 
1 0.800 
2 0.812 
3 0.805 
4 0.807 
5 0.795 
6 0.816 
Mean 0.805 
SD 0.0076 
% RSD 0.95 
 
Table 7.1.4: Results of Intra-day and Inter-day precision (n=3) 
EFV 
(µg/mL) 
Intra-day precision Inter-day  precision 
Mean diff. absorbance  
± SD 
% RSD Mean diff. absorbance  
± SD 
 
% RSD 
10 0.800 ± 0.0076 0.95 0.816 ± 0.0097 1.19 
20 1.428 ± 0.0152 1.06 1.419 ± 0.0186 1.31 
30 2.022 ± 0.0189 0.93 2.057 ± 0.0262 1.27 
 
7.1.2.1.6 Limit of detection and limit of quantification 
The limit of detection (LOD) for EFV was found to be 0.352 µg/mL, while the limit 
of quantification (LOQ) was 1.066 µg/mL. 
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7.1.2.1.7 Robustness  
The method was found to be robust as the results were not significantly affected 
by slight variation in extraction time, wavelength and temperature.  
 
7.1.2.2 Analysis of Tablet Dosage Form  
The proposed UV spectrophotometric method was successfully applied for 
determination of EFV in tablet dosage form. The percentage of EFV was found to 
be satisfactory, which was comparable with the corresponding label claim.  
 
Table 7.1.5: Analysis results of tablet dosage form (n=3) 
 
Formulation Labelled amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
ESTIVA 600® 600 604.92 100.82 ± 1.31 
 
7.1.3 CONCLUSION:  
A UV spectrophotometric method has been developed and validated for the 
determination of EFV in tablet dosage form. The method was found to be specific 
as there was no interference of any excipients and impurities. The proposed 
method was found to be simple, accurate, precise and robust. Hence, it can be 
used successfully for the routine analysis of EFV in pharmaceutical dosage 
forms. 
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7.2 DETERMINATION OF TENOFOVIR DISOPROXIL FUMARATE IN TABLET 
DOSAGE FORM  
 
7.2.1 EXPERIMENTAL:  
7.2.1.1 Instrumentation  
       Same as described under 7.1.1.1 
7.2.1.2 Reagents and Materials  
 Tenofovir disoproxil fumarate (TNV) was kindly gifted by Aurobindo 
Pharmaceuticals Ltd., Hyderabad, India. 
 Tablets (TENOF®, Genix Pharma) containing tenofovir disoproxil 
fumarate (300 mg) were purchased from local market. 
 Methanol AR grade (SD Fine Chemicals Pvt. Ltd., Ahmedabad, India)  
 Whatman filter paper no. 41  
 Hydrochloric acid (36%) AR grade (Finar Chemicals Pvt. Ltd, 
Ahmedabad, India)  
 
7.2.1.3 Preparation of standard solution 
Accurately weighed TNV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with methanol to obtain a standard stock 
solution (1 mg/mL).  
 
7.2.1.3A  Preparation of hydrochloric acid (0.1N) 
Same as described under 7.1.1.3A 
7.2.1.3B Preparation of working standard solution (10 µg/mL) 
Standard solution (0.1 mL) was transferred in a 10 mL volumetric flask and 
diluted to the mark with 0.1N HCl. 
 
7.2.1.4 Selection of Wavelength for Determination  
TNV working standard solution (10 µg/mL) was scanned in the spectrum mode 
between 200 and 400 nm, using 0.1N HCl as a blank. The wavelength of 
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maximum absorbance (λ max) was observed at 258.50 nm. Then 1st derivative 
spectrum of TNV was calculated by UV Probe 2.31 software which shown peak 
maxima at 247.06 nm and peak minima at 273.45 nm. Both these wavelengths 
were selected for analysis. 
 
7.2.1.5 Analysis of Tablet Dosage Form  
Twenty tablets were weighed and average weight was calculated. The tablets 
were powdered, a quantity of powder equivalent to 25 mg TNV was weighed and 
transferred to a 25 mL volumetric flask containing 15 mL methanol, and 
sonicated for 15 minutes. The flask was allowed to stand at room temperature for 
5 min and the volume was made up to the mark with methanol to obtain the 
sample stock solution (1 mg/mL). The solution was filtered through whatman filter 
paper no. 41. An aliquot (0.2 mL) was transferred to a 10 mL volumetric flask and 
diluted to the mark with 0.1N HCl to obtain a sample solution (20 µg/mL). The 
spectrum was recorded and 1st derivative spectrum was calculated. The 
absorbances were noted at 247.06 nm as well as 273.45 nm. The amplitude 
difference of the absorbances between these two wavelengths was calculated 
and amount of TNV present per tablet was calculated from the regression 
equation. 
 
7.2.1.6 METHOD VALIDATION  
As per ICH guidelines Q2 (R1), the method validation parameters studied were 
solution stability, specificity, linearity, accuracy, precision, limit of detection, limit 
of quantitation and robustness.  
 
7.2.1.6.1 Solution Stability  
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentage of initial time period was compared with these 
two time periods. The change in the assay percentage was calculated. The 
difference between assay results should not be more than 2 % for formulation, 
and 0.5% for API. 
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7.2.1.6.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte accurately 
and specifically in the presence of component that may be expected to be 
present in the sample matrix. First derivative spectra of standard and sample 
solutions of TNV in 0.1N HCl were compared in order to provide an indication of 
specificity of the method.  
 
7.2.1.6.3 Linearity (Calibration Curve)  
Standard solutions (0.05, 0.1, 0.15, 0.2, 0.25 and 0.30 mL equivalent to 5, 10, 15, 
20, 25 and 30 μg/mL) were transferred in a series of 10 mL volumetric flasks, and 
diluted to the mark with 0.1N HCl. The absorbances of each solution were 
measured at 247.06 nm as well as 273.45 nm and amplitude difference was 
calculated for each solution. Calibration curve was constructed by plotting 
amplitude difference versus concentrations, and the regression equation was 
calculated. Each response was average of three determinations.  
 
7.2.1.6.4 Accuracy (% Recovery)  
Accuracy of the method was determined by calculating recovery of TNV by the 
standard addition method. Known amount of standard solutions of TNV (0, 5, 10 
and 15 μg/mL) were added to a pre-analysed sample solution of TNV (10 
μg/mL). The percentage recovery was calculated by measuring the amplitude 
differences and fitting these values into the regression equation of the calibration 
curve. Each response was average of three determinations. 
 
7.2.1.6.5 Precision  
The repeatability of TNV was checked by repeatedly (n = 6) measuring amplitude 
differences of TNV solution (10 μg/mL). The intra-day and inter-day precisions of 
the proposed method was determined by measuring the corresponding 
responses 3 times on the same day and on 3 different days over a period of 1 
week for 3 different concentrations of TNV (10, 20 and 30 μg/mL). The results 
were reported in terms of relative standard deviation.  
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7.2.1.6.6 Limit of Detection and Limit of Quantification  
Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ =10 x σ/S 
 
7.2.1.6.7 Robustness  
Robustness was studied by analyzing the samples of TNV by deliberate variation 
in the method parameters. The change in the response of TNV was noted. 
Robustness of the method was studied by changing the extraction time of TNV 
from tablet dosage form by ±2 min, wavelength by ± 1 nm and temperature by 25 
± 2 0C. The changes in the response of TNV were noted and compared with the 
original one.  
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7.2.2  RESULTS AND DISCUSSION:  
The satisfactory results were obtained with 0.1N HCl.  The wavelength of 
maximum absorbance of TNV in 0.1N HCl was found to be at 258.50 nm (Figure 
7.2.1). 
 
Figure 7.2.1: UV spectrums of TNV in 0.1N HCl. 
In 1st derivative spectrums of TNV in 0.1N HCl, peak maxima and peak minima 
were obtained at 247.06 nm and 273.45 nm respectively (Figure 7.2.2). 
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(a) 
 
(b) 
Figure 7.2.2: Spectra of TNV from (a) standard (15 μg/mL)  and (b) tablet dosage 
form (20 μg/mL) 
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7.2.2.1 METHOD VALIDATION  
7.2.2.1.1 Solution Stability  
The change in assay results after storage at 250C (24 hours) and 2 - 80C (3 days) 
was evaluated. It was found that the difference in assay results was not more 
than 2 % for formulation, and 0.5% for API, indicating stability of TNV solution.  
 
7.2.2.1.2 Specificity  
The analytical method was found to be specific as no interference of excipients 
and impurities was found in determination of the TNV  
 
7.2.2.1.3 Linearity  
The Beer’s law was obeyed. Linear correlation was obtained between amplitude 
difference and concentration of TNV in the range of 5-30 μg/mL. The linearity of 
the calibration curve was validated by the value of correlation coefficient of the 
regression (r). The optical and regression characteristics are listed in Table 7.2.1. 
 
 
Figure 7.2.3: Calibration curve of TNV 
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                  Table 7.2.1: Optical and regression characteristics (n=3) 
Parameter TNV 
Linearity range (µg/mL) 5-30 
Linearity equation y = 0.033x + 0.001 
LOD (µg/mL) 0.269 
LOQ (µg/mL) 0.815 
Correlation coefficient (r) 0.9980 
 
7.2.2.1.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 97.68 - 98.79 %, which indicated 
accuracy of the method. 
 
Table 7.2.2: Results of recovery study (n=3) 
Amount 
taken 
(µg/mL) 
 
Amount 
added 
(µg/mL) 
 
Amount 
found 
(µg/mL) 
Recovery ± S.D, % % RSD 
10 0 9.84 98.41 ± 1.06 1.06 
10 5 14.65 97.68 ± 0.87 0.87 
10 10 19.63 98.17 ± 1.26 1.26 
10 15 24.69 98.79 ± 0.79 0.79 
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7.2.2.1.5 Precision 
The % RSD for repeatability of TNV was found to be 1.105. The value of % RSD 
for intra-day precision was found to be in the range of 0.35 - 0.85% and inter-day 
precision was found to be in the range of 0.95 - 1.59%, which indicated that the 
method was precise. 
                              Table 7.2.3 Results of repeatability (n=6) 
Drug 
 
TNV 
Amplitude diff. 
1 0.328 
2 0.321 
3 0.323 
4 0.325 
5 0.331 
6 0.327 
Mean 0.325 
SD 0.0036 
% RSD 1.105 
 
Table 7.2.4 Results of Intra-day and Inter-day precision (n=3) 
TNV 
(µg/mL) 
Intra-day precision Inter-day precision 
Mean amplitude diff. 
± SD 
% RSD Mean amplitude diff. 
± SD 
 
% RSD 
10 0.328 ± 0.0028 0.85 0.327 ± 0.0052 1.59 
20 0.672 ± 0.0024 0.35 0.672 ± 0.0065 0.96 
30 1.021 ± 0.0059 0.57 1.023 ± 0.0098 0.95 
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7.2.2.1.6 Limit of detection and limit of quantification 
The limit of detection (LOD) for TNV was found to be 0.269 µg/mL, while the limit 
of quantification (LOQ) was 0.815 µg/mL. 
 
7.2.2.1.7 Robustness  
The method was found to be robust as the results were not significantly affected 
by slight variation in extraction time, wavelength and temperature.  
 
7.2.2.2 Analysis of Tablet Dosage Form  
The proposed UV spectrophotometric method was successfully applied for 
determination of TNV in tablet dosage form. The percentage of TNV was found to 
be satisfactory, which was comparable with the corresponding label claim.  
Table 7.2.5: Analysis results of tablet dosage form (n=3) 
Formulation Labelled amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
TENOF® 300 294.75 98.25 ± 0.42 
 
7.2.3 CONCLUSION:  
A UV spectrophotometric method has been developed and validated for the 
determination of TNV in tablet dosage form. The method was found to be specific 
as there was no interference of any excipients and impurities. The proposed 
method was found to be simple, accurate, precise and robust. Hence, it can be 
used successfully for the routine analysis of TNV in pharmaceutical dosage 
forms. 
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7.3 DETERMINATION OF RITONAVIR IN TABLET DOSAGE FORM  
 
7.3.1 EXPERIMENTAL:  
7.3.1.1 Instrumentation  
 Same as described under 7.1.1.1 
7.3.1.2 Reagents and Materials  
 Ritonavir (RTV) was kindly gifted by Emcure Pharmaceuticals Ltd., 
Pune, India. 
 Tablets (VIRITON®, Ranbaxy, Mumbai) containing Ritonavir (100 mg) 
were purchased from local market. 
 Methanol AR grade (SD Fine Chemicals Pvt. Ltd., Ahmedabad, India)  
 Whatman filter paper no. 41  
 Hydrochloric acid (36%) and sodium hydroxide AR grade (Finar 
Chemicals Pvt. Ltd, Ahmedabad, India)  
 
7.3.1.3 Preparation of standard solution 
Accurately weighed RTV (25 mg) was transferred to a 25 mL volumetric flask, 
dissolved in and diluted to the mark with methanol to obtain a standard stock 
solution (1 mg/mL). Aliquot (1 mL) from the stock solution was transferred to 10 
mL volumetric flask and diluted up to the mark with methanol to obtain the 
working standard solution (100 µg/mL) 
 
7.3.1.3A  Preparation of hydrochloric acid (0.1N) 
Same as described under 7.1.1.3A 
 
7.3.1.3B  Preparation of sodium hydroxide (0.1N) 
Same as described under 7.1.1.3B 
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7.3.1.4 Selection of Wavelength for Determination  
Aliquot (1 mL) was taken from RTV stock solution (100 µg/mL) in duplicate 10 ml 
volumetric flasks and volumes were made up with 0.1N HCl and 0.1N NaOH 
respectively to prepare standard solutions containing 10 μg/ml RTV in 0.1N HCl 
and 0.1N NaOH.  The above solutions were scanned in the UV range of 200 nm 
to 400 nm to obtain difference spectra by keeping acidic form (i.e. RTV in 0.1N 
HCl) in sample cell and basic form (i.e. RTV in 0.1N NaOH) in reference cell 
using 0.1N HCl (in sample cell) and 0.1N NaOH (in reference cell) as  blank. The 
maximum absorbance was observed at 256.80 nm which was selected for 
analysis. 
 
7.3.1.5 Analysis of Tablet Dosage Form  
Twenty tablets were weighed and average weight was calculated. The tablets 
were finely powdered. A quantity of powder equivalent to 25 mg RTV was 
accurately weighed and transferred to a 25 mL volumetric flask containing 15 mL 
methanol, and sonicated for 15 minutes. The flask was allowed to stand at room 
temperature for 5 min and the volume was made up to the mark with methanol to 
obtain the sample stock solution (1 mg/mL). An aliquot (1 mL)  from the stock 
solution was transferred to 10 mL volumetric flask and diluted up to the mark with 
methanol to obtain 100 µg/mL RVT. The solution was filtered through whatman 
filter paper no. 41. An aliquot (2 mL) was taken in duplicate 10 mL volumetric 
flasks, and diluted up to the mark with 0.1N HCl and 0.1N NaOH respectively to 
prepare tablet test solutions containing 20 μg/mL RTV in 0.1N HCl and 0.1N 
NaOH.  The above solutions were scanned in the UV range of 200 nm to 400 nm 
to obtain difference spectra by keeping acidic form (i.e. RTV in 0.1N HCl) in 
sample cell and basic form (i.e. RTV in 0.1N NaOH) in reference cell using 0.1N 
HCl (in sample cell) and 0.1N NaOH (in reference cell) as  blank. The difference 
absorbance of the sample solution was noted at 256.80 nm which was put in 
regression equation to calculate the amount of RTV. 
 
 
CHAPTER 7                                                                UV SPECTROPHOTOMETRIC METHODS 
 
176 
 
7.3.1.6 METHOD VALIDATION  
As per ICH guidelines Q2 (R1), the method validation parameters studied were 
solution stability, specificity, linearity, accuracy, precision, limit of detection, limit 
of quantitation and robustness.  
 
7.3.1.6.1 Solution Stability  
Sample solutions were kept at 25 ± 2°C (24 hours) and 2 - 80C (3 days), 
respectively. Assay percentage of initial time period was compared with these 
two time periods. The change in the assay percentage was calculated. The 
difference between assay results should not be more than 2 % for formulation, 
and 0.5% for API. 
 
7.3.1.6.2 Specificity  
Specificity of an analytical method is its ability to measure the analyte accurately 
and specifically in the presence of component that may be expected to be 
present in the sample matrix. Difference spectra of standard and sample 
solutions of RTV in 0.1N HCl (in sample cell) and 0.1N NaOH (in reference cell) 
were compared in order to provide an indication of specificity of the method.  
 
7.3.1.6.3 Linearity (Calibration Curve)  
Standard solutions (0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mL equivalent to 5, 10, 15, 20, 
25 and 30 μg/mL) were transferred in a series of duplicate 10 mL volumetric 
flasks and volumes were made up with 0.1N HCl and 0.1N NaOH respectively to 
prepare series of standard solutions containing 5- 30 μg/mL RTV (standard) in 
0.1N HCl and 0.1N NaOH. All the above solutions were scanned in the UV range 
of 200 nm to 400 nm to obtain their difference spectra by keeping acidic form (i.e. 
RTV in 0.1N HCl) in sample cell and basic form (i.e. RTV in 0.1N NaOH) in 
reference cell. Difference absorbance at 256.80 nm was noted for each solution. 
Calibration curve was constructed by plotting difference absorbance versus 
concentrations, and the regression equation was calculated. Each response was 
average of three determinations.  
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7.3.1.6.4 Accuracy (% Recovery)  
Accuracy of the method was determined by calculating recovery of RTV by the 
standard addition method. Known amount of standard solutions of RTV (0, 5, 10 
and 15 μg/mL) were added to a pre-analyzed sample solution of RTV (10 
μg/mL). The percentage recovery was calculated by measuring the difference 
absorbances and fitting these values into the regression equation of the 
calibration curve. Each response was average of three determinations. 
7.3.1.6.5 Precision  
The repeatability of RTV was checked by repeatedly (n = 6) measuring difference 
absorbances of RTV solution (20 μg/mL).  
The intra-day and inter-day precisions of the proposed method was determined 
by measuring the corresponding responses 3 times on the same day and on 3 
different days over a period of 1 week for 3 different concentrations of RTV (10, 
20 and 30 μg/mL). The results were reported in terms of relative standard 
deviation.  
 
7.3.1.6.6 Limit of Detection and Limit of Quantification  
 Limit of detection (LOD) and the limit of quantification (LOQ) were calculated 
using the standard deviation of response (σ) and slope (S) of the calibration 
curve. 
LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
 
7.3.1.6.7 Robustness  
Robustness was studied by analyzing the samples of RTV by deliberate variation 
in the method parameters. The change in the response of RTV was noted. 
Robustness of the method was studied by changing the extraction time of RTV 
from tablet dosage form by ± 2 min, wavelength by ±1 nm and temperature by 25 
± 2 0C. The changes in the response of RTV were noted and compared with the 
original one.  
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7.3.2  RESULTS AND DISCUSSION:  
The satisfactory results were obtained with 0.1N HCl (in sample cell) and 0.1 
NaOH(in reference cell). The wavelength of maximum absorbance of RTV in 
0.1N HCl (sample) and 0.1N NaOH (reference) was found to be at 256.80 nm 
(Figure 7.3.1). 
 
(a) 
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(b) 
Figure 7.3.1: Difference spectra of RTV in 0.1 N HCl (sample) and 0.1N NaOH 
(reference) from (a) standard (25 μg/mL) and (b) tablet dosage form (20 μg/mL) 
 
7.3.2.1 METHOD VALIDATION  
7.3.2.1.1 Solution Stability  
The change in assay results after storage at 250C (24 hours) and 2 - 80C (3 days) 
was evaluated. It was found that the difference in assay results was not more 
than 2 % for formulation, and 0.5% for API, indicating stability of RTV solution.  
 
7.3.2.1.2 Specificity  
The analytical method was found to be specific as no interference of excipients 
and impurities was found in determination of the RTV  
 
 
CHAPTER 7                                                                UV SPECTROPHOTOMETRIC METHODS 
 
180 
 
7.3.2.1.3 Linearity  
The Beer’s law was obeyed. Linear correlation was obtained between difference 
absorbance and concentration of RTV in the range of 5-30 μg/mL. The linearity of 
the calibration curve was validated by the value of correlation coefficient of the 
regression (r). The optical and regression characteristics are listed in Table 7.3.1. 
 
 
Figure 7.3.2: Calibration curve of RTV 
                   
                  Table 7.3.1: Optical and regression characteristics (n=3) 
Parameter RTV 
Linearity range (µg/mL) 5-30 
Linearity equation y = 0.008x – 0.005 
LOD (µg/mL) 0.627 
LOQ (µg/mL) 1.90 
Correlation coefficient (r) 0.9970 
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7.3.2.1.4 Accuracy (% Recovery) 
The accuracy study was carried out by the standard addition method. The 
percent recoveries were found in the range of 97.26 – 101.85 %, which indicated 
accuracy of the method. 
 
Table 7.3.2: Results of recovery study (n=3) 
Amount 
taken 
(µg/mL) 
 
Amount 
added 
(µg/mL) 
 
Amount 
found 
(µg/mL) 
 
Recovery ± S.D, % % RSD 
10 0 9.72 97.26 ± 1.21 1.24 
10 5 14.71 98.09 ± 0.82 0.83 
10 10 20.35 101.85 ± 1.27 1.24 
10 15 24.70 98.37 ± 1.39 1.41 
 
7.3.2.1.5 Precision 
The % RSD for repeatability of RTV was found to be 1.74. The value of % RSD 
for intra-day precision was found to be in the range of 0.90 – 1.31% and inter-day 
precision was found to be in the range of 1.54 - 1.89 %, which indicated that the 
method was precise. 
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                             Table 7.3.3:  Results of repeatability (n=6) 
Drug 
 
RTV 
Diff. absorbance 
1 0.162 
2 0.166 
3 0.160 
4 0.164 
5 0.168 
6 0.165 
Mean 0.164 
SD 0.0028 
% RSD 1.74 
 
Table 7.3.4: Results of Intra-day and Inter-day precision (n=3) 
RTV 
(µg/mL) 
Intra-day precision Inter-day  precision 
Mean diff. absorbance 
± SD 
 
% RSD Mean diff. absorbance 
± SD 
 
% RSD 
10 0.076 ± 0.0010 1.31 0.079 ± 0.0015 1.89 
20 0.166 ± 0.0015 0.90 0.162 ± 0.0025 1.54 
30 0.248 ± 0.0023 0.92 0.253 ± 0.0046 1.81 
 
7.3.2.1.6 Limit of detection and limit of quantification 
The limit of detection (LOD) for RTV was found to be 0.627 µg/mL, while the limit 
of quantification (LOQ) was 1.90 µg/mL. 
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7.3.2.1.7  Robustness  
The method was found to be robust as the results were not significantly affected 
by slight variation in extraction time, wavelength and temperature.  
 
7.3.2.2  Analysis of Tablet Dosage Form  
The proposed UV spectrophotometric method was successfully applied for 
determination of RTV in tablet dosage form. The percentage of RTV was found to 
be satisfactory, which was comparable with the corresponding label claim.  
 
Table 7.3.5: Analysis results of tablet dosage form (n=3) 
Formulation Labelled amount 
(mg) 
Amount found 
(mg) 
Assay ± SD, % 
VIRITON® 100 98.39 98.39 ± 0.97 
 
7.3.3 CONCLUSION:  
A UV spectrophotometric method has been developed and validated for the 
determination of RTV in tablet dosage form. The method was found to be specific 
as there was no interference of any excipients and impurities. The proposed 
method was found to be simple, accurate, precise and robust. Hence, it can be 
used successfully for the routine analysis of RTV in pharmaceutical dosage 
forms. 
  
CHAPTER 8 
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8.  DETERMINATION OF ANTIRETROVIRAL AGENTS IN 
HUMAN PLASMA 
8.1  RP-HPLC METHOD FOR DETERMINATION  OF  EFAVIRENZ IN 
HUMAN PLASMA. 
8.1.1  EXPERIMENTAL 
8.1.1.1 Instrumentation: 
High Performance Liquid Chromatography (HPLC) 
Model : Perkin Elmer series 200 
Make : Perkin Elmer, USA 
Column : C18 , Brownlee 
Particle size : 5 µm. 
Length : 250 mm 
Diameter : 4.6 mm 
Pump : Perkin Elmer series 200 pump, back pressure 5000 psi. 
Injector : Rhenodyne valve  
Injection volume : 20 µL 
Detector : UV-visible detector  model: Perkin Elmer series 200 
 
8.1.1.2  Chemicals and materials: 
 Efavirenz  was kindly gifted by Aurobindo Pharmaceuticals, Ltd Hyderabad. 
 Acetonitrile and water HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Ammonium acetate crystalline pure (E. Merck, Mumbai, India) 
 Nylon membrane filter 0.45 µm (Gelman laboratory, Mumbai, India) 
 
8.1.1.3  Chromatographic conditions 
Brownlee C18 column (250 mm x 4.6 mm i.d., 5 µm) was used at ambient 
temperature. The mobile phase comprised of acetonitrile : 10mM ammonium 
acetate buffer (pH 6.5 ± 0.05) (80:20 v/v). The mobile phase was filtered 
through 0.45 µm nylon membrane filter and was degassed before use. The 
elution was monitored at 254 nm. The injection volume was 20 µL. 
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8.1.1.4 Preparation of mobile phase 
The mobile phase was prepared by mixing 80 mL acetonitrile and 20 mL 
10mM ammonium acetate buffer (pH 6.5 ± 0.05) previously filtered through 
0.45 µm nylon membrane filter. The mobile phase was degassed for 15 
minutes by sonicating the solution before use. 
 
8.1.1.5 Preparation of EFV standard stock solution. 
Accurately weighed EFV (25mg) was transferred to 25 mL volumetric flask 
and dissolved and diluted up to the mark with acetonitrile to obtain a standard 
solution having concentration of EFV (1000 µg/mL). 
 
8.1.1.6 Extraction of sample (EFV) 
Drug/metabolite free plasma samples with fixed aliquots of EFV (50 µL) and 
volunteer plasma sample (950 µL) was taken in glass centrifuge tubes and 
mixed with 1.0mL acetonitrile for protein precipitation of plasma as well as 0.1 
mL saturated sodium chloride solution. The samples were vortexed for 1.0 
min., and then precipitated proteins were separated by centrifugation at 15000 
rpm for 15 min. Supernant from the tube was collected and filtered through 
0.45 µm nylon membrane filter before injection and then injected into the 
HPLC system. 
 
8.1.1.7 Selection of Wavelength for Determination 
The standard solutions of EFV were scanned in the range of 200 – 400 nm 
against reagent blank. Maximum absorbance for EFV was observed at 254 
nm which was selected for analysis. 
 
8.1.1.8  METHOD VALIDATION: 
8.1.1.8.1 Calibration Curve (Linearity) 
Accurately measured standard stock solutions of EFV (0.1, 0.2, 0.4, 0.8, 1.2, 
1.6, 2.0 and 2.4 mL) were transferred in a series of 10 mL volumetric flasks 
and diluted with acetonitrile. The above solutions (50 µL) were spiked with 
950 µL of drug free plasma to obtain EFV concentration of 500, 1000, 2000, 
4000, 6000, 8000, 10000 and 12000 ng/mL. 
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8.1.1.8.2 Accuracy 
Accuracy of the measurement of EFV in plasma was determined by standard 
addition method at four different concentration levels of EFV (6000, 8000, 
10000 and 12000 ng/mL). The working solution (4000 ng/mL) was transferred 
to four different glass tubes. To each tube, 950 µL of drug/metabolite free 
plasma was added. Further 2000, 4000, 6000 and 8000 ng/mL of solutions 
were serially added into these tubes. These samples were extracted as 
described above in the extraction procedure. 
 
8.1.1.8.3 Recovery 
EFV recoveries (relative and absolute) from human plasma were determined 
by spiking drug-free plasma (five replicates for each standard) with known 
amounts of the drug to achieve EFV concentrations of 500, 4000, 8000 and 
12000 ng/mL. The spiked samples were processed and analysed with the 
developed procedure. The relative (analytical) recovery was calculated by 
comparing the concentrations obtained from the drug-supplemented plasma 
with actual added amounts. The absolute ( extraction) recovery was obtained 
by comparing the observed peak areas obtained from the processed standard 
samples to direct injections of standard aqueous solutions prepared at 
concentrations which represented 100% recovery. 
 
8.1.1.8.4 Precision 
8.1.1.8.4.1 Method Precision (repeatability) 
Method precision experiment was performed by preparing the working 
solution of EFV (4000 ng/mL) for seven times and analysed as per described 
under recovery. 
 
8.1.1.8.4.2 Inter-day and intra-day precision 
The intra and inter day precisions of EFV assay in human plasma were 
assessed from replicate samples spiked at four different concentrations (500, 
4000, 8000 and 12000 ng/mL). The selection of concentrations for analysis 
was made according to definition of precision at low, medium and high 
concentrations of the linear range. The precision of the method is expressed 
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as the relative standard deviation (% RSD) of the mean estimated 
concentrations. 
 
8.1.1.8.5 Limit of detection and limit of quantification 
The limit of detection and the limit of quantification of the drug were calculated 
using the following equations. 
LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
Where σ is the standard deviation of the peak areas of the drug and S is the 
slope for the corresponding calibration curve. 
 
8.1.1.8.6 Stability 
The effect of frozen storage on EFV stability in human plasma was assessed 
through storing of EFV plasma samples at -700C over a period of 1 month. 
EFV plasma samples were analysed immediately after preparation and at 
selected time intervals after storage over the study period. Stability was 
defined as <10% loss of initial drug concentration. Moreover, stability in 
heparinized plasma samples through five freeze and thaw cycles (-700C ± 50C 
to room temperature) has been confirmed. Samples, after thawing, were 
allowed to stand on the bench top, under room lighting till 2 hr had elapsed 
since their removal from the freezer.  On the other hand , on-machine stability 
of the processed samples was evaluated by injecting the quality control 
samples, stored at room temperature in the HPLC, immediately after 
preparation and then at selected time intervals for 24 hr. 
 
8.1.1.8.7 Specificity 
The specificity of the assay for the analyte in the presence of endogenous 
substances in the matrix was assessed by comparing the response obtained 
from the concentration used to produce the calibration plots with response 
obtained from plasma of different persons. 
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8.1.2 RESULTS AND DISCUSSION 
8.1.2.1 Chromatography 
The mobile phase acetonitrile : 10mM ammonium acetate buffer (pH 6.5 ± 
0.05) (80:20 v/v) at the flow rate of 1.0 mL/min achieved optimum separation 
of efavirenz without interferences from endogenous components in the 
plasma. Figure 8.1.1, 8.1.2 and 8.1.3 represent typical chromatograms of 
drug-free human plasma and drug-free human plasma spiked with efavirenz 
(12000 ng/mL and 10000 ng/mL) respectively. As illustrated in these 
chromatograms, efavirenz eluted at retention time of approximately 4.42 min. 
The peak of interest was clearly resolved with no interfering peaks from 
endogenous components in the plasma within the time frame where efavirenz 
was eluted. 
 
 
Figure 8.1.1: Chromatogram of drug-free human plasma. 
CHAPTER 8                                                                 ANALYSIS IN PLASMA  
 
189 
 
             
 
Figure 8.1.2: Chromatogram of drug-free human plasma spiked with EFV  
(12000 ng/mL). 
          
 
Figure 8.1.3: Chromatogram of drug-free human plasma spiked with EFV 
(10000 ng/mL). 
 
8.1.2.2 VALIDATION OF THE METHOD 
8.1.2.2.1 Linearity 
Linear correlation was obtained between peak areas and concentrations of 
EFV in range of 500 - 12000 ng/mL. 
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The linearity of the calibration graphs was validated by the high value of 
correlation coefficients of the regression (Table 8.1.1).The linearity of the 
calibration graphs was validated by the high value of correlation coefficients of 
the regression (figure 8.1.4). 
 
 
Figure 8.1.4: Calibration curve of EFV 
 
Table 8.1.1: Optical and regression characteristic 
Parameter EFV 
Linearity 
range 
500 - 12000 ng/mL 
Regression 
equation (y) 
y = 31.03x - 6035 
Correlation 
coefficient (r) 
0.9950 
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8.1.2.2.2 Accuracy:  
The recovery experiments were carried out as in the text. The percent 
recoveries obtained were 86.11 to 92.57% for EFV. The results of recovery 
study are given in table 8.1.2 
 
Table 8.1.2: Data of recovery study (n = 5) 
 
Compound 
Amount 
taken 
(ng/mL) 
Amount 
added 
(ng/mL) 
Amount 
recovered 
(ng/mL) 
Accuracy 
± SD% 
 
 4000 2000 5460.00 91.00 ± 11.76 
EFV 4000 4000 6888.80 86.11 ±10.42 
 4000 6000 9257.00 92.57 ± 8.35 
 4000 8000 10718.40 89.32 ± 6.87 
 
8.1.2.2.3 Recovery: 
The recovery experiments were carried out as in the text. The absolute and 
relative mean recovery found to be 83.75% and 85.00%, respectively (Table 
8.3.3). 
 
Table 8.1.3: Absolute and Relative Recoveries of EFV from human plasma 
Nominal 
concentration 
(ng/mL) 
Absolute recovery 
(mean ± SD%) 
(n = 5) 
Relative recovery 
(mean ± SD%) 
(n = 5) 
500 82.65 ± 11.2 83.34 ± 10.6 
4000 84.89 ± 7.52 85.79 ±5.28 
8000 86.34 ± 8.28 86.21 ± 3.88 
12000 81.14 ± 9.71 84.68 ± 6.74 
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8.1.2.2.4   Precision  
8.1.2.2.4.1 Method precision (repeatability) 
Relative standard deviation of all the parameters was less than 15% (table 
8.1.4), which indicated that the proposed method was repeatable.  
 
Table 8.1.4: Method Precision data 
 
EFV (4000 
ng/mL) 
Retention time 
(min.) 
Peak area 
Tailing 
factor 
1 4.42 57424.8 1.42 
2 4.40 53634.2 1.40 
3 4.41 59276.6 1.41 
4 4.39 54766.0 1.41 
5 4.42 52865.9 1.42 
6 4.42 57145.6 1.40 
7 4.40 56358.5 1.42 
Mean 4.40 55924.5 1.411 
SD 0.012 2277.03 0.009 
% RSD 0.27 4.07 0.63 
 
8.1.2.2.4.2 Intra-day and inter-day precision: 
 The intraday precision (% RSD) ranged from 3.89 to 5.94% while the interday 
precision (% RSD) ranged from 5.05 to 7.90% (Table 8.1.5). The intra- and 
inter-day precision data showed that acceptable precision was obtained over 
the entire assay range. 
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Table 8.1.5: Intra and Inter- day precision of EFV in human plasma. 
Nominal 
concentration. 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
(% RSD) 
Intra-day (n = 7)   
500 502.72 ± 23.72 4.72 
4000 4005.36 ± 155.80 3.89 
8000 7989.54 ± 329.96 4.13 
12000 12011.65 ± 713.49 5.94 
Inter-day (n = 7)   
500 497.34 ± 31.23 6.28 
4000 3988.45 ± 201.41 5.05 
8000 7982.54 ± 530.83 6.65 
12000 12008.58 ± 948.67 7.90 
 
8.1.2.2.5 Limit of detection and limit of quantification: 
The limit of detection (LOD) of EFV was determined to be 119.82 ng/mL, 
whereas, quantitative limit (LOQ) was 382.43 ng/mL.  
 
8.1.2.2.6 Stability study: 
The stability results showed that efavirenz was stable for at least 4 weeks 
when kept frozen at -70 0C. Thus, analysis up to 4 weeks storage confirmed 
adequate EFV stability at this temperature. Moreover, the results of 
freeze/thaw stability indicate that EFV was stable in plasma for at least five 
freeze/thaw cycles (Table 8.1.6). 
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Table 8.1.6: Summary of stability testing of EFV in human plasma. 
 
Stability 
Nominal 
concentration 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
Precision 
(% RSD) 
Freeze/thaw (n = 5) 
500 486.22 4.87 
4000 3878.43 3.67 
8000 7539.54 5.22 
12000 11529.96 7.35 
Long term (n = 5) 
500 465.87 8.12 
4000 3773.63 6.42 
8000 7458.42 4.31 
12000 11464.26 5.64 
 
8.1.3 CONCLUSION 
The developed method was found to be simple, accurate, precise and 
repeatable. It can be applied for the determination of concentration of EFV in 
the human plasma for bioavailability and bioequivalence study. 
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8.2 RP-HPLC METHOD FOR DETERMINATION OF TENOFOVIR 
DISOPROXIL FUMARATE IN HUMAN PLASMA. 
8.2.1   EXPERIMENTAL 
8.2.1.1 Instrumentation 
   Same as described under 8.1.1.1 
 
8.2.1.2 Chemicals and materials: 
 Tenofovir disoproxil fumarate was kindly gifted by Aurobindo 
Pharmaceuticals, Ltd Hyderabad. 
 Acetonitrile and water HPLC grade (Rankem, RFCL Ltd., New 
Delhi) 
 Ammonium acetate crystalline pure (E. Merck, Mumbai, India) 
 Nylon membrane filter 0.45 µm (Gelman laboratory, Mumbai, India) 
 
8.2.1.3 Chromatographic conditions 
Brownlee C18 column (250 mm x 4.6 mm i.d., 5 µm) was used at ambient 
temperature. The mobile phase comprised of acetonitrile : 10 mM ammonium 
acetate buffer (pH 6.5 ± 0.05) (60:40 v/v). The mobile phase was filtered 
through 0.45 µm nylon membrane filter and was degassed before use. The 
elution was monitered at 254 nm. The injection volume was 20 µL. 
 
8.2.1.4 Preparation of mobile phase 
The mobile phase was prepared by mixing 60 mL acetonitrile and 40 mL 
10mM ammonium acetate buffer (pH 6.5 ± 0.05) previously filtered through 
0.45 µm nylon membrane filter. The mobile phase was degassed for 15 
minutes by sonicating the solution before use. 
 
8.2.1.5 Preparation of TNV standard stock solution. 
Accurately weighed TNV (25 mg) was transferred to 25 mL volumetric flask 
and dissolved and diluted up to the mark with acetonitrile to obtain a standard 
solution having concentration of TNV (1000 µg/mL). 
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8.2.1.6 Extraction of sample (TNV) 
Drug/metabolite free plasma samples with fixed aliquots of TNV ( 50 µL) and 
volunteer plasma sample (950 µL) was taken in glass centrifuge tubes and 
mixed with 1.0mL acetonitrile for protein precipitation of plasma as well as 0.1 
mL saturated sodium chloride solution. The samples were vortexed for 1.0 
min., and then precipitated proteins were separated by centrifugation at 15000 
rpm for 15 min. Supernant from the tube was collected and filtered through 
0.45 µm nylon membrane filter before injection and then injected into the 
HPLC system. 
 
8.2.1.7 Selection of Wavelength for Determination  
The standard solutions of TNV were scanned in the range of 200 – 400 nm 
against reagent blank. Significant absorbance for TNV was observed at 254 
nm which was selected for analysis. 
 
8.2.1.8 METHOD VALIDATION 
8.2.1.8.1 Calibration Curve (Linearity) 
Accurately measured standard stock solutions of TNV (0.01, 0.02, 0.1, 0.2, 
0.4, 0.6, 0.8 and 1.0 mL) were transferred in a series of 10 mL volumetric 
flasks and diluted with acetonitrile. The above solutions (50 µL) were spiked 
with 950 µL of drug free plasma to obtain TNV concentration of 50, 100, 500, 
1000, 2000, 3000, 4000 and 5000 ng/mL. 
 
8.2.1.8.2 Accuracy 
Accuracy of the measurement of TNV in plasma was determined by standard 
addition method at four different concentration levels of TNV (1500, 2000, 
2500 and  3000, ng/mL). The working solution (1000 ng/mL) was transferred 
to four different glass tubes. To each tube, 950 µL of drug/metabolite free 
plasma was added. Further 500, 1000, 1500 and 2000 ng/mL of solutions 
were serially added into these tubes. These samples were extracted as 
described above in the extraction procedure. 
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8.2.1.8.3 Recovery 
TNV recoveries (relative and absolute) from human plasma were determined 
by spiking drug-free plasma (five replicates for each standard) with known 
amounts of the drug to achieve TNV concentrations of  100, 500, 3000 and 
5000 ng/mL. The spiked samples were processed and analysed with the 
developed procedure. The relative (analytical) recovery was calculated by 
comparing the concentrations obtained from the drug-supplemented plasma 
with actual added amounts. The absolute ( extraction) recovery was obtained 
by comparing the observed peak areas obtained from the processed standard 
samples to direct injections of standard aqueous solutions prepared at 
concentrations which represented 100% recovery. 
 
8.2.1.8.4 Precision 
8.2.1.8.4.1 Method Precision (repeatability) 
Method precision experiment was performed by preparing the working 
solution of TNV (1000 ng/mL) for seven times and analysed as per described 
under recovery. 
 
8.2.1.8.4.2 Inter day and intraday precision 
The intra and inter day precisions of TNV assay in human plasma were 
assessed from replicate samples spiked at four different concentrations (100, 
500, 3000 and 5000 ng/mL). The selection of  concentrations for analysis was 
made according to definition of precision at low, medium and high 
concentrations of the linear range.The precision of the method is expressed 
as the relative standard deviation (% RSD) of the mean estimated 
concentrations. 
 
8.2.1.8.5 Limit of detection and limit of quantification: 
The limit of detection and the limit of quantification of the drug were calculated 
using the following equations. 
LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
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Where σ is the standard deviation of the peak areas of the drug and S is the 
slope for the corresponding calibration curve. 
 
8.2.1.8.6 Stability 
The effect of frozen storage on TNV stability in human plasma was assessed 
through storing of TNV plasma samples at -700C over a period of 1 month. 
TNV plasma samples were analysed immediately after preparation and at 
selected time intervals after storage over the study period. Stability was 
defined as <10% loss of initial drug concentration. Moreover, stability in 
heparinized plasma samples through five freeze and thaw cycles (-700C ± 50C 
to room temperature) has been confirmed. Samples, after thawing , were 
allowed to stand on the bench top, under room lighting till 2 hr had elapsed 
since their removal from the freezer.  On the other hand , on-machine stability 
of the processed samples was evaluated by injecting the quality control 
samples, stored at room temperature in the HPLC, immediately after 
preparation and then at selected time intervals for 24 hr. 
 
8.2.1.8.7 Specificity 
The specificity of the assay for the analyte in the presence of endogenous 
substances in the matrix was assessed by comparing the response obtained 
from the concentration used to produce the calibration plots with response 
obtained from plasma of different patients. 
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8.2.2 RESULTS AND DISCUSSION 
8.2.2.1 Chromatography 
The mobile phase acetonitrile : 10mM ammonium acetate buffer (pH 6.5 ± 
0.05) (60:40 v/v) at the flow rate of 1.0 mL/min achieved optimum separation 
of TNV without interferences from endogenous components in the plasma. 
Figure 8.2.1, 8.2.2 and 8.2.3 represent typical chromatograms of drug-free 
human plasma and drug-free human plasma spiked with TNV (5000 ng/mL 
and 3000 ng/mL) respectively. As illustrated in these chromatograms, TNV 
eluted at retention time of approximately 3.38 min. The peak of interest was 
clearly resolved with no interfering peaks from endogenous components in the 
plasma within the time frame where TNV was eluted. 
 
 
Figure 8.2.1: Chromatogram of drug-free human plasma. 
CHAPTER 8                                                                 ANALYSIS IN PLASMA  
 
200 
 
 
Figure 8.2.2: Chromatogram of drug-free human plasma spiked with TNV 
(5000 ng/mL). 
 
 
 
 
Figure 8.2.3: Chromatogram of drug-free human plasma spiked with TNV 
(3000 ng/mL). 
 
8.2.2.2 VALIDATION OF THE METHOD 
8.2.2.2.1 Linearity 
Linear correlation was obtained between peak areas and concentrations of 
TNV in range of 50 - 5000 ng/mL. The linearity of the calibration graphs was 
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validated by the high value of correlation coefficients of the regression (Table 
8.2.1).The linearity of the calibration graphs was validated by the high value of 
correlation coefficients of the regression (figure 8.2.4). 
 
 
Figure 8.2.4: Calibration curve of TNV 
 
Table 8.2.1: Optical and regression characteristic 
Parameter TNV 
Linearity 
range 
50 - 5000 ng/mL 
Regression 
equation (y) 
y = 12.40x – 298.6 
Correlation 
coefficient (r) 
0.9950 
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8.2.2.2.2 Accuracy 
The recovery experiments were carried out as in the text. The percent 
recoveries obtained were 86.06 to 91.51% for TNV. The results of recovery 
study are given in table 8.2.2 
 
Table 8.2.2: Data of recovery study (n = 5) 
Compound 
Amount 
taken 
(ng/mL) 
Amount 
added 
(ng/mL) 
Amount 
found 
(ng/mL) 
Accuracy 
± SD% 
 
 1000 500 1320.00 88.00 ± 3.24 
TNV 1000 1000 1830.20 91.51 ± 11.55 
 1000 1500 2151.50 86.06 ± 4.87 
 1000 2000 2722.80 90.76 ± 7.42 
 
8.2.2.2.3 Recovery: 
The recovery experiments were carried out as in the text. The absolute and 
relative mean recovery found to be 84.37% and 84.26%, respectively (Table 
8.2.3). 
 
Table 8.2.3: Absolute and Relative Recoveries of TNV from human plasma. 
Nominal concentration 
(ng/mL) 
Absolute recovery 
(mean ± SD%) 
(n = 5) 
Relative recovery 
(mean ± SD%) 
(n = 5) 
100 83.35 ± 10.1 82.21 ± 8.95 
500 82.71 ± 6.55 81.47 ± 6.32 
3000 85.24 ± 7.21 87.66  ± 5.57 
5000 86.18 ± 5.61 85.72 ± 3.28 
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8.2.2.2.4 Precision  
8.2.2.2.4.1 Method precision (repeatability) 
Relative standard deviation of all the parameters was less than 15% (table 
8.2.4), which indicated that the proposed method was repeatable.  
 
Table 8.2.4: Method Precision data 
TNV (1000 
ng/mL) 
Retention 
time 
(min.) 
Peak area 
Tailing 
factor 
1 3.38 11756.34 1.69 
2 3.36 9588.48 1.69 
3 3.38 12164.21 1.68 
4 3.38 11232.45 1.67 
5 3.28 10975.54 1.69 
6 3.22 13667.91 1.68 
7 3.38 11824.38 1.68 
Mean 3.34 11601.33 1.68 
SD 0.064 1241.01 0.0075 
% RSD 1.92 10.69 0.45 
 
8.2.2.2.4.2 Intra day and inter day precision: 
 The intraday precision (% RSD) ranged from 6.44 to 8.10% while the interday 
precision (% RSD) ranged from 8.57 to 10.60% (Table 8.2.5). The intra- and 
inter-day precision data showed that acceptable precision was obtained over 
the entire assay range. 
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Table 8.2.5: Intra and Inter- day precision of TNV  in human plasma. 
Nominal 
concentration. 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
(% RSD) 
Intra-day (n = 7)   
100 102.40 ± 6.81 6.65 
500 489.55 ± 39.65 8.10 
3000 2976.49 ± 210.43 7.07 
5000 5024.72 ± 323.59 6.44 
Inter-day (n =7)   
100 97.23 ± 8.33 8.57 
500 508.67 ± 53.91 10.60 
3000 3018.39 ± 298.21 9.88 
5000 4922.86 ± 441.08 8.96 
 
8.2.2.2.5 Limit of detection and limit of quantification 
The limit of detection (LOD) of TNV was determined to be 14.86 ng/mL, 
whereas, quantitative limit (LOQ) was 46.78 ng/mL.  
 
8.2.2.2.6 Stability study: 
The stability results showed that TNV was stable for at least 3 weeks when 
kept frozen at -70 0C. Thus, analysis up to 3 weeks storage confirmed 
adequate TNV stability at this temperature. Moreover, the results of 
freeze/thaw stability indicate that TNV was stable in plasma for at least five 
freeze/thaw cycles (Table 8.2.6). 
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Table  8.2.6: Summary of stability testing of TNV in human plasma. 
 
Stability 
Nominal 
concentration 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
Precision 
(% RSD) 
Freeze/thaw (n = 5) 
100 92.68 5.51 
500 482.71 7.35 
3000 2868.65 3.96 
5000 4814.52 8.64 
Long term (n = 5) 
100 91.12 4.61 
500 491.08 9.86 
3000 2911.76 7.74 
5000 4708.31 5.63 
 
8.2.3 CONCLUSION 
The developed method was found to be simple, accurate, precise and 
repeatable. It can be applied for the determination of concentration of TNV in 
the human plasma for bioavailability and bioequivalence studies. 
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8.3 RP-HPLC METHOD FOR DETERMINATION OF LOPINAVIR AND 
RITONAVIR IN HUMAN PLASMA. 
8.3.1  EXPERIMENTAL 
8.3.1.1 Instrumentation 
     Same as described under 8.1.1.1 
 
8.3.1.2 Chemicals and materials: 
 Lopinavir and Ritonavir were kindly gifted by Emcure pharmaceuticals   
   ltd., Pune 
 Acetonitrile and water HPLC grade (Rankem, RFCL Ltd., New Delhi) 
 Ammonium acetate crystalline pure (E. Merck, Mumbai, India) 
 Orthophosphoric acid HPLC grade (Spectrochem Pvt. Ltd., Mumbai) 
 Nylon membrane filter 0.45 µm (Gelman laboratory, Mumbai, India) 
 
8.3.1.3 Chromatographic conditions 
Brownlee C18 column (250mm x 4.6mm i.d., 5 µm) was used at ambient 
temperature. The mobile phase comprised of acetonitrile : 10 mM ammonium 
acetate buffer (pH 4.5 ± 0.05 adjusted with orthphosphoric acid) : methanol 
(40:30:30 v/v/v). The mobile phase was filtered through 0.45 µm nylon 
membrane filter and was degassed before use. The elution was monitered at 
210 nm. The injection volume was 20 µL. 
 
8.3.1.4  Preparation of mobile phase 
The mobile phase was prepared by mixing 40 mL acetonitrile, 30 mL 10mM 
ammonium acetate buffer (pH 4.5 ± 0.05 adjusted with orthphosphoric acid) 
and 30 mL methanol previously filtered through 0.45 µm nylon membrane 
filter. The mobile phase was degassed for 15 minutes by sonicating the 
solution before use. 
 
8.3.1.5  Preparation of LPV and RTV standard stock solution. 
Accurately weighed LPV and RTV (25 mg each) were transferred to same 25 
mL volumetric flask and dissolved and diluted up to the mark with acetonitrile 
CHAPTER 8                                                                 ANALYSIS IN PLASMA  
 
207 
 
to obtain a standard solution having concentration of LPV and RTV (1000 
µg/mL). 
 
8.3.1.6  Extraction of sample (LPV and RTV) 
Drug/metabolite free plasma samples with fixed aliquots of LPV and RTV (50 
µL) and volunteer plasma sample (950 µL) was taken in glass centrifuge 
tubes and mixed with 1.0 mL acetonitrile for protein precipitation of plasma as 
well as 0.1 mL saturated sodium chloride solution. The samples were 
vortexed for 1.0 min., and then precipitated proteins were separated by 
centrifugation at 15000 rpm for 15 min. Supernant from the tube was collected 
and filtered through 0.45 µm nylon membrane filter before injection and then 
injected into the HPLC system. 
 
8.3.1.7  Selection of Wavelength for Determination 
The standard solutions of LPV and RTV were scanned in the range of 200 -
400 nm against reagent blank. Both the drugs showed significant absorbance 
at 210 nm which was selected for analysis. 
 
8.3.1.8  METHOD VALIDATION 
8.3.1.8.1  Calibration Curve (Linearity) 
Accurately measured standard stock solution containing  LPV and RTV (0.06, 
0.2,  0.4, 0.8, 1.2, 2.0, 2.4 and 3.2 mL) were transferred in a series of 10 mL 
volumetric flasks and diluted with acetonitrile. The above solutions (50 µL) 
were spiked with 950 µL of drug free plasma to obtain LPV and RTV 
concentration of  300, 1000, 2000, 4000, 6000, 10000, 12000 and 16000 
ng/mL. 
 
8.3.1.8.2  Accuracy 
Accuracy of the measurement of LPV and RTV in plasma was determined by 
standard addition method at four different concentration levels of LPV and 
RTV (6000, 8000, 10000 and 12000 ng/mL). The working solution (4000 
ng/mL) was transferred to four different glass tubes. To each tube, 950 µL of 
drug/metabolite free plasma was added. Further 2000, 4000, 6000 and 8000 
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ng/mL of solutions were serially added into these tubes. These samples were 
extracted as described above in the extraction procedure. 
 
8.3.1.8.3  Recovery 
LPV and RTV recovery (relative and absolute) from human plasma were 
determined by spiking drug-free plasma (five replicates for each standard) 
with known amounts of the drug to achieve TNV concentrations of 300, 2000, 
6000 and 12000 ng/mL. The spiked samples were processed and analysed 
with the developed procedure. The relative (analytical) recovery was 
calculated by comparing the concentrations obtained from the drug-
supplemented plasma with actual added amounts. The absolute ( extraction) 
recovery was obtained by comparing the observed peak areas obtained from 
the processed standard samples to direct injections of standard aqueous 
solutions prepared at concentrations which represented 100% recovery. 
 
8.3.1.8.4  Precision 
8.3.1.8.4.1  Method Precision (repeatability) 
Method precision experiment was performed by preparing the working 
solution of LPV and RTV (4000 ng/mL) for seven times and analysed as per 
described under recovery. 
 
8.3.1.8.4.2  Inter day and intra day precision 
The intra and inter day precisions of LPV and RTV assay in human plasma 
were assessed from replicate samples spiked at four different concentrations 
(300, 2000, 6000 and 12000 ng/mL). The selection of  concentrations for 
analysis was made according to definition of precision at low, medium and 
high concentrations of the linear range. The precision of the method is 
expressed as the relative standard deviation (% RSD) of the mean estimated 
concentrations. 
 
8.3.1.8.5  Limit of  detection and limit of quantification 
The limit of detection and the limit of quantification of the drug were calculated 
using the following equations. 
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LOD = 3.3 x σ/S 
LOQ = 10 x σ/S 
Where σ is the standard deviation of the peak areas of the drug and S is the 
slope for the corresponding calibration curve. 
 
8.3.1.8.6  Stability 
The effect of frozen storage on LPV and RTV stability in human plasma was 
assessed through storing of LPV and RTV plasma samples at -700C over a 
period of 1 month. LPV and RTV plasma samples were analysed immediately 
after preparation and at selected time intervals after storage over the study 
period. Stability was defined as <10% loss of initial drug concentration. 
Moreover, stability in heparinized plasma samples through five freeze and 
thaw cycles (-700C ± 50C to room temperature) has been confirmed. Samples, 
after thawing, were allowed to stand on the bench top, under room lighting till 
2 hr had elapsed since their removal from the freezer.  On the other hand , 
on-machine stability of the processed samples was evaluated by injecting the 
quality control samples, stored at room temperature in the HPLC, immediately 
after preparation and then at selected time intervals for 24 hr. 
 
8.3.1.8.7  Specificity 
The specificity of the assay for the analyte in the presence of endogenous 
substances in the matrix was assessed by comparing the response obtained 
from the concentration used to produce the calibration plots with response 
obtained from plasma of different patients. 
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8.3.2 RESULTS AND DISCUSSION 
8.3.2.1 Chromatography 
The mobile phase acetonitrile : 10mM ammonium acetate buffer (pH 4.5 ± 
0.05 adjusted with orthphosphoric acid) : methanol (40:30:30 v/v/v) at the flow 
rate of 1.0 mL/min achieved optimum separation of LPV and RTV without 
interferences from endogenous components in the plasma. Figure 8.3.1, 8.3.2 
and 8.3.3 represent typical chromatograms of drug-free human plasma and 
drug-free human plasma spiked with LPV  and RTV (16000 ng/mL and 12000 
ng/mL) respectively. As illustrated in these chromatograms, LPV and RTV 
eluted at retention times of approximately 12.58 min and 10.30 min 
respectively. The peaks of interest were clearly resolved with no interfering 
peaks from endogenous components in the plasma within the time frame 
where LPV and RTV were eluted. 
               
 
Figure 8.3.1: Chromatogram of drug-free human plasma. 
 
Enlargement of Figure 8.3.1 
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Figure 8.3.2: Chromatogram of drug-free human plasma spiked with RTV and    
LPV (16000 ng/mL). 
 
 
Enlargement of Figure 8.3.2 
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Figure 8.3.3: Chromatogram of drug-free human plasma spiked with RTV and 
LPV (12000 ng/mL). 
 
 
Enlargement of Figure 8.3.3 
 
8.3.2.2  VALIDATION OF THE METHOD 
8.3.2.2.1 Linearity 
Linear correlation was obtained between peak areas and concentrations of 
LPV and RTV in range of 300 - 16000 ng/mL. The linearity of the calibration 
graphs were validated by the high value of correlation coefficients of the 
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regression (Table 8.3.1).The linearity of the calibration graphs were validated 
by the high value of correlation coefficients of the regression (figure 8.3.4 and 
8.3.5). 
 
 
Figure 8.3.4: Calibration curve of RTV 
 
 
Figure 8.3.5: Calibration curve of LPV 
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Table 8.3.1: Optical and regression characteristics 
Parameter RTV LPV 
Linearity 
range 300 - 16000 ng/mL 300 - 16000 ng/mL 
Regression 
equation (y) 
y = 47.44x + 37962 y = 58.66x - 18573 
Correlation 
coefficient (r) 
0.9930 0.9930 
 
8.3.2.2.2 Accuracy  
The recovery experiments were carried out as in the text. The percent 
recoveries obtained were 86.38 to 93.24% for RTV and 88.56 to 92.34% for 
LPV. The results of recovery study are given in Table 8.3.2. 
 
Table 8.3.2: Data of recovery study (n = 5) 
 
Compound 
Amount 
taken 
(ng/mL) 
Amount 
added 
(ng/mL) 
Amount 
recovered 
(ng/mL) 
Accuracy 
± SD% 
 
 4000 2000 5268.00 87.80 ± 6.30 
RTV 4000 4000 7172.00 89.65 ± 10.89 
 4000 6000 9324.00 93.24 ± 7.71 
 4000 8000 10365.60 86. 38  ± 10.53 
 4000 2000 5540.40 92.34 ± 8.28 
LPV 4000 4000 7084.80 88.56± 12.48 
 4000 6000 9164.00 91.64± 7.23 
 4000 8000 10491.60 87.43  ± 5.76 
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8.3.2.2.3 Recovery 
The recovery experiments were carried out as in the text. The absolute and 
relative mean recovery found to be 86.44% and 85.81%  for RTV as well as 
86.68% and 85.77% for LPV respectively (Table 8.3.3 and 8.3.4). 
 
Table 8.3.3: Absolute and Relative Recoveries of RTV from human plasma. 
 
Nominal concentration 
(ng/mL) 
Absolute recovery 
(mean ± SD%) 
(n = 5) 
Relative recovery 
(mean ± SD%) 
(n = 5) 
300 85.12 ± 8.83 84.28 ± 10.7 
2000 87.35 ± 5.43 86.82 ± 7.24 
6000 84.56 ± 9.57 88.42 ± 4.98 
12000 88.74 ± 11.64 83.74 ± 2.74 
 
 
Table 8.3.4: Absolute and Relative Recoveries of LPV from human plasma. 
 
Nominal concentration 
(ng/mL) 
Absolute recovery 
(mean ± SD%) 
(n = 5) 
Relative recovery 
(mean ± SD%) 
(n = 5) 
300 89.67 ± 11.4 85.32 ± 6.29 
2000 85.78 ± 9.54 83.37 ± 8.21 
6000 87.94 ± 7.58 89.13  ± 11.42 
12000 83.34 ± 5.51 85.28 ± 4.46 
 
 
8.3.2.2.4    Precision  
8.3.2.2.4.1 Method precision (repeatability) 
Relative standard deviation of all the parameters was less than 15% (Table 
8.3.5 and 8.3.6), which indicated that the proposed method was repeatable.  
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Table 8.3.5: Method Precision data for RTV 
 
RTV (4000 
ng/mL) 
Retention 
time 
(min.) 
Peak area 
Tailing 
factor 
1 10.30 205254.4 1.20 
2 9.96 179423.7 1.22 
3 10.38 224376.3 1.20 
4 10.35 202532.1 1.19 
5 10.37 187654.3 1.20 
6 10.38 218765.2 1.21 
7 10.32 233542.9 1.20 
Mean 10.29 207364.1 1.20 
SD 0.15 19586.01 0.0095 
% RSD 1.46 9.44 0.79 
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Table 8.3.6: Method Precision data for LPV 
 
LPV (4000 
ng/mL) 
Retention 
time 
(min.) 
Peak area 
Tailing 
factor 
1 12.58 193992.6 1.18 
2 12.22 168575.2 1.17 
3 12.34 224563.3 1.19 
4 12.52 209874.8 1.18 
5 12.55 198734.3 1.18 
6 12.55 236458.7 1.19 
7 12.92 207545.6 1.20 
Mean 12.525 205677.8 1.184 
SD 0.22 21933.93 0.0097 
% RSD 1.74 10.66 0.82 
 
8.3.2.2.4.2  Intraday and inter day precision: 
 The intra-day precision (% RSD) ranged from 6.73 to 9.86% and 6.57 to 
10.76% for RTV and LPV respectively while the inter-day precision (% RSD) 
ranged from 9.40 to 12.26% and 9.27 to 12.07% for RTV and LPV 
respectively (Table 8.3.7 and 8.3.8). The intra- and inter-day precision data 
showed that acceptable precision was obtained over the entire assay range. 
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Table 8.3.7: Intra and Inter- day precision of RTV  in human plasma. 
Nominal 
concentration. 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
(% RSD) 
Intra-day (n = 7)   
300 304.71± 30.04 9.86 
2000 1983.37 ± 133.48 6.73 
6000 6022.45 ± 445.66 7.40 
12000 11968.26± 1072.35 8.96 
Inter-day (n = 7)   
300 289.23± 32.33 11.18 
2000 2004.34± 188.40 9.40 
6000 5813.74 ± 572.07 9.84 
12000 12014.38 ± 1472.96 12.26 
 
Table 8.3.8: Intra- and Inter- day precision of LPV in human plasma. 
Nominal 
concentration. 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
(% RSD) 
Intra-day (n = 7)   
300 294.22± 21.27 7.23 
2000 2003.56 ± 215.58 10.76 
6000 5888.71 ± 495.82 8.42 
12000 11976.34± 786.84 6.57 
Inter-day (n = 7)   
300 287.36± 29.79 10.37 
2000 1989.58± 240.14 12.07 
6000 6011.26 ± 626.97 10.43 
12000 11983.48 ± 1110.86 9.27 
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8.3.2.2.5 Limit of detection and limit of quantification 
The limit of detection (LOD) of RTV and LPV were found to be 67.86 ng/mL 
and 86.80 ng/mL, whereas, quantitative limit (LOQ) were  193.75 ng/mL and 
258.47 ng/mL respectively.  
 
8.3.2.2.6 Stability study 
The stability results showed that LPV and RTV were stable for at least 4 
weeks when kept frozen at -70 0C. Thus, analysis up to 4 weeks storage 
confirmed adequate LPV and RTV stability at this temperature. Moreover, the 
results of freeze/thaw stability indicate that LPV and RTV were stable in 
plasma for at least five freeze/thaw cycles (Table 8.3.9 and 8.3.10). 
 
Table 8.3.9: Summary of stability testing of RTV in human plasma. 
 
Stability 
Nominal 
concentration 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
Precision 
(% RSD) 
Freeze/thaw (n = 5) 
300 296.34 8.57 
2000 1981.66 6.90 
6000 5934.32 9.82 
12000 11575.49 3.45 
Long term ( n = 5) 
300 276.12 7.53 
2000 1964.56 5.35 
6000 5781.42 10.63 
12000 11384.58 8.46 
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Table 8.3.10: Summary of stability testing of LPV in human plasma. 
 
Stability 
Nominal 
concentration 
(ng/mL) 
Observed 
concentration. 
(ng/mL) 
 
Precision 
(% RSD) 
Freeze/thaw (n = 5) 
300 282.23 6.72 
2000 1957.38 9.45 
6000 5768.58 7.43 
12000 11354.39 10.36 
Long term (n = 5) 
300 271.34 8.30 
2000 1872.48 10.52 
6000 5739.45 6.37 
12000 11458.76 5.23 
 
8.3.3 CONCLUSION 
The developed method was found to be simple, accurate, precise and 
repeatable. It can be applied for the determination of concentration of lopinavir 
and ritonavir in the human plasma for bioavailability and bioequivalence 
studies. 
  
CHAPTER 9 
 
STATISTICAL COMPARISION 
OF THE DEVELOPED 
METHODS 
 
CHAPTER 9                                            COMPARISION OF THE  METHODS 
 
221 
 
9. STATISTICAL COMPARISION OF THE DEVELOPED 
METHODS 
9.1. DETERMINATION OF TENOFOVIR DISOPROXIL FUMARATE IN 
TABLET DOSAGE FORM 
 
Table 9.1: Comparision of HPLC, HPTLC and UV method for determination of 
TNV 
Parameters HPLC HPTLC UV 
TNV ± SD, % (n=3) 98.82 ± 1.61 98.90 ± 1.47 98.25 ± 0.42 
Tabulated F- Value 5.591 
Calculated F- Value 0.334 
 
The assay results for TNV in tablet dosage form, obtained using HPLC, 
HPTLC and UV spectrophotometric methods were compared statistically by 
applying the F-test. The calculated F- value (0.334) for TNV is less than the 
tabulated F- value (5.591) at the 95% confidence interval. Therefore no 
significant difference was found in the content of TNV determined by the 
proposed HPLC, HPTLC and UV spectrophotometric methods. 
Fcalculated < Ftabulated 
 
9.2. DETERMINATION OF EFAVIRENZ IN TABLET DOSAGE FORM 
 
Table 9.2: Comparision of HPLC, HPTLC and UV method for determination of 
EFV 
Parameters HPLC HPTLC UV 
EFV ± SD, % (n=3) 99.65 ± 1.72 99.11 ± 1.70 100.82 ± 1.31 
Tabulated F- Value 5.591 
Calculated F- Value 0.814 
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The assay results for EFV in tablet dosage form, obtained using HPLC, 
HPTLC and UV spectrophotometric methods were compared statistically by 
applying the F-test. The calculated F- value (0.814) for EFV is less than the 
tabulated F- value (5.591) at the 95% confidence interval. Therefore no 
significant difference was found in the content of EFV determined by the 
proposed HPLC, HPTLC and UV spectrophotometric methods. 
Fcalculated < Ftabulated  
 
9.3. SIMULTANEOUS DETERMINATION OF LOPINAVIR AND RITONAVIR 
IN TABLET DOSAGE FORM 
 
Table 9.3: Comparision of HPLC and HPTLC method for determination of LPV 
and RTV 
Parameters LPV RTV 
HPLC HPTLC HPLC HPTLC 
Drug ± SD, % (n=3) 98.99 ± 1.21 99.10 ± 1.87 99.67 ± 1.25 98.72 ± 0.77 
Tabulated t- Value 4.30 4.30 
Calculated t- Value 0.088 0.976 
 
The assay results for LPV and RTV in tablet dosage form, obtained using 
HPLC  and HPTLC methods were compared statistically by applying the two 
tail paired t-test. The calculated t- value for LPV (0.088) and RTV (0.976)  is 
less than the tabulated t- value (4.30) at the 95% confidence interval. 
Therefore no significant difference was found in the content of LPV and RTV 
determined by the proposed HPLC and HPTLC methods. 
tcalculated < ttabulated  
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10. SUMMARY 
 Anti retroviral agents and their tablet dosage forms which are available 
in the market, i.e., Efavirenz tablet, Tenofovir disoproxil fumarate tablet, 
Lopinavir and Ritonavir combined tablets as well as Ritonavir tablet 
were selected for the study. 
 Various methods including spectrophotometric, RP-HPLC, HPTLC etc. 
were reviewed for the estimation of Efavirenz, Tenofovir disoproxil 
fumarate, Lopinavir and Ritonavir in alone as well as combined dosage 
form. 
 Stability indicating RP-HPLC method was developed for the estimation 
of Efavirenz. Forced degradation study was carried out under acidic, 
alkaline, neutral, oxidative, thermal and photolytic conditions. The 
degraded products were well resolved from Efavirenz, indicating the 
method can also be useful for the estimation of Efavirenz in presence 
of degraded product. The developed RP- HPLC method was applied 
and optimized for the estimation of Efavirenz in human plasma. 
 Stability indicating RP-HPLC method was developed for the estimation 
of Tenofovir disoproxil fumarate. Forced degradation study was carried 
out under acidic, alkaline, neutral, oxidative, thermal and photolytic 
conditions. The degraded products were well resolved from Tenofovir 
disoproxil fumarate, indicating the method can also be useful for the 
estimation of Tenofovir disoproxil fumarate in presence of degraded 
product. The developed RP- HPLC method was applied and optimized 
for the estimation of Tenofovir disoproxil fumarate in human plasma.   
 RP-HPLC method was developed for the estimation of Lopinavir and 
Ritonavir in their combined tablet dosage form. The developed RP- 
HPLC method was applied and optimized for the estimation of 
Lopinavir and Ritonavir in human plasma.   
 HPTLC method was developed for the estimation of Tenofovir 
disoproxil fumarate and Efavirenz  in tablet dosage form.   
 HPTLC method was developed for the estimation of Lopinavir and 
Ritonavir in their combined tablet dosage form. 
CHAPTER 10                                                                                    SUMMARY 
 
224 
 
 First derivative UV spectrophotometric method was developed for the 
estimation of Tenofovir disoproxil fumarate in tablet dosage form.   
 Difference spectrometric method was developed for the estimation of 
Efavirenz and Ritonavir in tablet dosage form.   
 The developed HPLC, HPTLC and UV spectrophotometric methods 
were validated as per ICH guideline for accuracy, linearity, precision, 
robustness, limit of detection and limit of quantification.   
 The optimized bioanalytical RP-HPLC methods (for the analysis of 
antiretroviral agents in human plasma) were validated as per USFDA 
guideline for accuracy, linearity, precision and stability. 
 The developed HPLC, HPTLC and UV spectrophotometric methods 
were compared statistically by applying the F-test and t-test. The 
calculated F-value and t-value were found to be less than the tabulated 
F-value and t-value indicated no significant difference in the content of 
antiretroviral agents determined by the proposed methods. 
 
 
  
 
 
  
CHAPTER 11 
 
PUBLICATIONS  
AND     
PRESENTATIONS 
 
CHAPTER 11                                    PUBLICATIONS AND PRESENTATIONS 
 
225 
 
11. PUBLICATIONS AND PRESENTATIONS 
RESEARCH PAPERS PUBLISHED 
 
1. Mardia R. B., Suhagia B. N., Pasha T. Y., Chauhan S. P. and Solanki S. 
D., Development and validation of HPTLC method for simultaneous 
analysis of lopinavir and ritonavir in their combined tablet dosage form, 
International journal for pharmaceutical research scholars 2012, 1(1), 39 
- 44.  
 
2. Mardia R. B., Suhagia B. N., Pasha T. Y., Chauhan S. P. and Solanki S. 
D., Development and validation of HPTLC method for estimation of 
tenofovir disoproxil fumarate in tablet dosage form, Journal of 
pharmaceutical science and bioscientific research  2012, 2(2), 73-76. 
 
RESEARCH PAPERS PRESENTED 
Following research papers presented in the National level conference 
“Advances in Chromatography” held at Ganpat University, Kherva, 
Mehsana, Gujarat, India on 9th and 10th April 2012. 
1. Development and validation of RP-HPLC method for simultaneous 
analysis of lopinavir and ritonavir in their combined tablet dosage form. 
2. Development and validation of RP-HPLC method for estimation of 
tenofovir disoproxil fumarate in tablet dosage form. 
3. Development and validation of normal phase HPTLC method for 
simultaneous analysis of lopinavir and ritonavir in their combined tablet 
dosage form. 
4. Development and validation of normal phase HPTLC method for 
estimation of tenofovir disoproxil fumarate in tablet dosage form. 
 
 
